PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
7905757-0	1993	Salmeterol: a novel, long-acting beta 2-agonist.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	33-39
7905757-1	1993	OBJECTIVE: The clinical pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of the long-acting beta 2-agonist salmeterol are reviewed.	salmeterol xinafoate	129-139	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	114-120
7905757-8	1993	DATA SYNTHESIS: Salmeterol is a selective, beta 2-agonist that has been studied in the treatment of exercise-induced, nocturnal, and allergen-induced asthma.	salmeterol xinafoate	16-26	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	43-49
7905757-18	1993	CONCLUSIONS: Salmeterol is an effective beta 2-agonist in the treatment of asthma.	salmeterol xinafoate	13-23	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	40-46
8296255-0	1993	Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients.	salmeterol xinafoate	88-98	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	73-79
7905340-7	1993	Relaxant responses to salmeterol were fully reversed by the selective beta 2-adrenoceptor blocking drug, ICI 118551, demonstrating the involvement of beta 2-adrenoceptors.	salmeterol xinafoate	22-32	adrenoceptor beta 2	Homo sapiens	70-89
7902176-0	1993	Salmeterol, a long-acting beta 2-adrenoceptor agonist mediating cyclic AMP accumulation in a neuronal cell line.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	26-45
7902176-7	1993	The beta 2-adrenoceptor antagonist, ICI 118551, inhibited the responses to both salmeterol (apparent KD 2.2 nM) and isoprenaline (apparent KD 1.6 nM).	salmeterol xinafoate	80-90	adrenoceptor beta 2	Homo sapiens	4-23
7902176-13	1993	Whereas salmeterol has a slow onset of action in airway smooth muscle compared to other beta 2-adrenoceptor agonists, in B50 monolayers both salmeterol and isoprenaline produced a rapid increase in cyclic AMP accumulation (t1/2 1.1 min and 0.4 min respectively).	salmeterol xinafoate	141-151	adrenoceptor beta 2	Homo sapiens	88-107
8105520-3	1993	We studied the efficacy of the recently developed long acting inhaled beta 2-agonist salmeterol with respect to protection against exercise-induced bronchoconstriction.	salmeterol xinafoate	85-95	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	70-76
7950447-1	1993	The study aimed at estimating the acting duration of salmeterol (Serevent, Glaxo), a long-term beta 2-agonist bronchodilator, when given in a single dose (50 micrograms).	salmeterol xinafoate	53-63	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	95-101
8103646-8	1993	After treatment with salmeterol 50 micrograms, s-EPX, but not s-ECP, increased significantly 24 h after challenge, but was normal at 48 h. After salmeterol 100 micrograms, no change in s-EPX or s-ECP was found.	salmeterol xinafoate	21-31	eosinophil peroxidase	Homo sapiens	49-52
8102918-1	1993	It has been suggested that the new long-acting beta 2-agonist, salmeterol, has anti-inflammatory properties--properties which should improve airway responsiveness (AR).	salmeterol xinafoate	63-73	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	47-53
8095902-1	1993	The ability of the long-acting beta-adrenoceptor agonists eformoterol and salmeterol to inhibit leukotriene (LT) B4 (100 nM; approximately EC70)-induced hydrogen peroxide (H2O2) generation by guinea-pig peritoneal eosinophils was investigated and compared with salbutamol.	salmeterol xinafoate	74-84	prostaglandin reductase 1	Cavia porcellus	96-115
8100652-1	1993	BACKGROUND: Formoterol and salmeterol are new long acting beta 2 adrenoceptor agonists.	salmeterol xinafoate	27-37	beta-2 adrenergic receptor	Cavia porcellus	58-77
8095419-0	1993	Investigations into factors determining the duration of action of the beta 2-adrenoceptor agonist, salmeterol.	salmeterol xinafoate	99-109	adrenoceptor beta 2	Rattus norvegicus	70-89
8095419-2	1993	This study has explored the mechanism underlying the long duration of action of the beta 2-adrenoceptor agonist, salmeterol.	salmeterol xinafoate	113-123	adrenoceptor beta 2	Rattus norvegicus	84-103
8095419-14	1993	These data are consistent with the mechanism in which salmeterol binds adjacent to the active site of the beta 2-adrenoceptor, such that the drug cannot be washed out of the tissue, yet can interact with and activate the receptor.	salmeterol xinafoate	54-64	adrenoceptor beta 2	Rattus norvegicus	106-125
8093705-1	1993	BACKGROUND: Salmeterol is a new inhaled selective beta 2-adrenergic receptor agonist with a long duration of action.	salmeterol xinafoate	12-22	adrenoceptor beta 2	Homo sapiens	50-76
8105155-0	1993	Salmeterol: an inhaled beta 2-agonist with prolonged duration of action.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	23-29
8105155-1	1993	Salmeterol (Serevent) is an inhaled beta 2-receptor agonist with more than twelve hours" effect duration compared with 4-6 hours for the more short-acting substances bitolterol, fenoterol, salbutamol, and terbutaline.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	36-42
8105155-1	1993	Salmeterol (Serevent) is an inhaled beta 2-receptor agonist with more than twelve hours" effect duration compared with 4-6 hours for the more short-acting substances bitolterol, fenoterol, salbutamol, and terbutaline.	salmeterol xinafoate	12-20	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	36-42
1358932-1	1992	BACKGROUND: In adults with asthma, the selective beta 2-adrenergic agonist salmeterol has a prolonged bronchodilator and bronchoprotective effect.	salmeterol xinafoate	75-85	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	49-55
1357550-0	1992	Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma.	salmeterol xinafoate	64-74	adrenoceptor beta 2	Homo sapiens	35-54
8493629-2	1993	BACKGROUND: Salmeterol is a potent selective beta 2 agonist that has been shown to have a duration of action in excess of 12 hours.	salmeterol xinafoate	12-22	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	45-51
8100394-1	1993	The new generation of long-acting beta 2-agonists, represented by salmeterol and formoterol, inhibit a number of the processes involved in acute inflammation in the lung: inflammatory mediator release, vascular permeability and inflammatory cell accumulation.	salmeterol xinafoate	66-76	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	34-40
8103622-1	1993	Formoterol and salmeterol are chemically distinct, highly selective beta-2-adrenoceptor agonists developed to provide sustained (12h+) relief of airway obstruction in diseases such as asthma.	salmeterol xinafoate	15-25	adrenoceptor beta 2	Homo sapiens	68-87
8103622-4	1993	Salmeterol, but not formoterol, behaves as a beta-adrenoceptor antagonist in some experimental models due to its considerably weaker efficacy at the beta 2-adrenoceptor in vitro although their are no established clinical consequences of this antagonism.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	149-168
8099695-2	1993	Salmeterol is > 10,000 times more lipophilic than salbutamol and has greater affinity for the beta 2-adrenoceptor.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	97-116
8099695-5	1993	Its mechanism of action can be explained by binding to a specific exo-site domain of the beta 2-receptor protein to produce continuous stimulation of the active site of the receptor, which gives salmeterol a profile of pharmacological activity unlike that of other beta 2-agonists.	salmeterol xinafoate	195-205	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	89-95
8099695-6	1993	Due to its potent and prolonged activation of beta 2-adrenoceptors in airway smooth muscle cells, endothelial cells, mast cells and epithelial cells, salmeterol induces prolonged bronchodilatation, reduced vascular permeability, inhibition of inflammatory mediators, stimulation of ciliary function and modulation of ion and water transport across the bronchial mucosa.	salmeterol xinafoate	150-160	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	46-52
1357554-2	1992	We compared a new long-acting, inhaled beta 2-adrenoceptor agonist, salmeterol, with a short-acting beta 2-agonist, albuterol, in the treatment of mild-to-moderate asthma.	salmeterol xinafoate	68-78	adrenoceptor beta 2	Homo sapiens	39-58
1357554-2	1992	We compared a new long-acting, inhaled beta 2-adrenoceptor agonist, salmeterol, with a short-acting beta 2-agonist, albuterol, in the treatment of mild-to-moderate asthma.	salmeterol xinafoate	68-78	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	39-45
1361250-3	1992	Salmeterol inhibits pulmonary inflammation induced by PAF in guinea pigs.	salmeterol xinafoate	0-10	PCNA clamp associated factor	Homo sapiens	54-57
1361250-4	1992	METHODS: The effect of salmeterol on effects induced by PAF was investigated in eight normal subjects who inhaled salmeterol (50 micrograms) twice daily or a matched placebo for one week before challenge with PAF.	salmeterol xinafoate	23-33	PCNA clamp associated factor	Homo sapiens	56-59
1361250-10	1992	After salmeterol treatment mean reductions five minutes after inhaled PAF were 59 (45-73)%, 40 (19-61)%, and 82 (71-93)% of baseline respectively.	salmeterol xinafoate	6-16	PCNA clamp associated factor	Homo sapiens	70-73
1361250-11	1992	At 30 minutes after treatment with PAF the neutrophil count rebounded to 143 (82-204)% of baseline after placebo and to 127 (93-161)% after inhaled salmeterol.	salmeterol xinafoate	148-158	PCNA clamp associated factor	Homo sapiens	35-38
1360657-12	1992	It is concluded that salmeterol, in comparison to formoterol, is a partial beta 2-adrenoceptor agonist and has, at high concentrations, an additional unspecific inhibitory action.	salmeterol xinafoate	21-31	beta-2 adrenergic receptor	Cavia porcellus	75-94
1355645-1	1992	The effect of inhaled salmeterol xinafoate, a long acting beta 2 agonist, on exercise induced asthma was studied in a double blind, crossover, and placebo controlled trial.	salmeterol xinafoate	22-42	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	58-64
1361068-7	1992	Salmeterol 100 micrograms twice daily was consistently superior to salmeterol 50 micrograms twice daily in morning and evening PEFR measurements (mean differences between the treatments: 10-14 l min-1 for morning, 95% CI-0, 22 l min-1, P = 0.047; and 10-15 l min-1 for evening, 95% CI 2, 22 l min-1, P = 0.023).	salmeterol xinafoate	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	195-200
1361068-7	1992	Salmeterol 100 micrograms twice daily was consistently superior to salmeterol 50 micrograms twice daily in morning and evening PEFR measurements (mean differences between the treatments: 10-14 l min-1 for morning, 95% CI-0, 22 l min-1, P = 0.047; and 10-15 l min-1 for evening, 95% CI 2, 22 l min-1, P = 0.023).	salmeterol xinafoate	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	229-234
1361068-7	1992	Salmeterol 100 micrograms twice daily was consistently superior to salmeterol 50 micrograms twice daily in morning and evening PEFR measurements (mean differences between the treatments: 10-14 l min-1 for morning, 95% CI-0, 22 l min-1, P = 0.047; and 10-15 l min-1 for evening, 95% CI 2, 22 l min-1, P = 0.023).	salmeterol xinafoate	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	229-234
1361068-7	1992	Salmeterol 100 micrograms twice daily was consistently superior to salmeterol 50 micrograms twice daily in morning and evening PEFR measurements (mean differences between the treatments: 10-14 l min-1 for morning, 95% CI-0, 22 l min-1, P = 0.047; and 10-15 l min-1 for evening, 95% CI 2, 22 l min-1, P = 0.023).	salmeterol xinafoate	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	229-234
1358381-9	1992	Formoterol and salmeterol reduced the secretion of IL-1 beta only at the highest dose (1 x 10(-5) M).	salmeterol xinafoate	15-25	interleukin 1 beta	Homo sapiens	51-60
1346963-7	1992	The recent availability of novel, longer-acting inhaled beta 2-agonists such as salmeterol and formoterol will also make necessary a careful reappraisal of their long term use in patients with asthma.	salmeterol xinafoate	80-90	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	56-62
1354536-2	1992	The long-acting beta 2-adrenoceptor agonist, salmeterol has been evaluated for its anti-inflammatory effects in the guinea-pig lung and skin.	salmeterol xinafoate	45-55	beta-2 adrenergic receptor	Cavia porcellus	16-35
1359777-1	1992	Salmeterol xinafoate, like salbutamol (albuterol), is a saligenin derivative, and a selective beta 2-adrenoceptor agonist.	salmeterol xinafoate	0-20	adrenoceptor beta 2	Homo sapiens	94-113
1359777-9	1992	Thus, salmeterol may be particularly useful in patients requiring regular treatment with beta 2-agonists for nocturnal asthma and results of trials in progress involving large numbers of patients are awaited with interest.	salmeterol xinafoate	6-16	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	89-95
1346793-0	1992	Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	26-32
1346794-1	1992	Salmeterol (SM) is a novel beta 2-adrenoceptor agonist with a duration of action in excess of 12 hours.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	27-46
1346794-1	1992	Salmeterol (SM) is a novel beta 2-adrenoceptor agonist with a duration of action in excess of 12 hours.	salmeterol xinafoate	12-14	adrenoceptor beta 2	Homo sapiens	27-46
1360770-1	1992	Formoterol and salmeterol are 2 newly developed beta 2-adrenoceptor agonists for inhalation with prolonged duration of effect compared with currently available beta 2-agonists.	salmeterol xinafoate	15-25	beta-2 adrenergic receptor	Cavia porcellus	48-67
1350364-1	1992	Salmeterol is an original molecule with a selective-beta-2-sympathomimetic effect which is intended to a prolonged treatment of asthma.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	52-58
1350370-2	1992	Salmeterol is a highly selective beta-2 agonist that is from 2 to 15 times more potent than salbutamol on beta-2 receptors of bronchial smooth muscle and 10,000 times more potent than isoprenaline on beta-1 receptors.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	33-39
1350370-2	1992	Salmeterol is a highly selective beta-2 agonist that is from 2 to 15 times more potent than salbutamol on beta-2 receptors of bronchial smooth muscle and 10,000 times more potent than isoprenaline on beta-1 receptors.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	106-112
1686740-0	1991	Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo.	salmeterol xinafoate	0-10	beta-2 adrenergic receptor	Cavia porcellus	33-52
1687365-0	1991	Estimation of the efficacy and affinity of the beta 2-adrenoceptor agonist salmeterol in guinea-pig trachea.	salmeterol xinafoate	75-85	beta-2 adrenergic receptor	Cavia porcellus	47-66
1687365-2	1991	We have attempted to estimate the affinity and efficacy of the new beta 2-adrenoceptor agonist salmeterol in the guinea-pig isolated trachea and to compare these estimates with those obtained for salbutamol.	salmeterol xinafoate	95-105	beta-2 adrenergic receptor	Cavia porcellus	67-86
1686740-19	1991	On the guinea-pig isolated gastric fundus strip, a putative beta3-adrenoceptor containing preparation, salbutamol and salmeterol had only modest agonist activity, being 20-30 fold less potent than isoprenaline and the selective ,beta3-adrenoceptor agonist, BRL 35135.7.	salmeterol xinafoate	118-128	beta-3 adrenergic receptor	Cavia porcellus	60-78
1686740-19	1991	On the guinea-pig isolated gastric fundus strip, a putative beta3-adrenoceptor containing preparation, salbutamol and salmeterol had only modest agonist activity, being 20-30 fold less potent than isoprenaline and the selective ,beta3-adrenoceptor agonist, BRL 35135.7.	salmeterol xinafoate	118-128	beta-3 adrenergic receptor	Cavia porcellus	229-247
1686740-22	1991	Salmeterol is therefore a potent and selective beta2-adrenoceptor agonist with a remarkably long duration of action in isolated superfused airways smooth muscle.	salmeterol xinafoate	0-10	beta-2 adrenergic receptor	Cavia porcellus	47-65
1687131-4	1991	All three doses of salmeterol had significant efficacy, manifested by increased morning and evening peak expiratory flow rate (PEFR) (by 35-59 l.min-1 and 11-38 l.min-1, respectively), by reduced diurnal variation in PEFR, and by reduced requirement for additional bronchodilator for symptomatic relief.	salmeterol xinafoate	19-29	CD59 molecule (CD59 blood group)	Homo sapiens	145-150
1687131-4	1991	All three doses of salmeterol had significant efficacy, manifested by increased morning and evening peak expiratory flow rate (PEFR) (by 35-59 l.min-1 and 11-38 l.min-1, respectively), by reduced diurnal variation in PEFR, and by reduced requirement for additional bronchodilator for symptomatic relief.	salmeterol xinafoate	19-29	CD59 molecule (CD59 blood group)	Homo sapiens	163-168
1675178-1	1991	New long-acting beta 2-adrenoceptor agonists, formoterol and salmeterol, may soon appear in several European countries for treatment of asthma.	salmeterol xinafoate	61-71	adrenoceptor beta 2	Homo sapiens	16-35
1723379-2	1991	Salmeterol xinafoate, like salbutamol (albuterol), is a saligenin derivative, and a selective beta 2-adrenoceptor agonist.	salmeterol xinafoate	0-20	adrenoceptor beta 2	Homo sapiens	94-113
1723379-9	1991	Thus, salmeterol may be particularly useful in patients requiring regular treatment with beta 2-agonists for nocturnal asthma and results of trials in progress involving large numbers of patients are awaited with interest.	salmeterol xinafoate	6-16	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	89-95
1683037-0	1991	[Treatment of asthma with salmeterol--a new prolonged-action inhalatory beta 2 agonist].	salmeterol xinafoate	26-36	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	72-78
1686530-3	1991	Salmeterol, a new long-acting, beta 2-adrenoceptor agonist has been developed and shown to induce persistent relaxation of airways smooth muscle in vitro and sustained bronchodilatation in vivo, and to have significant anti-inflammatory activity in the lung, suppressing inflammatory mediator release and inflammatory cell infiltration and inhibiting vascular permeability and oedema formation.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	31-50
1975162-2	1990	Salmeterol (SM) is a new beta 2-adrenoceptor agonist for inhaled use that has been shown to produce long-lasting bronchodilation in asthmatic patients.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	25-44
1980220-0	1990	Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	98-104
1975162-2	1990	Salmeterol (SM) is a new beta 2-adrenoceptor agonist for inhaled use that has been shown to produce long-lasting bronchodilation in asthmatic patients.	salmeterol xinafoate	12-14	adrenoceptor beta 2	Homo sapiens	25-44
1974667-2	1990	Of the substance synthesized and tested it was concluded that salmeterol represented a new class of beta 2-stimulants that because of their exceptionally long duration of action have potential clinical advantages over current available beta 2-stimulants in the treatment of asthma.	salmeterol xinafoate	62-72	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	100-106
1974668-9	1990	In guinea pig airways in vivo, SALM inhibited histamine-induced plasma protein extravasation for approximately 8 h. Salmeterol is a potent and selective beta 2-adrenoceptor agonist with a unique profile of action.	salmeterol xinafoate	116-126	beta-2 adrenergic receptor	Cavia porcellus	153-172
1974680-1	1990	Long-term treatment studies with formoterol and salmeterol show that these inhaled long-acting beta 2-agonists compared to available beta 2-agonists produce better bronchodilation, decrease the need for additional doses, decrease asthma symptoms, and are strongly preferred by the patients.	salmeterol xinafoate	48-58	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	95-101
34952438-0	2022	Optimization of two charge transfer reactions for colorimetric determination of two beta 2 agonist drugs, salmeterol xinafoate and salbutamol, in pharmaceutical and biological samples.	salmeterol xinafoate	106-126	ATPase H+ transporting V0 subunit a2	Homo sapiens	84-90
25526818-4	2015	Here we report the effect of salmeterol (Sal), a selective ss2AR agonist, on IFN-gamma(+) CD4 and IFN-gamma(+) CD8 T cells following stimulation with Cytomegalovirus lysate (CMVL-strain AD169) or individual peptides spanning the entire region of the HCMV pp65 protein (pp65).	salmeterol xinafoate	29-39	interferon gamma	Homo sapiens	77-86
25526818-4	2015	Here we report the effect of salmeterol (Sal), a selective ss2AR agonist, on IFN-gamma(+) CD4 and IFN-gamma(+) CD8 T cells following stimulation with Cytomegalovirus lysate (CMVL-strain AD169) or individual peptides spanning the entire region of the HCMV pp65 protein (pp65).	salmeterol xinafoate	29-39	CD8a molecule	Homo sapiens	111-114
25526818-4	2015	Here we report the effect of salmeterol (Sal), a selective ss2AR agonist, on IFN-gamma(+) CD4 and IFN-gamma(+) CD8 T cells following stimulation with Cytomegalovirus lysate (CMVL-strain AD169) or individual peptides spanning the entire region of the HCMV pp65 protein (pp65).	salmeterol xinafoate	41-44	interferon gamma	Homo sapiens	77-86
25526818-4	2015	Here we report the effect of salmeterol (Sal), a selective ss2AR agonist, on IFN-gamma(+) CD4 and IFN-gamma(+) CD8 T cells following stimulation with Cytomegalovirus lysate (CMVL-strain AD169) or individual peptides spanning the entire region of the HCMV pp65 protein (pp65).	salmeterol xinafoate	41-44	interferon gamma	Homo sapiens	98-107
25526818-4	2015	Here we report the effect of salmeterol (Sal), a selective ss2AR agonist, on IFN-gamma(+) CD4 and IFN-gamma(+) CD8 T cells following stimulation with Cytomegalovirus lysate (CMVL-strain AD169) or individual peptides spanning the entire region of the HCMV pp65 protein (pp65).	salmeterol xinafoate	41-44	CD8a molecule	Homo sapiens	111-114
25526818-6	2015	The results show that Sal reduced the percentage of IFN-gamma(+) CD4 and IFN-gamma(+) CD8 T cells both when applied directly to isolated T cells, and indirectly via treatment of APC.	salmeterol xinafoate	22-25	interferon gamma	Homo sapiens	52-61
25526818-6	2015	The results show that Sal reduced the percentage of IFN-gamma(+) CD4 and IFN-gamma(+) CD8 T cells both when applied directly to isolated T cells, and indirectly via treatment of APC.	salmeterol xinafoate	22-25	interferon gamma	Homo sapiens	73-82
25526818-6	2015	The results show that Sal reduced the percentage of IFN-gamma(+) CD4 and IFN-gamma(+) CD8 T cells both when applied directly to isolated T cells, and indirectly via treatment of APC.	salmeterol xinafoate	22-25	CD8a molecule	Homo sapiens	86-89
25526818-8	2015	Similarly, the results show that Sal suppressed cytotoxicity of both CD8 T and NK cells in vitro following stimulation with Chinese hamster ovary cell line transfected with MICA(*009) (T-CHO) and the human erythromyeloblastoid leukemic (K562) cell line.	salmeterol xinafoate	33-36	CD8a molecule	Homo sapiens	69-72
34780174-8	2021	In particular, we identify unique allosteric signal transmission mechanisms between the Nb80-binding site and the extracellular domains in conformations modulated by a full agonist, BI167107, and a G-protein-biased partial agonist, salmeterol, involving mainly TM1 and TM2, and TM5, respectively.	salmeterol xinafoate	232-242	tropomyosin 3	Homo sapiens	278-281
8650060-0	1995	[Effect of 16-week use of salmeterol on ECP levels, pulmonary function tests and bronchial hyperreactivity in patients with chronic obstructive lung disease].	salmeterol xinafoate	26-36	ribonuclease A family member 3	Homo sapiens	40-43
8650060-5	1995	We concluded that salmeterol didn"t change lung function test but decreased bronchial hyperreactivity and decreased ECP level in serum and sputum.	salmeterol xinafoate	18-28	ribonuclease A family member 3	Homo sapiens	116-119
34762840-10	2021	In children, we identified a significant admixture mapping peak for superior responsiveness to 5 x ICS versus 100 mug fluticasone plus salmeterol on chromosome 12 (odds ratio (ORlocal African) 3 95, 95% CI 2 02-7 72, p=6 1 x 10-5) fine mapped to a locus adjacent to RNFT2 and NOS1 (rs73399224, ORallele dose 0 17, 95% CI 0 07-0 42, p=8 4 x 10-5).	salmeterol xinafoate	135-145	ring finger protein, transmembrane 2	Homo sapiens	266-271
34762840-10	2021	In children, we identified a significant admixture mapping peak for superior responsiveness to 5 x ICS versus 100 mug fluticasone plus salmeterol on chromosome 12 (odds ratio (ORlocal African) 3 95, 95% CI 2 02-7 72, p=6 1 x 10-5) fine mapped to a locus adjacent to RNFT2 and NOS1 (rs73399224, ORallele dose 0 17, 95% CI 0 07-0 42, p=8 4 x 10-5).	salmeterol xinafoate	135-145	nitric oxide synthase 1	Homo sapiens	276-280
33210444-1	2021	As of 2020, use of beta2-agonist salmeterol is restricted by the World Anti-Doping Agency (WADA) and is only permitted by inhalation at therapeutic doses not exceeding 200 mug in 24 h. In contrast to beta2-agonists salbutamol and formoterol, WADA has not established a urine threshold for salmeterol despite its muscle hypertrophic actions observed in animals.	salmeterol xinafoate	33-43	ATPase H+ transporting V0 subunit a2	Homo sapiens	19-24
34334369-12	2021	Significance Statement The cell membrane"s functional role behind the duration of action of long-acting beta2-adrenergic receptor (beta2-AR) agonists such as salmeterol has been a subject of debate for a long time.	salmeterol xinafoate	158-168	adrenoceptor beta 2	Homo sapiens	104-129
34334369-12	2021	Significance Statement The cell membrane"s functional role behind the duration of action of long-acting beta2-adrenergic receptor (beta2-AR) agonists such as salmeterol has been a subject of debate for a long time.	salmeterol xinafoate	158-168	adenosine A2a receptor	Homo sapiens	131-139
34334369-13	2021	We investigated the binding and unbinding mechanisms of the three commonly used beta2-AR agonists, salmeterol, formoterol, and salbutamol, using advanced simulation techniques.	salmeterol xinafoate	99-109	adenosine A2a receptor	Homo sapiens	80-88
34571824-7	2021	We further showed that the early-released, but not the late-released, IL-10 was crucial for mediating and potentiating the anti-inflammatory function of a beta2-adrenergic receptor agonist salmeterol.	salmeterol xinafoate	189-199	interleukin 10	Mus musculus	70-75
34571824-7	2021	We further showed that the early-released, but not the late-released, IL-10 was crucial for mediating and potentiating the anti-inflammatory function of a beta2-adrenergic receptor agonist salmeterol.	salmeterol xinafoate	189-199	adrenergic receptor, beta 2	Mus musculus	155-180
34022889-2	2021	This study was aimed to evaluate beta-2 adrenergic agonist (Beta-2 Adrenergic Agonist, BAA) Salmeterol and beta blocker (Beta Blocker, BB) Propranolol on the gene expression of the ovarian pro- and anti-inflammatory mediators, inflammatory responses of immune system, ovarian functions and, hormones in the laying hens on the late stage of production period.	salmeterol xinafoate	92-102	ATPase H+ transporting V0 subunit a2	Gallus gallus	33-39
34022889-2	2021	This study was aimed to evaluate beta-2 adrenergic agonist (Beta-2 Adrenergic Agonist, BAA) Salmeterol and beta blocker (Beta Blocker, BB) Propranolol on the gene expression of the ovarian pro- and anti-inflammatory mediators, inflammatory responses of immune system, ovarian functions and, hormones in the laying hens on the late stage of production period.	salmeterol xinafoate	92-102	ATPase H+ transporting V0 subunit a2	Gallus gallus	60-66
33852162-3	2021	However, an increase in serious adverse events with the use of both regular formoterol and regular salmeterol (long-acting beta2-agonists) compared with placebo for chronic asthma has been demonstrated in previous Cochrane Reviews.	salmeterol xinafoate	99-109	ATPase H+ transporting V0 subunit a2	Homo sapiens	123-128
34812056-4	2021	Next, old rats were injected with the alpha2-adrenoceptor antagonist 2-methoxy idazoxan or beta2-adrenoceptor agonist salmeterol for 21 days.	salmeterol xinafoate	118-128	adrenoceptor beta 2	Rattus norvegicus	91-109
34812056-6	2021	Moreover, treatments with L-DOPS, 2-methoxy idazoxan, or salmeterol significantly increased the protein levels of phosphorylated Akt in rat striatum and SN.	salmeterol xinafoate	57-67	AKT serine/threonine kinase 1	Rattus norvegicus	129-132
2904183-0	1988	Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	38-57
2904183-1	1988	Salmeterol is a new inhaled beta 2 adrenoceptor agonist, which has been shown in animal experiments to produce a more prolonged bronchodilator effect than currently available beta 2 adrenoceptor agonists.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	28-47
33543552-4	2021	The suggested procedure was capable of SAL determination over concentrations ranging 200-2000 ng.mL-1 with excellent correlation coefficient of 0.9995.	salmeterol xinafoate	39-42	L1 cell adhesion molecule	Mus musculus	97-101
33210444-1	2021	As of 2020, use of beta2-agonist salmeterol is restricted by the World Anti-Doping Agency (WADA) and is only permitted by inhalation at therapeutic doses not exceeding 200 mug in 24 h. In contrast to beta2-agonists salbutamol and formoterol, WADA has not established a urine threshold for salmeterol despite its muscle hypertrophic actions observed in animals.	salmeterol xinafoate	289-299	ATPase H+ transporting V0 subunit a2	Homo sapiens	19-24
33220672-2	2020	Here we report the preparation of structural isomers of salmeterol and albuterol, which can be obtained from the same starting material as the corresponding beta2-agonists, depending on the synthetic approach employed.	salmeterol xinafoate	56-66	ATPase H+ transporting V0 subunit a2	Homo sapiens	157-162
32325119-5	2020	A drug screening campaign showed that the beta2-adrenergic receptor (beta2-AR) agonists clenbuterol hydrochloride (CLEN) and salmeterol xinafoate (SALM) increase the proliferation rate of neural progenitor cells from the Ts65Dn model of DS.	salmeterol xinafoate	147-151	adenosine A2a receptor	Mus musculus	69-77
33251412-6	2020	Our results indicated that combining dexamethasone with fast long-acting beta-2 adrenergic agonists (LABAs), such as formoterol and salmeterol, can ease respiratory symptoms hastily, until dexamethasone"s anti-inflammatory and immunosuppressant effects kick in.	salmeterol xinafoate	132-142	ATPase H+ transporting V0 subunit a2	Homo sapiens	73-79
32325119-5	2020	A drug screening campaign showed that the beta2-adrenergic receptor (beta2-AR) agonists clenbuterol hydrochloride (CLEN) and salmeterol xinafoate (SALM) increase the proliferation rate of neural progenitor cells from the Ts65Dn model of DS.	salmeterol xinafoate	147-151	reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65	Mus musculus	221-227
32325119-0	2020	Neonatal therapy with clenbuterol and salmeterol restores spinogenesis and dendritic complexity in the dentate gyrus of the Ts65Dn model of Down syndrome.	salmeterol xinafoate	38-48	reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65	Mus musculus	124-130
32325119-5	2020	A drug screening campaign showed that the beta2-adrenergic receptor (beta2-AR) agonists clenbuterol hydrochloride (CLEN) and salmeterol xinafoate (SALM) increase the proliferation rate of neural progenitor cells from the Ts65Dn model of DS.	salmeterol xinafoate	125-145	adrenergic receptor, beta 2	Mus musculus	42-67
32325119-5	2020	A drug screening campaign showed that the beta2-adrenergic receptor (beta2-AR) agonists clenbuterol hydrochloride (CLEN) and salmeterol xinafoate (SALM) increase the proliferation rate of neural progenitor cells from the Ts65Dn model of DS.	salmeterol xinafoate	125-145	adenosine A2a receptor	Mus musculus	69-77
32325119-5	2020	A drug screening campaign showed that the beta2-adrenergic receptor (beta2-AR) agonists clenbuterol hydrochloride (CLEN) and salmeterol xinafoate (SALM) increase the proliferation rate of neural progenitor cells from the Ts65Dn model of DS.	salmeterol xinafoate	125-145	reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65	Mus musculus	221-227
32325119-5	2020	A drug screening campaign showed that the beta2-adrenergic receptor (beta2-AR) agonists clenbuterol hydrochloride (CLEN) and salmeterol xinafoate (SALM) increase the proliferation rate of neural progenitor cells from the Ts65Dn model of DS.	salmeterol xinafoate	147-151	adrenergic receptor, beta 2	Mus musculus	42-67
31128979-10	2019	Our multivariable analysis found that the control group had 3.2 more prescriptions (95% CI, 1.4-7.1; P = 0.006) of either ipratropium or salmeterol in the past 2 years than the MS group, even if controlling for other confounders.	salmeterol xinafoate	137-147	EH domain containing 2	Homo sapiens	155-161
32314556-1	2020	Salmeterol is a long acting beta2-agonist (LABA) widely used for treatment of airways disease.	salmeterol xinafoate	0-10	ATPase H+ transporting V0 subunit a2	Homo sapiens	28-33
32314556-2	2020	There is evidence that beta2-agonists, including salmeterol, have the potential for performance enhancing effects when delivered at supratherapeutic doses.	salmeterol xinafoate	49-59	ATPase H+ transporting V0 subunit a2	Homo sapiens	23-28
30933849-6	2019	In addition, Salmeterol upregulates the expression of arginase-1 and CXCL14.	salmeterol xinafoate	13-23	chemokine (C-X-C motif) ligand 14	Mus musculus	69-75
30933849-2	2019	Previously, we showed that Salmeterol, a long-acting beta2-adrenergic receptor (beta2-AR) agonist, has neuroprotective effects in PD models in vitro and in vivo through the beta-arrestin2-dependent inhibition of pro-inflammatory M1-type mediator production.	salmeterol xinafoate	27-37	adrenergic receptor, beta 2	Mus musculus	53-78
30933849-7	2019	Furthermore, using siRNA approach we found that silencing of the transcription factor Creb abrogates the Salmeterol-mediated production of IL-10 in LPS-activated BV2 cells, but silencing of beta-arrestin2 with Arrb2 siRNA did not.	salmeterol xinafoate	105-115	cAMP responsive element binding protein 1	Mus musculus	86-90
30933849-2	2019	Previously, we showed that Salmeterol, a long-acting beta2-adrenergic receptor (beta2-AR) agonist, has neuroprotective effects in PD models in vitro and in vivo through the beta-arrestin2-dependent inhibition of pro-inflammatory M1-type mediator production.	salmeterol xinafoate	27-37	adrenergic receptor, beta 2	Mus musculus	80-88
30933849-2	2019	Previously, we showed that Salmeterol, a long-acting beta2-adrenergic receptor (beta2-AR) agonist, has neuroprotective effects in PD models in vitro and in vivo through the beta-arrestin2-dependent inhibition of pro-inflammatory M1-type mediator production.	salmeterol xinafoate	27-37	arrestin, beta 2	Mus musculus	173-187
30933849-4	2019	Salmeterol inhibited the production of LPS-induced mediators of the pro-inflammatory M1 phenotype such as tumor necrosis factor-alpha (TNF-alpha), IL-(interleukin) 18, IL-6, chemokines (CCL2, CCL3, CCL4) and reactive oxygen species from BV2 cells.	salmeterol xinafoate	0-10	tumor necrosis factor	Mus musculus	106-133
30933849-7	2019	Furthermore, using siRNA approach we found that silencing of the transcription factor Creb abrogates the Salmeterol-mediated production of IL-10 in LPS-activated BV2 cells, but silencing of beta-arrestin2 with Arrb2 siRNA did not.	salmeterol xinafoate	105-115	interleukin 10	Mus musculus	139-144
30933849-4	2019	Salmeterol inhibited the production of LPS-induced mediators of the pro-inflammatory M1 phenotype such as tumor necrosis factor-alpha (TNF-alpha), IL-(interleukin) 18, IL-6, chemokines (CCL2, CCL3, CCL4) and reactive oxygen species from BV2 cells.	salmeterol xinafoate	0-10	tumor necrosis factor	Mus musculus	135-144
30933849-4	2019	Salmeterol inhibited the production of LPS-induced mediators of the pro-inflammatory M1 phenotype such as tumor necrosis factor-alpha (TNF-alpha), IL-(interleukin) 18, IL-6, chemokines (CCL2, CCL3, CCL4) and reactive oxygen species from BV2 cells.	salmeterol xinafoate	0-10	interleukin 6	Mus musculus	168-172
30803275-3	2019	In this study we have evaluated the selective beta2 agonist salmeterol in GAA knockout mice in combination with an AAV vector expressing human GAA specifically in the liver.	salmeterol xinafoate	60-70	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Mus musculus	46-51
30933849-4	2019	Salmeterol inhibited the production of LPS-induced mediators of the pro-inflammatory M1 phenotype such as tumor necrosis factor-alpha (TNF-alpha), IL-(interleukin) 18, IL-6, chemokines (CCL2, CCL3, CCL4) and reactive oxygen species from BV2 cells.	salmeterol xinafoate	0-10	chemokine (C-C motif) ligand 2	Mus musculus	186-190
30933849-4	2019	Salmeterol inhibited the production of LPS-induced mediators of the pro-inflammatory M1 phenotype such as tumor necrosis factor-alpha (TNF-alpha), IL-(interleukin) 18, IL-6, chemokines (CCL2, CCL3, CCL4) and reactive oxygen species from BV2 cells.	salmeterol xinafoate	0-10	chemokine (C-C motif) ligand 3	Mus musculus	192-196
30933849-4	2019	Salmeterol inhibited the production of LPS-induced mediators of the pro-inflammatory M1 phenotype such as tumor necrosis factor-alpha (TNF-alpha), IL-(interleukin) 18, IL-6, chemokines (CCL2, CCL3, CCL4) and reactive oxygen species from BV2 cells.	salmeterol xinafoate	0-10	chemokine (C-C motif) ligand 4	Mus musculus	198-202
30933849-5	2019	Conversely, treatment with Salmeterol and other beta2-AR agonists robustly enhances the production of the M2 cytokine IL-10 from LPS-activated microglia.	salmeterol xinafoate	27-37	adrenergic receptor, beta 2	Mus musculus	48-56
30933849-5	2019	Conversely, treatment with Salmeterol and other beta2-AR agonists robustly enhances the production of the M2 cytokine IL-10 from LPS-activated microglia.	salmeterol xinafoate	27-37	interleukin 10	Mus musculus	118-123
30933849-6	2019	In addition, Salmeterol upregulates the expression of arginase-1 and CXCL14.	salmeterol xinafoate	13-23	arginase, liver	Mus musculus	54-64
30803275-7	2019	Salmeterol treatment decreased abnormalities of autophagy in the quadriceps, as shown be lower LC3 and p62.	salmeterol xinafoate	0-10	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	95-98
30803275-7	2019	Salmeterol treatment decreased abnormalities of autophagy in the quadriceps, as shown be lower LC3 and p62.	salmeterol xinafoate	0-10	nucleoporin 62	Homo sapiens	103-106
30352316-8	2018	Additionally, Salmeterol suppressed nuclear translocation of nuclear factor kappa-B (NF-kappaB) p65 by inhibiting the IkappaB-alpha degradation and TAK1 (transforming growth factor-beta-activated kinase1) phosphorylation.	salmeterol xinafoate	14-24	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	61-83
30753866-7	2019	Both formoterol and salmeterol counteracted the effect of CSE on GC-induced GILZ expression but not on nuclear translocation or phosphorylation.	salmeterol xinafoate	20-30	TSC22 domain family member 3	Homo sapiens	76-80
30465781-2	2019	The HSF enhanced uptake and transport of fluticasone propionate across the epithelial barrier when alone and in presence of salmeterol.	salmeterol xinafoate	124-134	interleukin 6	Homo sapiens	4-7
30933783-1	2019	A simple selective luminescent dependent approach was established for quantitation of two selective beta2 agonists namely; Fenoterol hydrobromide (FEN) and Salmeterol xinafoate (SAL).	salmeterol xinafoate	156-176	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	100-105
30933783-1	2019	A simple selective luminescent dependent approach was established for quantitation of two selective beta2 agonists namely; Fenoterol hydrobromide (FEN) and Salmeterol xinafoate (SAL).	salmeterol xinafoate	178-181	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	100-105
31042379-4	2019	Molecular dynamics simulations suggest that the difference in G protein efficacy and beta-arrestin recruitment of the hybrid ( S)-22, the full agonist epinephrine, and the beta2-selective, G protein-biased partial agonist salmeterol depends on specific hydrogen bonding between Ser5.46 and Asn6.55, and the aromatic head group of the ligands.	salmeterol xinafoate	222-232	G protein-coupled receptor 162	Homo sapiens	172-177
30352316-0	2018	beta-arrestin2 regulates the anti-inflammatory effects of Salmeterol in lipopolysaccharide-stimulated BV2 cells.	salmeterol xinafoate	58-68	arrestin, beta 2	Mus musculus	0-14
30352316-7	2018	Salmeterol inhibited LPS-induced release of the pro-inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and nitric oxide from BV2 cells.	salmeterol xinafoate	0-10	tumor necrosis factor	Mus musculus	83-110
30352316-7	2018	Salmeterol inhibited LPS-induced release of the pro-inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and nitric oxide from BV2 cells.	salmeterol xinafoate	0-10	tumor necrosis factor	Mus musculus	112-121
30352316-7	2018	Salmeterol inhibited LPS-induced release of the pro-inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and nitric oxide from BV2 cells.	salmeterol xinafoate	0-10	interleukin 1 beta	Mus musculus	124-141
30352316-7	2018	Salmeterol inhibited LPS-induced release of the pro-inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and nitric oxide from BV2 cells.	salmeterol xinafoate	0-10	interleukin 1 beta	Mus musculus	143-151
30352316-8	2018	Additionally, Salmeterol suppressed nuclear translocation of nuclear factor kappa-B (NF-kappaB) p65 by inhibiting the IkappaB-alpha degradation and TAK1 (transforming growth factor-beta-activated kinase1) phosphorylation.	salmeterol xinafoate	14-24	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	85-94
30352316-8	2018	Additionally, Salmeterol suppressed nuclear translocation of nuclear factor kappa-B (NF-kappaB) p65 by inhibiting the IkappaB-alpha degradation and TAK1 (transforming growth factor-beta-activated kinase1) phosphorylation.	salmeterol xinafoate	14-24	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	96-99
30352316-8	2018	Additionally, Salmeterol suppressed nuclear translocation of nuclear factor kappa-B (NF-kappaB) p65 by inhibiting the IkappaB-alpha degradation and TAK1 (transforming growth factor-beta-activated kinase1) phosphorylation.	salmeterol xinafoate	14-24	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	118-131
30352316-8	2018	Additionally, Salmeterol suppressed nuclear translocation of nuclear factor kappa-B (NF-kappaB) p65 by inhibiting the IkappaB-alpha degradation and TAK1 (transforming growth factor-beta-activated kinase1) phosphorylation.	salmeterol xinafoate	14-24	mitogen-activated protein kinase kinase kinase 7	Mus musculus	148-152
30352316-8	2018	Additionally, Salmeterol suppressed nuclear translocation of nuclear factor kappa-B (NF-kappaB) p65 by inhibiting the IkappaB-alpha degradation and TAK1 (transforming growth factor-beta-activated kinase1) phosphorylation.	salmeterol xinafoate	14-24	mitogen-activated protein kinase kinase kinase 7	Mus musculus	154-203
30352316-9	2018	We have also found that Salmeterol increases the expression of beta-arrestin2 and enhances the interaction between beta-arrestin2 and TAB1 (TAK1-binding protein), reduced TAK1/TAB1 mediated activation of NFkappaB and expression of pro-inflammatory genes.	salmeterol xinafoate	24-34	arrestin, beta 2	Mus musculus	63-77
30352316-9	2018	We have also found that Salmeterol increases the expression of beta-arrestin2 and enhances the interaction between beta-arrestin2 and TAB1 (TAK1-binding protein), reduced TAK1/TAB1 mediated activation of NFkappaB and expression of pro-inflammatory genes.	salmeterol xinafoate	24-34	arrestin, beta 2	Mus musculus	115-129
30352316-9	2018	We have also found that Salmeterol increases the expression of beta-arrestin2 and enhances the interaction between beta-arrestin2 and TAB1 (TAK1-binding protein), reduced TAK1/TAB1 mediated activation of NFkappaB and expression of pro-inflammatory genes.	salmeterol xinafoate	24-34	mitogen-activated protein kinase kinase kinase 7	Mus musculus	140-144
30352316-9	2018	We have also found that Salmeterol increases the expression of beta-arrestin2 and enhances the interaction between beta-arrestin2 and TAB1 (TAK1-binding protein), reduced TAK1/TAB1 mediated activation of NFkappaB and expression of pro-inflammatory genes.	salmeterol xinafoate	24-34	mitogen-activated protein kinase kinase kinase 7	Mus musculus	171-175
30352316-9	2018	We have also found that Salmeterol increases the expression of beta-arrestin2 and enhances the interaction between beta-arrestin2 and TAB1 (TAK1-binding protein), reduced TAK1/TAB1 mediated activation of NFkappaB and expression of pro-inflammatory genes.	salmeterol xinafoate	24-34	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	204-212
30352316-10	2018	Furthermore, silencing of beta-arrestin2 abrogates the anti-inflammatory effects of Salmeterol in LPS-stimulated BV2 cells.	salmeterol xinafoate	84-94	arrestin, beta 2	Mus musculus	26-40
30352316-11	2018	Our findings suggest that the anti-inflammatory properties of Salmeterol is beta-arrestin2 dependent and also offers novel therapeutics targeting inflammatory pathways to prevent microglial cell activation and neuronal loss in neuroinflammatory diseases like PD.	salmeterol xinafoate	62-72	arrestin, beta 2	Mus musculus	76-90
30322801-6	2018	In this study, we demonstrate that chronic treatment with salbutamol, salmeterol, and formoterol inhibited insulin-induced glucose uptake and GLUT4 synthesis in H9c2 myoblast cells.	salmeterol xinafoate	70-80	insulin	Homo sapiens	107-114
30327561-1	2018	Salmeterol is a partial agonist for the beta2 adrenergic receptor (beta2AR) and the first long-acting beta2AR agonist to be widely used clinically for the treatment of asthma and chronic obstructive pulmonary disease.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	40-65
30327561-1	2018	Salmeterol is a partial agonist for the beta2 adrenergic receptor (beta2AR) and the first long-acting beta2AR agonist to be widely used clinically for the treatment of asthma and chronic obstructive pulmonary disease.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	67-74
30327561-1	2018	Salmeterol is a partial agonist for the beta2 adrenergic receptor (beta2AR) and the first long-acting beta2AR agonist to be widely used clinically for the treatment of asthma and chronic obstructive pulmonary disease.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	102-109
30327561-3	2018	To understand its unusual pharmacological action and partial agonism, we obtained the crystal structure of salmeterol-bound beta2AR in complex with an active-state-stabilizing nanobody.	salmeterol xinafoate	107-117	adrenoceptor beta 2	Homo sapiens	124-131
30322801-6	2018	In this study, we demonstrate that chronic treatment with salbutamol, salmeterol, and formoterol inhibited insulin-induced glucose uptake and GLUT4 synthesis in H9c2 myoblast cells.	salmeterol xinafoate	70-80	solute carrier family 2 member 4	Rattus norvegicus	142-147
29544104-1	2018	BACKGROUND: Salmeterol (a long acting beta2-agonist) is a chiral molecule.	salmeterol xinafoate	12-22	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	38-43
29708303-1	2018	Simple, precise and selective spectrofluorimetric technique was evolved for quantitation of selective beta2 agonist drug namely salmeterol xinafoate (SAL).	salmeterol xinafoate	128-148	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	102-107
29708303-1	2018	Simple, precise and selective spectrofluorimetric technique was evolved for quantitation of selective beta2 agonist drug namely salmeterol xinafoate (SAL).	salmeterol xinafoate	150-153	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	102-107
29653961-2	2018	Operational model-fitting established that the long-acting beta2-adrenoceptor agonists (LABA) indacaterol, salmeterol, formoterol, and picumeterol were full agonists on BEAS-2B cells transfected with a cAMP-response element reporter but differed in efficacy (indacaterol >= formoterol > salmeterol >= picumeterol).	salmeterol xinafoate	293-303	adrenoceptor beta 2	Homo sapiens	59-77
29653961-2	2018	Operational model-fitting established that the long-acting beta2-adrenoceptor agonists (LABA) indacaterol, salmeterol, formoterol, and picumeterol were full agonists on BEAS-2B cells transfected with a cAMP-response element reporter but differed in efficacy (indacaterol >= formoterol > salmeterol >= picumeterol).	salmeterol xinafoate	107-117	adrenoceptor beta 2	Homo sapiens	59-77
29332144-1	2018	Long-acting beta2-agonists (LABAs) such as formoterol and salmeterol are used for prolonged bronchodilatation in asthma, usually in combination with inhaled corticosteroids (ICSs).	salmeterol xinafoate	58-68	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	12-17
29794744-1	2018	RATIONALE: This combination of fluticasone propionate (FP) and the long-acting beta2-agonist salmeterol (Salm) can control the symptoms of asthma and COPD better than FP or Salm on their own and better than the combination of inhaled corticosteroids plus montelukast.	salmeterol xinafoate	93-103	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	79-84
28833774-3	2017	RESULTS: We evaluated the effects of fluticasone propionate (FP) and of salmeterol (SM), on the response of well-differentiated cultured bronchial epithelial cells to interleukin-13 (IL-13).	salmeterol xinafoate	72-82	interleukin 13	Homo sapiens	167-181
29447945-0	2018	Salmeterol, agonist of beta2-aderenergic receptor, prevents systemic inflammation via inhibiting NLRP3 inflammasome.	salmeterol xinafoate	0-10	adrenergic receptor, beta 2	Mus musculus	23-49
29447945-0	2018	Salmeterol, agonist of beta2-aderenergic receptor, prevents systemic inflammation via inhibiting NLRP3 inflammasome.	salmeterol xinafoate	0-10	NLR family, pyrin domain containing 3	Mus musculus	97-102
29447945-1	2018	beta2-Aderenergic receptor (beta2AR) agonist, Salmeterol exhibits anti-inflammatory activities.	salmeterol xinafoate	46-56	adrenergic receptor, beta 2	Mus musculus	0-26
29447945-1	2018	beta2-Aderenergic receptor (beta2AR) agonist, Salmeterol exhibits anti-inflammatory activities.	salmeterol xinafoate	46-56	adrenergic receptor, beta 2	Mus musculus	28-35
29447945-6	2018	We found that Salmeterol (10-10 M-10-7 M) prevented the cleavage of caspase-1 and the activation of NLRP3 inflammasome, reduced the release of pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) in vitro.	salmeterol xinafoate	14-24	caspase 1	Mus musculus	68-77
29447945-6	2018	We found that Salmeterol (10-10 M-10-7 M) prevented the cleavage of caspase-1 and the activation of NLRP3 inflammasome, reduced the release of pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) in vitro.	salmeterol xinafoate	14-24	NLR family, pyrin domain containing 3	Mus musculus	100-105
29447945-6	2018	We found that Salmeterol (10-10 M-10-7 M) prevented the cleavage of caspase-1 and the activation of NLRP3 inflammasome, reduced the release of pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) in vitro.	salmeterol xinafoate	14-24	tumor necrosis factor	Mus musculus	199-208
29447945-6	2018	We found that Salmeterol (10-10 M-10-7 M) prevented the cleavage of caspase-1 and the activation of NLRP3 inflammasome, reduced the release of pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) in vitro.	salmeterol xinafoate	14-24	interleukin 1 beta	Mus musculus	214-231
29447945-6	2018	We found that Salmeterol (10-10 M-10-7 M) prevented the cleavage of caspase-1 and the activation of NLRP3 inflammasome, reduced the release of pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) in vitro.	salmeterol xinafoate	14-24	interleukin 1 beta	Mus musculus	233-241
29447945-8	2018	In vivo study showed that Salmeterol decreased the serum concentrations of pro-inflammatory cytokines IL-1beta and TNF-alpha, blocked cleavage of caspase-1 and release of IL-1beta in BMDM.	salmeterol xinafoate	26-36	interleukin 1 beta	Mus musculus	102-110
29447945-8	2018	In vivo study showed that Salmeterol decreased the serum concentrations of pro-inflammatory cytokines IL-1beta and TNF-alpha, blocked cleavage of caspase-1 and release of IL-1beta in BMDM.	salmeterol xinafoate	26-36	tumor necrosis factor	Mus musculus	115-124
29447945-8	2018	In vivo study showed that Salmeterol decreased the serum concentrations of pro-inflammatory cytokines IL-1beta and TNF-alpha, blocked cleavage of caspase-1 and release of IL-1beta in BMDM.	salmeterol xinafoate	26-36	caspase 1	Mus musculus	146-155
29447945-8	2018	In vivo study showed that Salmeterol decreased the serum concentrations of pro-inflammatory cytokines IL-1beta and TNF-alpha, blocked cleavage of caspase-1 and release of IL-1beta in BMDM.	salmeterol xinafoate	26-36	interleukin 1 beta	Mus musculus	171-179
29447945-9	2018	These findings imply that Salmeterol at low concentrations (10-10 M-10-7 M) shows anti-inflammatory effect via inhibiting NLRP3 inflammasome.	salmeterol xinafoate	26-36	NLR family, pyrin domain containing 3	Mus musculus	122-127
29447945-10	2018	The underlying mechanisms is dosage-dependent: Salmeterol at 10-10 M shows anti-inflammatory effects through beta-arrestin2 pathway, and 10-7 M Salmeterol inhibits inflammation via both classical G-protein coupled receptor (GPCR)/cAMP pathway and beta-arrestin2 pathway.	salmeterol xinafoate	47-57	arrestin, beta 2	Mus musculus	109-123
29447945-10	2018	The underlying mechanisms is dosage-dependent: Salmeterol at 10-10 M shows anti-inflammatory effects through beta-arrestin2 pathway, and 10-7 M Salmeterol inhibits inflammation via both classical G-protein coupled receptor (GPCR)/cAMP pathway and beta-arrestin2 pathway.	salmeterol xinafoate	144-154	arrestin, beta 2	Mus musculus	247-261
28833774-3	2017	RESULTS: We evaluated the effects of fluticasone propionate (FP) and of salmeterol (SM), on the response of well-differentiated cultured bronchial epithelial cells to interleukin-13 (IL-13).	salmeterol xinafoate	84-86	interleukin 13	Homo sapiens	167-181
29162108-6	2017	RESULTS: Salmeterol reduced the proliferation, myofibroblastic differentiation and CCR7 expression of fibrocytes from healthy subjects and non-severe asthma patients.	salmeterol xinafoate	9-19	C-C motif chemokine receptor 7	Homo sapiens	83-87
26909542-8	2016	In Ova S/C PNMT-KO mice, formoterol and salmeterol restored the asthma-like phenotype comparable to Ova S/C wild-type mice.	salmeterol xinafoate	40-50	phenylethanolamine-N-methyltransferase	Mus musculus	11-15
28033454-3	2017	Salmeterol is a chiral compound consisting of (R)- and (S)-enantiomers, normally administered as racemic (rac-) mixture via inhalation.	salmeterol xinafoate	0-10	AKT serine/threonine kinase 1	Homo sapiens	97-111
28398147-0	2017	Salmeterol, a Long-Acting beta2-Adrenergic Receptor Agonist, Inhibits Macrophage Activation by Lipopolysaccharide From Porphyromonas gingivalis.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	26-51
28398147-1	2017	BACKGROUND: Salmeterol is a long-acting beta2-adrenergic receptor agonist used to treat chronic obstructive pulmonary disease.	salmeterol xinafoate	12-22	adrenoceptor beta 2	Homo sapiens	40-65
28398147-3	2017	In this study, the authors sought to determine if salmeterol had a similar inhibitory effect on the inflammatory response of the murine macrophage cell line RAW264.7 and human monocyte THP-1 to LPS from Porphyromonas gingivalis (PgLPS), an oral microbe implicated in the pathogenesis of periodontal disease.	salmeterol xinafoate	50-60	GLI family zinc finger 2	Homo sapiens	185-190
28398147-8	2017	RESULTS: Pretreatment with salmeterol significantly inhibited production of proinflammatory mediators by RAW264.7 and THP-1 cells.	salmeterol xinafoate	27-37	GLI family zinc finger 2	Homo sapiens	118-123
28398147-9	2017	Salmeterol downregulated PgLPS-mediated phosphorylation of the extracellular signal-regulated kinase 1/2 and c-Jun N-terminal kinase but not p38 mitogen-activated protein kinases (MAPKs).	salmeterol xinafoate	0-10	mitogen-activated protein kinase 3	Homo sapiens	63-104
28398147-10	2017	Salmeterol also attenuated activation of NF-kappaB via inhibition of nuclear translocation of p65-NFkappaB, the transcriptional activity of NF-kappaB and IkappaBalpha phosphorylation.	salmeterol xinafoate	0-10	nuclear factor kappa B subunit 1	Homo sapiens	41-50
28398147-10	2017	Salmeterol also attenuated activation of NF-kappaB via inhibition of nuclear translocation of p65-NFkappaB, the transcriptional activity of NF-kappaB and IkappaBalpha phosphorylation.	salmeterol xinafoate	0-10	RELA proto-oncogene, NF-kB subunit	Homo sapiens	94-97
28398147-10	2017	Salmeterol also attenuated activation of NF-kappaB via inhibition of nuclear translocation of p65-NFkappaB, the transcriptional activity of NF-kappaB and IkappaBalpha phosphorylation.	salmeterol xinafoate	0-10	nuclear factor kappa B subunit 1	Homo sapiens	98-106
28398147-10	2017	Salmeterol also attenuated activation of NF-kappaB via inhibition of nuclear translocation of p65-NFkappaB, the transcriptional activity of NF-kappaB and IkappaBalpha phosphorylation.	salmeterol xinafoate	0-10	nuclear factor kappa B subunit 1	Homo sapiens	140-149
28398147-10	2017	Salmeterol also attenuated activation of NF-kappaB via inhibition of nuclear translocation of p65-NFkappaB, the transcriptional activity of NF-kappaB and IkappaBalpha phosphorylation.	salmeterol xinafoate	0-10	NFKB inhibitor alpha	Homo sapiens	154-166
27164986-1	2016	The World Anti-Doping Agency (WADA) currently allows therapeutic use of the beta2-agonists salbutamol, formoterol and salmeterol when delivered via inhalation despite some evidence suggesting these anti-asthma drugs may be performance enhancing.	salmeterol xinafoate	118-128	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	76-81
28374512-1	2017	Salmeterol (SAL) is a long-acting beta2-adrenergic agonist, which is widely used in the therapy of asthma.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	34-39
28374512-1	2017	Salmeterol (SAL) is a long-acting beta2-adrenergic agonist, which is widely used in the therapy of asthma.	salmeterol xinafoate	12-15	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	34-39
28097668-1	2017	Salmeterol is a man-made beta-2-adrenergic receptor agonist used to relieve bronchospasm associated with inflammatory airway disease in horses.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	25-51
28637505-2	2017	We compare the expression of beta2-adrenoceptors and the inhibitory effect of formoterol and salmeterol on the LPS-induced release of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6 and a range of chemokines (CCL2, 3, 4, and IL-8) by human lung macrophages (LMs) and MDMs.	salmeterol xinafoate	93-103	tumor necrosis factor	Homo sapiens	134-167
28637505-7	2017	Salmeterol and formoterol exerted an inhibitory effect on the LPS-induced production of TNF-alpha, IL-6, CCL2, CCL3, and CCL4 in MDMs.	salmeterol xinafoate	0-10	tumor necrosis factor	Homo sapiens	88-97
28637505-7	2017	Salmeterol and formoterol exerted an inhibitory effect on the LPS-induced production of TNF-alpha, IL-6, CCL2, CCL3, and CCL4 in MDMs.	salmeterol xinafoate	0-10	interleukin 6	Homo sapiens	99-103
28637505-7	2017	Salmeterol and formoterol exerted an inhibitory effect on the LPS-induced production of TNF-alpha, IL-6, CCL2, CCL3, and CCL4 in MDMs.	salmeterol xinafoate	0-10	C-C motif chemokine ligand 2	Homo sapiens	105-109
28637505-7	2017	Salmeterol and formoterol exerted an inhibitory effect on the LPS-induced production of TNF-alpha, IL-6, CCL2, CCL3, and CCL4 in MDMs.	salmeterol xinafoate	0-10	C-C motif chemokine ligand 3	Homo sapiens	111-115
28637505-7	2017	Salmeterol and formoterol exerted an inhibitory effect on the LPS-induced production of TNF-alpha, IL-6, CCL2, CCL3, and CCL4 in MDMs.	salmeterol xinafoate	0-10	C-C motif chemokine ligand 4	Homo sapiens	121-125
27742702-0	2016	TRAIL deficiency and PP2A activation with salmeterol ameliorates egg allergen-driven eosinophilic esophagitis.	salmeterol xinafoate	42-52	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	Mus musculus	21-25
27742702-8	2016	Salmeterol administration to wild-type mice with experimental EoE restored PP2A activity and also prevented esophageal eosinophilia, inflammatory cytokine expression, and remodeling, which was comparable to the treatment effect of dexamethasone.	salmeterol xinafoate	0-10	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	Mus musculus	75-79
27742702-9	2016	TRAIL and PP2A regulate inflammation and fibrosis in experimental EoE, which can be therapeutically modulated by salmeterol.	salmeterol xinafoate	113-123	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	0-5
27742702-9	2016	TRAIL and PP2A regulate inflammation and fibrosis in experimental EoE, which can be therapeutically modulated by salmeterol.	salmeterol xinafoate	113-123	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	Mus musculus	10-14
27222010-9	2016	Finally, the long-acting ADRB2-specific agonist, salmeterol, markedly reduced the cytokine secretion capacity of CD8(+) T cells in response to infection with vesicular stomatitis virus.	salmeterol xinafoate	49-59	adrenoceptor beta 2	Homo sapiens	25-30
27222010-9	2016	Finally, the long-acting ADRB2-specific agonist, salmeterol, markedly reduced the cytokine secretion capacity of CD8(+) T cells in response to infection with vesicular stomatitis virus.	salmeterol xinafoate	49-59	CD8a molecule	Homo sapiens	113-116
26909542-9	2016	However, coadministration of either roflumilast or rolipram attenuated this formoterol- or salmeterol-driven phenotype in Ova S/C PNMT-KO.	salmeterol xinafoate	91-101	phenylethanolamine-N-methyltransferase	Mus musculus	130-134
27017193-6	2016	Heart GAA activity was significantly increased by either salmeterol (p<0.01) or DHEA (p<0.05), in comparison with untreated mice.	salmeterol xinafoate	57-67	glucosidase, alpha, acid	Mus musculus	6-9
27190062-5	2016	Bronchial epithelial cells were cultured with the short-acting beta2-agonist salbutamol or the long-acting beta2-agonist salmeterol prior to stimulation with HDE.	salmeterol xinafoate	121-131	hemoglobin, beta adult minor chain	Mus musculus	107-112
27023685-17	2016	A later subgroup analysis of the primary outcome revealed that factors associated with a statistically significant decrease in the occurrence of COPD exacerbations were male sex (P = 0.023), comorbid asthma (P = 0.026), and conversion from fluticasone/salmeterol to a more potent dose of mometasone/formoterol (P = 0.014).	salmeterol xinafoate	252-262	COPD	Homo sapiens	145-149
27023685-3	2016	Based on these data, a therapeutic interchange was implemented in the Kaiser Permanente Mid-Atlantic States region to convert patients with a COPD diagnosis from fluticasone/salmeterol to mometasone/formoterol.	salmeterol xinafoate	174-184	COPD	Homo sapiens	142-146
27023685-18	2016	CONCLUSIONS: There was a statistically significant decrease in the proportion of patients who experienced COPD exacerbations postconversion from fluticasone/salmeterol to mometasone/formoterol.	salmeterol xinafoate	157-167	COPD	Homo sapiens	106-110
27023685-4	2016	OBJECTIVE: To evaluate the impact of a therapeutic interchange from fluticasone/salmeterol to mometasone/formoterol on health outcomes in patients with COPD in a large ambulatory and managed care setting.	salmeterol xinafoate	80-90	COPD	Homo sapiens	152-156
27023685-5	2016	METHODS: The investigators retrospectively reviewed the electronic medical records of patients with a COPD diagnosis who had a prescription for fluticasone/salmeterol converted to mometasone/formoterol between March 6, 2011, to March 6, 2013.	salmeterol xinafoate	156-166	COPD	Homo sapiens	102-106
27023685-11	2016	The primary endpoint was the determination of the difference in the occurrence of COPD exacerbations 6 months pre- and postconversion from fluticasone/salmeterol to mometasone/formoterol.	salmeterol xinafoate	151-161	COPD	Homo sapiens	82-86
26327575-0	2015	Impact of ABCB1 single-nucleotide polymorphisms on treatment outcomes with salmeterol/fluticasone combination therapy for stable chronic obstructive pulmonary disease.	salmeterol xinafoate	75-85	ATP binding cassette subfamily B member 1	Homo sapiens	10-15
27885204-0	2016	GENETIC INTERACTIONS BETWEEN ADRB2 AND PTGER4 ON RESPONSES TO SALMETEROL OR MONTELUKAST IN JAPANESE PATIENTS WITH MILD PERSISTENT ASTHMA.	salmeterol xinafoate	62-72	adrenoceptor beta 2	Homo sapiens	29-34
27885204-0	2016	GENETIC INTERACTIONS BETWEEN ADRB2 AND PTGER4 ON RESPONSES TO SALMETEROL OR MONTELUKAST IN JAPANESE PATIENTS WITH MILD PERSISTENT ASTHMA.	salmeterol xinafoate	62-72	prostaglandin E receptor 4	Homo sapiens	39-45
27885204-3	2016	METHODS: We examined if genes encoding CYSLTR1, CYSLTR2, PTGER2 or PTGER4 could explain differential responses to salmeterol versus montelukast using the participants of the J-Blossom study.	salmeterol xinafoate	114-124	prostaglandin E receptor 4	Homo sapiens	67-73
27885204-8	2016	CONCLUSION: Our findings suggested that the interactions between two genetic loci at ADRB2 and PTGER4 is important in determining the differential response to salmeterol versus montelukast in patients with chronic adult asthma.	salmeterol xinafoate	159-169	adrenoceptor beta 2	Homo sapiens	85-90
27885204-8	2016	CONCLUSION: Our findings suggested that the interactions between two genetic loci at ADRB2 and PTGER4 is important in determining the differential response to salmeterol versus montelukast in patients with chronic adult asthma.	salmeterol xinafoate	159-169	prostaglandin E receptor 4	Homo sapiens	95-101
26605551-4	2015	We demonstrate that salmeterol aberrantly promotes activation of the allergic disease-related transcription factor signal transducer and activator of transcription 6 (STAT6) in multiple mouse and human cells.	salmeterol xinafoate	20-30	signal transducer and activator of transcription 6	Mus musculus	115-165
26605551-4	2015	We demonstrate that salmeterol aberrantly promotes activation of the allergic disease-related transcription factor signal transducer and activator of transcription 6 (STAT6) in multiple mouse and human cells.	salmeterol xinafoate	20-30	signal transducer and activator of transcription 6	Mus musculus	167-172
26605551-5	2015	A novel inhibitor of STAT6, PM-242H, inhibited initiation of allergic disease induced by airway fungal challenge, reversed established allergic airway disease in mice, and blocked salmeterol-dependent enhanced allergic airway disease.	salmeterol xinafoate	180-190	signal transducer and activator of transcription 6	Mus musculus	21-26
26327575-1	2015	OBJECTIVES: To investigate the relationship between ABCB1 single-nucleotide polymorphisms and the efficacy of salmeterol/fluticasone combination (SFC) inhalation therapy for stable chronic obstructive pulmonary disease (COPD) in a Chinese Han population.	salmeterol xinafoate	110-120	ATP binding cassette subfamily B member 1	Homo sapiens	52-57
25943421-1	2015	BACKGROUND: After the SMART trial evaluating the safety of salmeterol (long-acting beta-2-agonist (LABA)) in asthma patients, regulatory actions were taken to promote a guideline-adherent prescribing of LABA only to patients receiving inhaled corticosteroids (ICS).	salmeterol xinafoate	59-69	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	83-89
26100349-0	2015	Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD( ).	salmeterol xinafoate	15-25	COPD	Homo sapiens	29-33
26100349-6	2015	For low-risk patients, time to first COPD exacerbation and number of COPD exacerbations were numerically lower with tiotropium versus salmeterol.	salmeterol xinafoate	134-144	COPD	Homo sapiens	69-73
26100349-8	2015	DISCUSSION: This analysis confirms the higher efficacy of tiotropium versus salmeterol in prolonging time to first COPD exacerbation and reducing number of exacerbations in patients both at low and high exacerbation risk.	salmeterol xinafoate	76-86	COPD	Homo sapiens	115-119
25784721-1	2015	Salmeterol is a long-acting beta2-adrenergic receptor (beta2AR) agonist that is widely used as a bronchodilator for the treatment of persistent asthma and chronic obstructive pulmonary disease in conjunction with steroids.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	28-53
25784721-1	2015	Salmeterol is a long-acting beta2-adrenergic receptor (beta2AR) agonist that is widely used as a bronchodilator for the treatment of persistent asthma and chronic obstructive pulmonary disease in conjunction with steroids.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	55-62
25784721-2	2015	Previous studies demonstrated that salmeterol showed weak efficacy for activation of adenylyl cyclase; however, its efficacy in the complex desensitization of the beta2AR remains poorly understood.	salmeterol xinafoate	35-45	adrenoceptor beta 2	Homo sapiens	163-170
25784721-3	2015	In this work, we provide insights into the roles played by the G protein-coupled receptor kinase/arrestin and protein kinase A in salmeterol-mediated desensitization through bioluminescence resonance energy transfer (BRET) studies of liganded-beta2AR binding to arrestin and through kinetic studies of cAMP turnover.	salmeterol xinafoate	130-140	adrenoceptor beta 2	Homo sapiens	243-250
25784721-4	2015	First, BRET demonstrated a much reduced efficacy for salmeterol recruitment of arrestin to beta2AR relative to isoproterenol.	salmeterol xinafoate	53-63	adrenoceptor beta 2	Homo sapiens	91-98
26049917-2	2015	Long-acting beta2-adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases.	salmeterol xinafoate	56-66	adrenoceptor beta 2	Homo sapiens	12-30
26487878-1	2015	BACKGROUND: Formoterol and salmeterol are two long-acting beta2-agonists given by inhalation, with bronchodilating effects lasting for at least 12 h after a single administration.	salmeterol xinafoate	27-37	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	58-63
25823821-2	2015	Here we report that Shp2 is modified by SUMO1 at lysine residue 590 (K590) in its C-terminus, which is reduced by SUMO1-specific protease SENP1.	salmeterol xinafoate	69-73	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	20-24
25823821-2	2015	Here we report that Shp2 is modified by SUMO1 at lysine residue 590 (K590) in its C-terminus, which is reduced by SUMO1-specific protease SENP1.	salmeterol xinafoate	69-73	small ubiquitin like modifier 1	Homo sapiens	40-45
25823821-2	2015	Here we report that Shp2 is modified by SUMO1 at lysine residue 590 (K590) in its C-terminus, which is reduced by SUMO1-specific protease SENP1.	salmeterol xinafoate	69-73	small ubiquitin like modifier 1	Homo sapiens	114-119
25823821-2	2015	Here we report that Shp2 is modified by SUMO1 at lysine residue 590 (K590) in its C-terminus, which is reduced by SUMO1-specific protease SENP1.	salmeterol xinafoate	69-73	SUMO specific peptidase 1	Homo sapiens	138-143
25823821-5	2015	More surprisingly, we show that human Shp2 (hShp2) and mouse Shp2 (mShp2) have differential effects on ERK activation as a result of different SUMOylation level, which is due to the event of K590 at hShp2 substituted by R594 at mShp2.	salmeterol xinafoate	191-195	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	38-42
25823821-5	2015	More surprisingly, we show that human Shp2 (hShp2) and mouse Shp2 (mShp2) have differential effects on ERK activation as a result of different SUMOylation level, which is due to the event of K590 at hShp2 substituted by R594 at mShp2.	salmeterol xinafoate	191-195	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	44-49
25823821-5	2015	More surprisingly, we show that human Shp2 (hShp2) and mouse Shp2 (mShp2) have differential effects on ERK activation as a result of different SUMOylation level, which is due to the event of K590 at hShp2 substituted by R594 at mShp2.	salmeterol xinafoate	191-195	protein tyrosine phosphatase, non-receptor type 11	Mus musculus	45-49
25823821-5	2015	More surprisingly, we show that human Shp2 (hShp2) and mouse Shp2 (mShp2) have differential effects on ERK activation as a result of different SUMOylation level, which is due to the event of K590 at hShp2 substituted by R594 at mShp2.	salmeterol xinafoate	191-195	protein tyrosine phosphatase, non-receptor type 11	Mus musculus	67-72
25823821-5	2015	More surprisingly, we show that human Shp2 (hShp2) and mouse Shp2 (mShp2) have differential effects on ERK activation as a result of different SUMOylation level, which is due to the event of K590 at hShp2 substituted by R594 at mShp2.	salmeterol xinafoate	191-195	mitogen-activated protein kinase 1	Mus musculus	103-106
25823821-5	2015	More surprisingly, we show that human Shp2 (hShp2) and mouse Shp2 (mShp2) have differential effects on ERK activation as a result of different SUMOylation level, which is due to the event of K590 at hShp2 substituted by R594 at mShp2.	salmeterol xinafoate	191-195	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	199-204
25823821-5	2015	More surprisingly, we show that human Shp2 (hShp2) and mouse Shp2 (mShp2) have differential effects on ERK activation as a result of different SUMOylation level, which is due to the event of K590 at hShp2 substituted by R594 at mShp2.	salmeterol xinafoate	191-195	protein tyrosine phosphatase, non-receptor type 11	Mus musculus	228-233
25799096-8	2015	beta2-AR tachyphylaxis was induced with salbutamol, salmeterol and formoterol on guinea pig tracheas.	salmeterol xinafoate	52-62	adrenoceptor beta 2	Homo sapiens	0-8
25926729-5	2015	Combinations of inhaled corticosteroids and long-acting beta2-agonists such as fluticasone and salmeterol, have been shown to be effective for improving symptoms, health status, and reducing exacerbations in both diseases.	salmeterol xinafoate	95-105	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	56-61
25324048-0	2015	Salmeterol"s extreme beta2 selectivity is due to residues in both extracellular loops and transmembrane domains.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	21-26
25324048-1	2015	Salmeterol is a long-acting beta2-agonist, widely used as an inhaled treatment of asthma and chronic obstructive pulmonary disease.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	28-33
25324048-5	2015	Extracellular loop 3 (and specifically amino acid K305) had the largest single effect by reducing salmeterol"s affinity for the beta2-adrenoceptor by 31-fold.	salmeterol xinafoate	98-108	adrenoceptor beta 2	Homo sapiens	128-146
25324048-7	2015	Combining these, in the double mutant beta2-H296K-K305D, reduced salmeterol"s affinity by 275-fold, to within 4-fold of that of the beta1-adrenoceptor, without affecting the affinity or selectivity of other beta2-agonists (salbutamol, formoterol, fenoterol, clenbuterol, or adrenaline).	salmeterol xinafoate	65-75	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	38-43
25324048-7	2015	Combining these, in the double mutant beta2-H296K-K305D, reduced salmeterol"s affinity by 275-fold, to within 4-fold of that of the beta1-adrenoceptor, without affecting the affinity or selectivity of other beta2-agonists (salbutamol, formoterol, fenoterol, clenbuterol, or adrenaline).	salmeterol xinafoate	65-75	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	207-212
24681963-0	2014	The effects of a Gly16Arg ADRB2 polymorphism on responses to salmeterol or montelukast in Japanese patients with mild persistent asthma.	salmeterol xinafoate	61-71	adrenoceptor beta 2	Homo sapiens	26-31
24863408-5	2014	While the beta2-adrenoceptor-selective antagonist ICI 118,551 completely blocked adrenaline-induced TG2 mRNA expression, the beta2-adrenoceptor specific agonist salmeterol increased TG2 expression.	salmeterol xinafoate	161-171	adrenergic receptor, beta 2	Mus musculus	125-143
24863408-5	2014	While the beta2-adrenoceptor-selective antagonist ICI 118,551 completely blocked adrenaline-induced TG2 mRNA expression, the beta2-adrenoceptor specific agonist salmeterol increased TG2 expression.	salmeterol xinafoate	161-171	transglutaminase 2, C polypeptide	Mus musculus	182-185
24076367-13	2014	CONCLUSIONS: After a single dose of long-acting bronchodilator salmeterol, significant improvements are observed in all ILPs and in FIV1 and PIF after tiotropium.	salmeterol xinafoate	63-73	PIF1 5'-to-3' DNA helicase	Homo sapiens	141-144
24388637-0	2014	Salmeterol attenuates chemotactic responses in rhinovirus-induced exacerbation of allergic airways disease by modulating protein phosphatase 2A.	salmeterol xinafoate	0-10	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	Mus musculus	129-143
24388637-9	2014	Salmeterol, but not dexamethasone, increased PP2A activity, which reduced CCL11, CCL20, and CXCL2 expression and reduced levels of phosphorylated extracellular signal-regulated kinase 1 and active nuclear factor kappaB subunits in the lungs.	salmeterol xinafoate	0-10	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	Mus musculus	45-49
24388637-9	2014	Salmeterol, but not dexamethasone, increased PP2A activity, which reduced CCL11, CCL20, and CXCL2 expression and reduced levels of phosphorylated extracellular signal-regulated kinase 1 and active nuclear factor kappaB subunits in the lungs.	salmeterol xinafoate	0-10	chemokine (C-C motif) ligand 11	Mus musculus	74-79
24388637-9	2014	Salmeterol, but not dexamethasone, increased PP2A activity, which reduced CCL11, CCL20, and CXCL2 expression and reduced levels of phosphorylated extracellular signal-regulated kinase 1 and active nuclear factor kappaB subunits in the lungs.	salmeterol xinafoate	0-10	chemokine (C-C motif) ligand 20	Mus musculus	81-86
24388637-9	2014	Salmeterol, but not dexamethasone, increased PP2A activity, which reduced CCL11, CCL20, and CXCL2 expression and reduced levels of phosphorylated extracellular signal-regulated kinase 1 and active nuclear factor kappaB subunits in the lungs.	salmeterol xinafoate	0-10	chemokine (C-X-C motif) ligand 2	Mus musculus	92-97
24388637-9	2014	Salmeterol, but not dexamethasone, increased PP2A activity, which reduced CCL11, CCL20, and CXCL2 expression and reduced levels of phosphorylated extracellular signal-regulated kinase 1 and active nuclear factor kappaB subunits in the lungs.	salmeterol xinafoate	0-10	mitogen-activated protein kinase 3	Mus musculus	146-185
24388637-10	2014	The anti-inflammatory effect of salmeterol was blocked by targeting the catalytic subunit of PP2A with small RNA interference.	salmeterol xinafoate	32-42	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	Mus musculus	93-97
24388637-12	2014	Salmeterol also directly activated immunoprecipitated PP2A in vitro isolated from human airway epithelial cells.	salmeterol xinafoate	0-10	protein phosphatase 2 phosphatase activator	Homo sapiens	54-58
24388637-13	2014	CONCLUSIONS: Salmeterol exerts anti-inflammatory effects by increasing PP2A activity in AAD and rhinovirus-induced lung inflammation, which might potentially account for some of its clinical benefits.	salmeterol xinafoate	13-23	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	Mus musculus	71-75
26051688-1	2015	Salmeterol xinafoate is a potent and a long-acting beta2-adrenoceptor agonist.	salmeterol xinafoate	0-20	adrenoceptor beta 2	Homo sapiens	51-69
24721141-1	2014	BACKGROUND: To evaluate the effect of variation of the Arg16Gly polymorphism of the beta2-adrenergic receptor gene on clinical response to salmeterol administered with fluticasone propionate in Chinese Han asthmatic patients.	salmeterol xinafoate	139-149	adrenoceptor beta 2	Homo sapiens	84-109
24561123-8	2014	Our results suggest that beta2AR activation with salmeterol can induce the dissociation of heterotrimeric G-proteins, Galphabetagamma, into Galpha and Gbetagamma subunits, which in turn activates downstream signaling cascades.	salmeterol xinafoate	49-59	adrenoceptor beta 2	Homo sapiens	25-32
24561123-8	2014	Our results suggest that beta2AR activation with salmeterol can induce the dissociation of heterotrimeric G-proteins, Galphabetagamma, into Galpha and Gbetagamma subunits, which in turn activates downstream signaling cascades.	salmeterol xinafoate	49-59	succinate-CoA ligase GDP/ADP-forming subunit alpha	Homo sapiens	118-124
27905766-2	2014	Long-acting beta-2 agonists (formoterol, salmeterol) and / or tiotropium are recommended for long-term drug treatment from stage II.	salmeterol xinafoate	41-51	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	12-18
24374096-3	2014	This adrenaline-induced REDD1 expression was completely blocked by beta2-adrenoceptor selective antagonist ICI 118,551, whereas beta2-adrenoceptor specific agonist salmeterol markedly enhanced REDD1 expression.	salmeterol xinafoate	164-174	adrenergic receptor, beta 2	Mus musculus	128-146
24374096-3	2014	This adrenaline-induced REDD1 expression was completely blocked by beta2-adrenoceptor selective antagonist ICI 118,551, whereas beta2-adrenoceptor specific agonist salmeterol markedly enhanced REDD1 expression.	salmeterol xinafoate	164-174	DNA-damage-inducible transcript 4	Mus musculus	193-198
24669382-17	2014	When an inhaled long-acting drug is contemplated, it is best to choose a beta-2 agonist (formoterol or salmeterol), used either continuously or on demand.	salmeterol xinafoate	103-113	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	73-79
24163441-3	2014	In human bronchial epithelial BEAS-2B cells (bronchial epithelium + adenovirus 12-SV40 hybrid), regulator of G-protein signaling (RGS) 2 mRNA and protein were synergistically induced in response to combinations of long-acting beta2-adrenoceptor agonist (LABA) (salmeterol, formoterol) plus glucocorticoid (dexamethasone, fluticasone propionate, budesonide).	salmeterol xinafoate	261-271	regulator of G protein signaling 2	Homo sapiens	96-136
24126345-8	2014	CM from glial cells treated with the beta2-adrenoceptor agonists salmeterol and clenbuterol, but not the beta1-adrenoceptor agonist xamoterol, mimicked the ability of NA to increase neuronal complexity.	salmeterol xinafoate	65-75	adrenoceptor beta 2	Rattus norvegicus	37-55
24163441-7	2014	This was significantly attenuated by salmeterol plus dexamethasone pretreatment, or RGS2 overexpression, and the protective effect of salmeterol plus dexamethasone was abolished by RGS2 RNA silencing.	salmeterol xinafoate	134-144	regulator of G protein signaling 2	Homo sapiens	181-185
23973634-3	2013	The main novelty of the present work deals with the analysis of salmeterol in dried blood spot with significant advantages with regard to invasive sampling, volume of blood used (<20 muL), storage and transport of biological materials and requirements for special biohazard arrangements.	salmeterol xinafoate	64-74	tripartite motif containing 37	Homo sapiens	186-189
24163441-8	2014	Although methacholine and U46619 induced interleukin-8 (IL-8) release and this was inhibited by RGS2 overexpression, the repression of U46619-induced IL-8 release by salmeterol plus dexamethasone was unaffected by RGS2 knockdown.	salmeterol xinafoate	166-176	regulator of G protein signaling 2	Homo sapiens	96-100
24163441-8	2014	Although methacholine and U46619 induced interleukin-8 (IL-8) release and this was inhibited by RGS2 overexpression, the repression of U46619-induced IL-8 release by salmeterol plus dexamethasone was unaffected by RGS2 knockdown.	salmeterol xinafoate	166-176	C-X-C motif chemokine ligand 8	Homo sapiens	150-154
23925644-2	2014	The recent Groningen and Leiden Universities study of Corticosteroids in Obstructive Lung Disease (GLUCOLD) study suggested that particular phenotypes of COPD benefit from fluticasone+-salmeterol by reducing the rate of FEV1 decline, yet the underlying mechanisms are unknown.	salmeterol xinafoate	185-195	COPD	Homo sapiens	154-158
24010736-10	2013	Nominally statistically significant decreases were demonstrated in daytime (p = 0.023), night-time (p = 0.041) and 24 h (p = 0.019) short-acting beta 2 agonist usage with FP/salmeterol + GSK2190915 300 mg vs. FP/salmeterol + placebo.	salmeterol xinafoate	174-184	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	145-151
24010736-10	2013	Nominally statistically significant decreases were demonstrated in daytime (p = 0.023), night-time (p = 0.041) and 24 h (p = 0.019) short-acting beta 2 agonist usage with FP/salmeterol + GSK2190915 300 mg vs. FP/salmeterol + placebo.	salmeterol xinafoate	212-222	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	145-151
24461901-0	2014	Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.	salmeterol xinafoate	49-59	COPD	Homo sapiens	89-93
24461901-2	2014	We aimed to establish whether ADRB2 polymorphisms differentially affected COPD exacerbation outcomes in response to tiotropium versus salmeterol.	salmeterol xinafoate	134-144	adrenoceptor beta 2	Homo sapiens	30-35
24228710-0	2013	Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide.	salmeterol xinafoate	8-18	adrenoceptor beta 2	Homo sapiens	69-74
23996715-2	2013	This study was designed to evaluate the effect of polymorphism of beta2 adrenoceptors on response to salmeterol and fluticasone (as inhaled Seretide).Sixty-four patients with either mild or moderate-severe asthma were evaluated in this study.	salmeterol xinafoate	101-111	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	66-71
23971870-2	2013	Long-acting muscarinic antagonists such as glycopyrronium and tiotropium, along with long-acting beta-2 agonists such as indacaterol, formoterol and salmeterol are the pillars of pharmacological therapy for the long-term management of patients with COPD.	salmeterol xinafoate	149-159	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	97-103
23548523-0	2013	Influence of beta(2)-adrenergic receptor polymorphisms on asthma exacerbation in children with severe asthma regularly receiving salmeterol.	salmeterol xinafoate	129-139	adrenoceptor beta 2	Homo sapiens	13-40
23348973-5	2013	The twice-daily beta2-agonists formoterol and salmeterol represent important advances.	salmeterol xinafoate	46-56	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	16-21
23098359-1	2013	OBJECTIVE: The long-acting beta2-agonist salmeterol in combination with the corticosteroid fluticasone propionate is used in clinical practice for the treatment of mild persistent asthma.	salmeterol xinafoate	41-51	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	27-32
23375225-1	2013	A novel class of dual pharmacology bronchodilators targeting both beta(2)-adrenoceptor and PDE4 was designed and synthesised by combining the pharmacophores of salmeterol and roflumilast or phthalazinone.	salmeterol xinafoate	160-170	adrenoceptor beta 2	Homo sapiens	66-86
23375225-1	2013	A novel class of dual pharmacology bronchodilators targeting both beta(2)-adrenoceptor and PDE4 was designed and synthesised by combining the pharmacophores of salmeterol and roflumilast or phthalazinone.	salmeterol xinafoate	160-170	phosphodiesterase 4A	Homo sapiens	91-95
23375225-2	2013	All the compounds exhibited better beta(2)-adrenoceptor agonist activities (pEC(50)=8.47-9.20) than the reference compound salmeterol (pEC(50)=8.3) and good inhibitory activity on PDE4B2 (IC(50)=0.235-1.093 muM).	salmeterol xinafoate	123-133	adrenoceptor beta 2	Homo sapiens	35-55
23296426-7	2013	Under lipopolysaccharide (LPS) stimulation, tumor necrosis factor (TNF)-alpha produced by splenic MNCs was 117% higher in LCR sham and 52% higher in LCR surgery compared with HCR sham and surgery rats; LPS-stimulated TNF-alpha production could not be inhibited by an alpha7 nicotinic acetylcholine receptor agonist, whereas inhibition by the beta(2) adrenergic agonist, salmeterol, was significantly less (-35%) than that obtained in HCR rats.	salmeterol xinafoate	370-380	tumor necrosis factor	Rattus norvegicus	44-77
22914602-4	2012	OBJECTIVE: To study the effects and signaling pathways of formoterol and salmeterol on polyriboinosinic polyribocytidylic acid (poly I:C)-induced IP-10 expression in BEAS-2B cells.	salmeterol xinafoate	73-83	C-X-C motif chemokine ligand 10	Homo sapiens	146-151
23302644-9	2013	Salmeterol, a specific beta(2)-AR agonist, broke beta(1)-AR/beta(2)-AR heterooligomers, and induced beta(2)-AR-specific internalization in cells co-expressing beta(1)-AR and beta(2)-AR.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	23-33
23302644-9	2013	Salmeterol, a specific beta(2)-AR agonist, broke beta(1)-AR/beta(2)-AR heterooligomers, and induced beta(2)-AR-specific internalization in cells co-expressing beta(1)-AR and beta(2)-AR.	salmeterol xinafoate	0-10	adrenoceptor beta 1	Homo sapiens	49-59
23302644-9	2013	Salmeterol, a specific beta(2)-AR agonist, broke beta(1)-AR/beta(2)-AR heterooligomers, and induced beta(2)-AR-specific internalization in cells co-expressing beta(1)-AR and beta(2)-AR.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	60-70
23302644-9	2013	Salmeterol, a specific beta(2)-AR agonist, broke beta(1)-AR/beta(2)-AR heterooligomers, and induced beta(2)-AR-specific internalization in cells co-expressing beta(1)-AR and beta(2)-AR.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	60-70
23302644-9	2013	Salmeterol, a specific beta(2)-AR agonist, broke beta(1)-AR/beta(2)-AR heterooligomers, and induced beta(2)-AR-specific internalization in cells co-expressing beta(1)-AR and beta(2)-AR.	salmeterol xinafoate	0-10	adrenoceptor beta 1	Homo sapiens	159-169
23302644-9	2013	Salmeterol, a specific beta(2)-AR agonist, broke beta(1)-AR/beta(2)-AR heterooligomers, and induced beta(2)-AR-specific internalization in cells co-expressing beta(1)-AR and beta(2)-AR.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	60-70
23302644-10	2013	The present study demonstrated that heterooligomerization between beta(1)-AR and beta(2)-AR accelerates the isoproterenol-promoted internalization of the beta(1)-AR, and that salmeterol induces beta(2)-AR-specific internalization in Chinese hamster ovary (CHO) cells stably co-expressing beta(1)-AR and beta(2)-AR.	salmeterol xinafoate	175-185	adrenoceptor beta 2	Homo sapiens	194-204
23302644-10	2013	The present study demonstrated that heterooligomerization between beta(1)-AR and beta(2)-AR accelerates the isoproterenol-promoted internalization of the beta(1)-AR, and that salmeterol induces beta(2)-AR-specific internalization in Chinese hamster ovary (CHO) cells stably co-expressing beta(1)-AR and beta(2)-AR.	salmeterol xinafoate	175-185	adrenoceptor beta 2	Homo sapiens	194-204
23533638-3	2013	To address this, we investigated MKP-1 gene expression and protein upregulation induced by two long-acting beta2-agonists (salmeterol and formoterol), alone or in combination with the corticosteroid fluticasone propionate (abbreviated as fluticasone) in primary human airway smooth muscle (ASM) cells in vitro.	salmeterol xinafoate	123-133	dual specificity phosphatase 1	Homo sapiens	33-38
23131487-1	2012	Salmeterol, a long-acting beta2-adrenergic receptor agonist used for the treatment of asthma and chronic obstructive pulmonary disease, has an adverse effects profile that is similar to that of salbutamol and other beta2-agonists.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	26-51
23131487-1	2012	Salmeterol, a long-acting beta2-adrenergic receptor agonist used for the treatment of asthma and chronic obstructive pulmonary disease, has an adverse effects profile that is similar to that of salbutamol and other beta2-agonists.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	26-31
23131487-10	2012	We hypothesize that stimulation of beta2-adrenergic receptors by inhalation of salmeterol caused this patient"s lactic acidosis.	salmeterol xinafoate	79-89	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	35-40
23034049-6	2012	RESULTS: Fluticasone and/or salmeterol at 1 and 100 nM inhibited CXCL10 release induced by IL-1beta and TNF-alpha, but not IFNgamma or all three cytokines (cytomix).	salmeterol xinafoate	28-38	C-X-C motif chemokine ligand 10	Homo sapiens	65-71
23034049-6	2012	RESULTS: Fluticasone and/or salmeterol at 1 and 100 nM inhibited CXCL10 release induced by IL-1beta and TNF-alpha, but not IFNgamma or all three cytokines (cytomix).	salmeterol xinafoate	28-38	interleukin 1 beta	Homo sapiens	91-99
23034049-6	2012	RESULTS: Fluticasone and/or salmeterol at 1 and 100 nM inhibited CXCL10 release induced by IL-1beta and TNF-alpha, but not IFNgamma or all three cytokines (cytomix).	salmeterol xinafoate	28-38	tumor necrosis factor	Homo sapiens	104-113
23034049-8	2012	In asthmatic ASMC low salmeterol, but not formoterol, concentrations increased cytomix-induced CXCL10 release and at 0.01 nM enhanced NF-kappaB activity.	salmeterol xinafoate	22-32	C-X-C motif chemokine ligand 10	Homo sapiens	95-101
23034049-9	2012	Salmeterol 0.1 nM together with fluticasone 0.1 and 10 nM still increased CXCL10 release.	salmeterol xinafoate	0-10	C-X-C motif chemokine ligand 10	Homo sapiens	74-80
22948082-5	2013	We investigated the effects of corticosteroids plus long-acting beta(2)-agonists (LABAs; fluticasone/salmeterol or budesonide/formoterol) on the expression of B7-H1.	salmeterol xinafoate	101-111	CD274 antigen	Mus musculus	159-164
22948082-14	2013	CONCLUSIONS: Fluticasone/salmeterol or budesonide/formoterol attenuate the virus-associated upregulation of B7-H1 on airway epithelial cells via suppression of NF-kB activation.	salmeterol xinafoate	25-35	CD274 antigen	Mus musculus	108-113
21740451-8	2012	Salmeterol, formoterol and indacaterol significantly reduced COPD exacerbations compared with placebo.	salmeterol xinafoate	0-10	COPD	Homo sapiens	61-65
22231554-1	2012	Salmeterol is a long-acting beta2-agonist that activates adenylate cyclase, causing long-lasting bronchodilation and has been used for many years to control asthma.	salmeterol xinafoate	0-10	hemoglobin, beta adult minor chain	Mus musculus	28-33
22231554-3	2012	We found that salmeterol decreases the production of pro-inflammatory cytokines in a model of allergen-challenged mice that expressed tumor-necrosis factor-alpha, interleukin-1 and interleukin-6.	salmeterol xinafoate	14-24	tumor necrosis factor	Mus musculus	134-161
22231554-3	2012	We found that salmeterol decreases the production of pro-inflammatory cytokines in a model of allergen-challenged mice that expressed tumor-necrosis factor-alpha, interleukin-1 and interleukin-6.	salmeterol xinafoate	14-24	interleukin 6	Mus musculus	181-194
21740451-9	2012	Salmeterol significantly reduced COPD exacerbations with both study arms exposed or not exposed to inhaled corticosteroids (ICS).	salmeterol xinafoate	0-10	COPD	Homo sapiens	33-37
21740451-14	2012	Salmeterol, formoterol and indacaterol significantly reduced COPD exacerbations compared with placebo.	salmeterol xinafoate	0-10	COPD	Homo sapiens	61-65
22306235-4	2012	Salmeterol or formoterol caused a concentration-dependent inhibition of tumor necrosis factor-alpha (TNFalpha) secretion with an IC50 of 0.33 pM (C.I.	salmeterol xinafoate	0-10	tumor necrosis factor	Homo sapiens	72-99
22409290-12	2012	The cost-effectiveness studies of tiotropium versus placebo, ipratropium or salmeterol pointed towards a reduction in total COPD-related healthcare costs for tiotropium in many but not all studies.	salmeterol xinafoate	76-86	COPD	Homo sapiens	124-128
22306235-4	2012	Salmeterol or formoterol caused a concentration-dependent inhibition of tumor necrosis factor-alpha (TNFalpha) secretion with an IC50 of 0.33 pM (C.I.	salmeterol xinafoate	0-10	tumor necrosis factor	Homo sapiens	101-109
22306235-10	2012	The inhibition of TNFalpha production with salmeterol was both beta2 adrenoceptor- and protein kinase A-dependent.	salmeterol xinafoate	43-53	tumor necrosis factor	Homo sapiens	18-26
22306235-10	2012	The inhibition of TNFalpha production with salmeterol was both beta2 adrenoceptor- and protein kinase A-dependent.	salmeterol xinafoate	43-53	adrenoceptor beta 2	Homo sapiens	63-82
22306235-12	2012	Roflumilast in combination with salmeterol, formoterol, or dexamethasone increased the inhibition of LPS-induced TNFalpha from human PBMC, in an additive manner.	salmeterol xinafoate	32-42	tumor necrosis factor	Homo sapiens	113-121
22155101-0	2012	Fluticasone propionate and Salmeterol combination induces SOCS-3 expression in airway epithelial cells.	salmeterol xinafoate	27-37	suppressor of cytokine signaling 3	Homo sapiens	58-64
22245487-3	2012	This pilot study investigated the acute effects of the long-acting beta-2 agonist, salmeterol, on alveolar fluid clearance after rapid saline intravenous infusion by evaluating diffusive and mechanical lung properties.	salmeterol xinafoate	83-93	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	67-73
22035853-7	2012	A combination of an inhaled corticosteroid and a long-acting beta-2 agonist was the reported therapy by 56.0% of patients, with the rate of controlled asthma and improved quality of life being higher in patients on extrafine beclomethasone/formoterol compared to budesonide/formoterol (p<0.05) and fluticasone/salmeterol (p<0.05 for quality of life).	salmeterol xinafoate	313-323	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	61-67
22328823-8	2012	In additional experiments, some cells were treated with 10 uM salmeterol for 24 h following transfection with IRS-1 shRNA.	salmeterol xinafoate	62-72	insulin receptor substrate 1	Homo sapiens	110-115
22110065-7	2011	Salmeterol (10 muM), a beta-2-adrenergic receptor agonist, significantly increased phosphorylation of both insulin receptor and Akt.	salmeterol xinafoate	0-10	AKT serine/threonine kinase 1	Homo sapiens	128-131
22328823-11	2012	Treatment with the selective beta-2-adrenergic receptor agonist, salmeterol, significantly decreased phosphorylation of IRS-1(Ser307).	salmeterol xinafoate	65-75	insulin receptor substrate 1	Homo sapiens	120-125
22328823-12	2012	Following IRS-1 shRNA transfection+salmeterol treatment, Bcl-2-associated X protein (Bax) and cytochrome c levels were significantly decreased.	salmeterol xinafoate	35-45	insulin receptor substrate 1	Homo sapiens	10-15
22328823-12	2012	Following IRS-1 shRNA transfection+salmeterol treatment, Bcl-2-associated X protein (Bax) and cytochrome c levels were significantly decreased.	salmeterol xinafoate	35-45	BCL2 associated X, apoptosis regulator	Homo sapiens	57-83
22328823-12	2012	Following IRS-1 shRNA transfection+salmeterol treatment, Bcl-2-associated X protein (Bax) and cytochrome c levels were significantly decreased.	salmeterol xinafoate	35-45	BCL2 associated X, apoptosis regulator	Homo sapiens	85-88
22328823-12	2012	Following IRS-1 shRNA transfection+salmeterol treatment, Bcl-2-associated X protein (Bax) and cytochrome c levels were significantly decreased.	salmeterol xinafoate	35-45	cytochrome c, somatic	Homo sapiens	94-106
22328823-13	2012	Salmeterol+IRS-1 shRNA also decreased cell death and increased protein levels of B-cell lymphoma-extra large (Bcl-xL), an anti-apoptotic factor.	salmeterol xinafoate	0-10	insulin receptor substrate 1	Homo sapiens	11-16
22328823-13	2012	Salmeterol+IRS-1 shRNA also decreased cell death and increased protein levels of B-cell lymphoma-extra large (Bcl-xL), an anti-apoptotic factor.	salmeterol xinafoate	0-10	BCL2 like 1	Homo sapiens	110-116
22328823-14	2012	CONCLUSIONS: In these studies, we show for the first time that salmeterol, a beta-2-adrenergic receptor agonist, can reduce retinal Muller cell death through IRS-1 actions.	salmeterol xinafoate	63-73	insulin receptor substrate 1	Homo sapiens	158-163
23300522-4	2012	We show that the select ligands bind preferentially to different predicted conformers of beta(2)AR, and identify a role of beta(2)AR extracellular region as an allosteric binding site for larger drugs such as salmeterol.	salmeterol xinafoate	209-219	adrenoceptor beta 2	Homo sapiens	89-98
23300522-4	2012	We show that the select ligands bind preferentially to different predicted conformers of beta(2)AR, and identify a role of beta(2)AR extracellular region as an allosteric binding site for larger drugs such as salmeterol.	salmeterol xinafoate	209-219	adrenoceptor beta 2	Homo sapiens	123-132
22110065-8	2011	TNF-alpha shRNA significantly decreased phosphorylation of IRS-1(Ser307), which was further decreased after salmeterol+TNF-alpha shRNA.	salmeterol xinafoate	108-118	tumor necrosis factor	Homo sapiens	0-9
22110065-7	2011	Salmeterol (10 muM), a beta-2-adrenergic receptor agonist, significantly increased phosphorylation of both insulin receptor and Akt.	salmeterol xinafoate	0-10	latexin	Homo sapiens	15-18
22110065-7	2011	Salmeterol (10 muM), a beta-2-adrenergic receptor agonist, significantly increased phosphorylation of both insulin receptor and Akt.	salmeterol xinafoate	0-10	insulin receptor	Homo sapiens	107-123
21552152-9	2011	Exposure of myoblasts and myotubes for 48 and 72 h at high salmeterol concentrations induced apoptosis by the activation of the intrinsic apoptotic pathway, as confirmed by the modulation of the apoptotic proteins Bcl-xL, caspase-9, and poly (ADP-ribose) polymerase and by the cytoplasmic release of Smac/DIABLO.	salmeterol xinafoate	59-69	BCL2-like 1	Mus musculus	214-220
22032685-0	2011	Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4+CD25+Foxp3+ regulatory T cells in COPD.	salmeterol xinafoate	57-67	CD4 molecule	Homo sapiens	102-105
21552152-1	2011	PURPOSE: Salmeterol is a beta2-adrenergic receptor agonist widely used for the treatment of asthma and chronic obstructive pulmonary disease.	salmeterol xinafoate	9-19	adrenergic receptor, beta 2	Mus musculus	25-50
21552152-9	2011	Exposure of myoblasts and myotubes for 48 and 72 h at high salmeterol concentrations induced apoptosis by the activation of the intrinsic apoptotic pathway, as confirmed by the modulation of the apoptotic proteins Bcl-xL, caspase-9, and poly (ADP-ribose) polymerase and by the cytoplasmic release of Smac/DIABLO.	salmeterol xinafoate	59-69	caspase 9	Mus musculus	222-231
21552152-9	2011	Exposure of myoblasts and myotubes for 48 and 72 h at high salmeterol concentrations induced apoptosis by the activation of the intrinsic apoptotic pathway, as confirmed by the modulation of the apoptotic proteins Bcl-xL, caspase-9, and poly (ADP-ribose) polymerase and by the cytoplasmic release of Smac/DIABLO.	salmeterol xinafoate	59-69	diablo, IAP-binding mitochondrial protein	Mus musculus	300-304
21552152-9	2011	Exposure of myoblasts and myotubes for 48 and 72 h at high salmeterol concentrations induced apoptosis by the activation of the intrinsic apoptotic pathway, as confirmed by the modulation of the apoptotic proteins Bcl-xL, caspase-9, and poly (ADP-ribose) polymerase and by the cytoplasmic release of Smac/DIABLO.	salmeterol xinafoate	59-69	diablo, IAP-binding mitochondrial protein	Mus musculus	305-311
22032685-0	2011	Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4+CD25+Foxp3+ regulatory T cells in COPD.	salmeterol xinafoate	57-67	forkhead box P3	Homo sapiens	111-116
21134482-1	2011	Long acting beta(2)-adrenoceptor agonists as exemplified by salmeterol and formoterol, exhibit reassertion behaviour in isolated airway preparations.	salmeterol xinafoate	60-70	adrenoceptor beta 2	Homo sapiens	12-32
21364311-3	2011	CASE SUMMARY: A previously healthy 64-year-old man presented with a four-month history of productive cough and progressive dyspnea despite a combination therapy with inhaled salmeterol (50 mug bid) and fluticasone (500 mug bid), sustained-release theophylline, and pranlukast because of suspicion of asthma.	salmeterol xinafoate	174-184	BH3 interacting domain death agonist	Homo sapiens	193-196
21306583-0	2011	Formoterol and salmeterol induce a similar degree of beta2-adrenoceptor tolerance in human small airways but via different mechanisms.	salmeterol xinafoate	15-25	adrenoceptor beta 2	Homo sapiens	53-71
21357659-2	2011	Although these agents first were used many years ago, progress in drug development has resulted in better tolerated, long-acting beta(2)-AR agonists (LABAs), such as formoterol and salmeterol.	salmeterol xinafoate	181-191	adrenoceptor beta 2	Homo sapiens	129-139
21335487-2	2011	The purpose of this study was to determine neuroprotective effects of long-acting beta2AR agonists such as salmeterol in rodent models of Parkinson"s disease.	salmeterol xinafoate	107-117	adenosine A2a receptor	Mus musculus	82-89
21335487-5	2011	Salmeterol significantly inhibited LPS-induced production of microglial proinflammatory neurotoxic mediators, such as TNF-alpha, superoxide, and NO, as well as the inhibition of TAK1-mediated phosphorylation of MAPK and p65 NF-kappaB.	salmeterol xinafoate	0-10	tumor necrosis factor	Mus musculus	118-127
21335487-5	2011	Salmeterol significantly inhibited LPS-induced production of microglial proinflammatory neurotoxic mediators, such as TNF-alpha, superoxide, and NO, as well as the inhibition of TAK1-mediated phosphorylation of MAPK and p65 NF-kappaB.	salmeterol xinafoate	0-10	mitogen-activated protein kinase kinase kinase 7	Mus musculus	178-182
21335487-5	2011	Salmeterol significantly inhibited LPS-induced production of microglial proinflammatory neurotoxic mediators, such as TNF-alpha, superoxide, and NO, as well as the inhibition of TAK1-mediated phosphorylation of MAPK and p65 NF-kappaB.	salmeterol xinafoate	0-10	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	220-233
21335487-6	2011	The anti-inflammatory effects of salmeterol required beta2AR expression in microglia but were not mediated through the conventional G protein-coupled receptor/cAMP pathway.	salmeterol xinafoate	33-43	adenosine A2a receptor	Mus musculus	53-60
21335487-7	2011	Rather, salmeterol failed to induce microglial cAMP production, could not be reversed by either protein kinase A inhibitors or an exchange protein directly activated by cAMP agonist, and was dependent on beta-arrestin2 expression.	salmeterol xinafoate	8-18	arrestin, beta 2	Mus musculus	204-218
21335487-8	2011	Taken together, our results demonstrate that administration of extremely low doses of salmeterol exhibit potent neuroprotective effects by inhibiting microglial cell activation through a beta2AR/beta-arrestin2-dependent but cAMP/protein kinase A-independent pathway.	salmeterol xinafoate	86-96	adenosine A2a receptor	Mus musculus	185-199
21536121-8	2011	The noradrenaline-induced enhancement of IL-33 production was completely blocked by beta(2)-adrenoceptor specific antagonist ICI 118,551, while beta(2)-adrenoceptor specific agonist salmeterol enhanced DC production of IL-33.	salmeterol xinafoate	182-192	adrenergic receptor, beta 2	Mus musculus	144-164
21536121-8	2011	The noradrenaline-induced enhancement of IL-33 production was completely blocked by beta(2)-adrenoceptor specific antagonist ICI 118,551, while beta(2)-adrenoceptor specific agonist salmeterol enhanced DC production of IL-33.	salmeterol xinafoate	182-192	interleukin 33	Mus musculus	219-224
21912333-1	2011	Salmeterol is a frequently prescribed beta2-agonist used for the treatment of asthma.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	38-43
21912333-2	2011	Due to performance-enhancing effects of some beta2-agonists, salmeterol appears on the prohibited list published by the World Anti-Doping Agency and its therapeutic use is allowed but restricted to inhalation.	salmeterol xinafoate	61-71	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	45-50
20656951-6	2011	We further examined the effects of corticosteroids and a long-acting beta(2)-agonist (salmeterol) on the expression levels of the TSLP gene in response to poly(I:C) in NHBE.	salmeterol xinafoate	86-96	thymic stromal lymphopoietin	Homo sapiens	130-134
20656951-10	2011	Moreover, the induction of TSLP mRNA and protein expression induced by poly(I:C) in NHBE was synergistically impaired by a corticosteroid and salmeterol.	salmeterol xinafoate	142-152	thymic stromal lymphopoietin	Homo sapiens	27-31
21814459-3	2011	Long-acting beta-2-agonists include the twice-daily drugs formoterol and salmeterol and, more recently, once-daily indacaterol.	salmeterol xinafoate	73-83	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	12-18
21134482-5	2011	Results are discussed in the context of the two theories proposed to explain the long duration of action of salmeterol (binding to a specific "exosite" of the beta(2)-adrenoceptor) and formoterol (membrane deposition: micro-kinetic theory).	salmeterol xinafoate	108-118	adrenoceptor beta 2	Homo sapiens	159-179
21504260-7	2011	Adjusted COPD-related total (medical plus pharmacy) costs were lower in the fluticasone propionate-salmeterol cohort ($240 vs $279 per patient per month, P <.05), mostly because of lower medical costs ($113 vs $160 per patient per month, P <.05).	salmeterol xinafoate	99-109	COPD	Homo sapiens	9-13
21942463-0	2011	Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.	salmeterol xinafoate	67-77	COPD	Homo sapiens	82-86
20625276-5	2010	Tiotropium, a long-acting anticholinergic, and salmeterol/fluticasone, a long-acting beta-agonist/inhaled corticosteroid combination, are Food and Drug Administration-approved maintenance therapies to reduce exacerbations of COPD.	salmeterol xinafoate	47-57	COPD	Homo sapiens	225-229
21633719-1	2011	OBJECTIVE: This study was designed to demonstrate that four weeks of fluticasone propionate (FP) 100 micrograms (mcg) combined with salmeterol 50 mcg twice daily (BID) via DISKUS( ) resulted in protection against bronchospasm induced by activity, as measured by standardized exercise challenge testing in pediatric and adolescent subjects who required regular use of inhaled corticosteroids for the treatment of persistent asthma.	salmeterol xinafoate	132-142	BH3 interacting domain death agonist	Homo sapiens	163-166
21034447-3	2010	Inhaled long-acting beta2-agonists (LABAs) have been licensed for the treatment of COPD since the late 1990s and include formoterol and salmeterol.	salmeterol xinafoate	136-146	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	20-25
20819623-12	2010	CONCLUSION: Salmeterol/fluticasone treatment reduced circulating C-reactive protein concentration in clinically stable moderate-to-severe chronic obstructive pulmonary disease patients after 6-month treatment.	salmeterol xinafoate	12-22	C-reactive protein	Homo sapiens	65-83
20590599-6	2010	KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the beta(2)-adrenoceptor over the beta(1) or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity.	salmeterol xinafoate	108-118	adrenoceptor beta 2	Homo sapiens	143-163
20590599-6	2010	KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the beta(2)-adrenoceptor over the beta(1) or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity.	salmeterol xinafoate	108-118	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	173-180
20819623-0	2010	Salmeterol/fluticasone treatment reduces circulating C-reactive protein level in patients with stable chronic obstructive pulmonary disease.	salmeterol xinafoate	0-10	C-reactive protein	Homo sapiens	53-71
20631816-0	2010	The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.	salmeterol xinafoate	35-45	COPD	Homo sapiens	97-101
20819623-3	2010	We evaluated the effect of salmeterol/fluticasone propionate on circulating C-reactive protein level in stable chronic obstructive pulmonary disease patients.	salmeterol xinafoate	27-37	C-reactive protein	Homo sapiens	76-94
20819623-9	2010	Compared with ipratropium/albuterol, the combination of salmeterol/fluticasone significantly reduced circulating level of C-reactive protein (-1.73 vs. 0.08 mg/L, respectively, P < 0.05) after 6-month treatment.	salmeterol xinafoate	56-66	C-reactive protein	Homo sapiens	122-140
20819623-11	2010	Salmeterol/fluticasone treatment subjects who had a decrease of circulating C-reactive protein level had a significant improvement in FEV(1) and St George"s Respiratory Questionnaire total scores compared with those who did not (185 vs. 83 ml and -5.71 vs. -1.79 units, respectively, both P < 0.01).	salmeterol xinafoate	0-10	C-reactive protein	Homo sapiens	76-94
19926732-6	2010	Formoterol and salmeterol inhibited LPS-stimulated release of TNF-alpha (mean effective concentration (EC(50)) 2.4+/-1.8 and 3.5+/-2.7 nM, respectively; n = 11-16), GM-CSF (EC(50) 24.6+/-2.1 and 52.4+/-40.8 nM, respectively, n = 11-12) but not CXCL8 from LPS-stimulated MDM.	salmeterol xinafoate	15-25	tumor necrosis factor	Homo sapiens	62-71
19926732-6	2010	Formoterol and salmeterol inhibited LPS-stimulated release of TNF-alpha (mean effective concentration (EC(50)) 2.4+/-1.8 and 3.5+/-2.7 nM, respectively; n = 11-16), GM-CSF (EC(50) 24.6+/-2.1 and 52.4+/-40.8 nM, respectively, n = 11-12) but not CXCL8 from LPS-stimulated MDM.	salmeterol xinafoate	15-25	colony stimulating factor 2	Homo sapiens	165-171
19926732-6	2010	Formoterol and salmeterol inhibited LPS-stimulated release of TNF-alpha (mean effective concentration (EC(50)) 2.4+/-1.8 and 3.5+/-2.7 nM, respectively; n = 11-16), GM-CSF (EC(50) 24.6+/-2.1 and 52.4+/-40.8 nM, respectively, n = 11-12) but not CXCL8 from LPS-stimulated MDM.	salmeterol xinafoate	15-25	C-X-C motif chemokine ligand 8	Homo sapiens	244-249
20631816-5	2010	The present non-systematic review summarizes the role of fluticasone propionate/salmeterol combination therapy in the prevention of exacerbations of COPD and its related effects on lung function, survival, health status, and healthcare costs.	salmeterol xinafoate	80-90	COPD	Homo sapiens	149-153
20045483-6	2010	The glucocorticoid dexamethasone and the short-acting beta2 adrenergic agonist (beta2 agonist) salbutamol suppressed IL-13-augumented basal [Ca(2+)](i), Ca(2+) release and SOCE, whereas the long-acting beta2 agonist salmeterol had no effect on altered Ca(2+) signaling in IL-13-treated ASMCs.	salmeterol xinafoate	216-226	interleukin 13	Rattus norvegicus	117-122
19666775-3	2009	Cultured human ASM cells and isolated rabbit ASM tissues exposed for 24 h to the long-acting beta2AR agonist salmeterol exhibited impaired acute beta2AR-mediated cAMP accumulation and relaxation, respectively, together with ASM constrictor hyperresponsiveness.	salmeterol xinafoate	109-119	adrenoceptor beta 2	Homo sapiens	93-100
20045483-8	2010	IL-13 promoted the proliferation of ASMCs stimulated by serum; this effect was inhibited by nonspecific Ca(2+) channel blockers SKF-96365 and NiCl(2), by salmeterol, but not by salbutamol and dexamethasone.	salmeterol xinafoate	154-164	interleukin 13	Rattus norvegicus	0-5
20423350-5	2010	KEY RESULTS: Pre-incubation with beta(2)-adrenoceptor agonists (salbutamol, salmeterol, formoterol) augmented the release and mRNA expression of IL-6 and IL-8 induced by IL-1beta and IL-1beta plus histamine, whereas NF-kappaB-dependent transcription was significantly repressed, and AP-1-dependent transcription was unaffected.	salmeterol xinafoate	76-86	adrenoceptor beta 2	Homo sapiens	33-53
20423350-5	2010	KEY RESULTS: Pre-incubation with beta(2)-adrenoceptor agonists (salbutamol, salmeterol, formoterol) augmented the release and mRNA expression of IL-6 and IL-8 induced by IL-1beta and IL-1beta plus histamine, whereas NF-kappaB-dependent transcription was significantly repressed, and AP-1-dependent transcription was unaffected.	salmeterol xinafoate	76-86	interleukin 6	Homo sapiens	145-149
20423350-5	2010	KEY RESULTS: Pre-incubation with beta(2)-adrenoceptor agonists (salbutamol, salmeterol, formoterol) augmented the release and mRNA expression of IL-6 and IL-8 induced by IL-1beta and IL-1beta plus histamine, whereas NF-kappaB-dependent transcription was significantly repressed, and AP-1-dependent transcription was unaffected.	salmeterol xinafoate	76-86	C-X-C motif chemokine ligand 8	Homo sapiens	154-158
20423350-5	2010	KEY RESULTS: Pre-incubation with beta(2)-adrenoceptor agonists (salbutamol, salmeterol, formoterol) augmented the release and mRNA expression of IL-6 and IL-8 induced by IL-1beta and IL-1beta plus histamine, whereas NF-kappaB-dependent transcription was significantly repressed, and AP-1-dependent transcription was unaffected.	salmeterol xinafoate	76-86	interleukin 1 beta	Homo sapiens	170-178
20423350-5	2010	KEY RESULTS: Pre-incubation with beta(2)-adrenoceptor agonists (salbutamol, salmeterol, formoterol) augmented the release and mRNA expression of IL-6 and IL-8 induced by IL-1beta and IL-1beta plus histamine, whereas NF-kappaB-dependent transcription was significantly repressed, and AP-1-dependent transcription was unaffected.	salmeterol xinafoate	76-86	interleukin 1 beta	Homo sapiens	183-191
20423350-8	2010	Addition of dexamethasone with salmeterol repressed IL-6 and IL-8 release to levels that were similar to the repression achieved in the absence of salmeterol.	salmeterol xinafoate	31-41	interleukin 6	Homo sapiens	52-56
20423350-8	2010	Addition of dexamethasone with salmeterol repressed IL-6 and IL-8 release to levels that were similar to the repression achieved in the absence of salmeterol.	salmeterol xinafoate	31-41	C-X-C motif chemokine ligand 8	Homo sapiens	61-65
20423350-9	2010	IL-6 release was enhanced when salmeterol was added before, concurrently or after IL-1beta plus histamine stimulation, whereas IL-8 release was only enhanced by salmeterol addition prior to stimulation.	salmeterol xinafoate	31-41	interleukin 6	Homo sapiens	0-4
20423350-9	2010	IL-6 release was enhanced when salmeterol was added before, concurrently or after IL-1beta plus histamine stimulation, whereas IL-8 release was only enhanced by salmeterol addition prior to stimulation.	salmeterol xinafoate	161-171	C-X-C motif chemokine ligand 8	Homo sapiens	127-131
20061444-13	2010	This suggests that differences exist between formoterol and salmeterol in beta(2)AR coupling/activation and/or signal transduction upstream of cAMP.	salmeterol xinafoate	60-70	adrenergic receptor, beta 2	Mus musculus	74-83
20865575-5	2010	Use of salmeterol in symptomatic moderate COPD cases has increased FEV(1) and slowed down annual functional progression.	salmeterol xinafoate	7-17	COPD	Homo sapiens	42-46
19800676-2	2009	We have shown that the Arg16 allele of the adrenergic beta(2)-receptor agonist gene (ADRB2) predisposes to exacerbations in young asthmatic patients taking regular salmeterol.	salmeterol xinafoate	164-174	adrenoceptor beta 2	Homo sapiens	85-90
19800676-10	2009	CONCLUSION: The Arg16 genotype of ADRB2 is associated with exacerbations in asthmatic children and young adults exposed daily to beta(2)-agonists, regardless of whether the exposure is to albuterol or long-acting agonists, such as salmeterol.	salmeterol xinafoate	231-241	adrenoceptor beta 2	Homo sapiens	34-39
19330844-2	2009	In this study, using rat primary mesencephalic neuron-glia cultures, we report that salmeterol, a long-acting beta2AR agonist, selectively induces dopaminergic (DA) neurotoxicity through its ability to activate microglia.	salmeterol xinafoate	84-94	adrenoceptor beta 2	Rattus norvegicus	110-117
19330844-3	2009	Salmeterol selectively increased the production of reactive oxygen species (ROS) by NADPH oxidase (PHOX), the major superoxide-producing enzyme in microglia.	salmeterol xinafoate	0-10	cytochrome b-245 alpha chain	Rattus norvegicus	99-103
19330844-4	2009	A key role of PHOX in mediating salmeterol-induced neurotoxicity was demonstrated by the inhibition of DA neurotoxicity in cultures pretreated with diphenylene-iodonium (DPI), an inhibitor of PHOX activity.	salmeterol xinafoate	32-42	cytochrome b-245 alpha chain	Rattus norvegicus	14-18
19330844-4	2009	A key role of PHOX in mediating salmeterol-induced neurotoxicity was demonstrated by the inhibition of DA neurotoxicity in cultures pretreated with diphenylene-iodonium (DPI), an inhibitor of PHOX activity.	salmeterol xinafoate	32-42	cytochrome b-245 alpha chain	Rattus norvegicus	192-196
20003162-0	2010	Suppressive effects of formoterol and salmeterol on eotaxin-1 in bronchial epithelial cells.	salmeterol xinafoate	38-48	C-C motif chemokine ligand 11	Homo sapiens	52-61
20003162-3	2010	Formoterol and salmeterol are two inhaled long acting beta(2) adrenoceptor agonists (LABAs), widely used for the local treatment of asthma.	salmeterol xinafoate	15-25	adrenoceptor beta 2	Homo sapiens	54-74
20003162-8	2010	Formoterol and salmeterol (10(-7)-10(-10) m) significantly down-regulated IL-4- induced eotaxin-1 expression in BEAS-2B cells.	salmeterol xinafoate	15-25	interleukin 4	Homo sapiens	74-78
20003162-8	2010	Formoterol and salmeterol (10(-7)-10(-10) m) significantly down-regulated IL-4- induced eotaxin-1 expression in BEAS-2B cells.	salmeterol xinafoate	15-25	C-C motif chemokine ligand 11	Homo sapiens	88-97
20003162-12	2010	Formoterol and salmeterol, two inhaled long-acting beta(2) agonists, down-regulated IL-4- induced eotaxin-1 expression in BEAS-2B cells.	salmeterol xinafoate	15-25	interleukin 4	Homo sapiens	84-88
20003162-12	2010	Formoterol and salmeterol, two inhaled long-acting beta(2) agonists, down-regulated IL-4- induced eotaxin-1 expression in BEAS-2B cells.	salmeterol xinafoate	15-25	C-C motif chemokine ligand 11	Homo sapiens	98-107
19330844-5	2009	Mechanistic studies revealed the activation of microglia by salmeterol results in the selective phosphorylation of ERK, a signaling pathway required for the translocation of the PHOX cytosolic subunit p47(phox) to the cell membrane.	salmeterol xinafoate	60-70	Eph receptor B1	Rattus norvegicus	115-118
19330844-5	2009	Mechanistic studies revealed the activation of microglia by salmeterol results in the selective phosphorylation of ERK, a signaling pathway required for the translocation of the PHOX cytosolic subunit p47(phox) to the cell membrane.	salmeterol xinafoate	60-70	cytochrome b-245 alpha chain	Rattus norvegicus	178-182
19330844-5	2009	Mechanistic studies revealed the activation of microglia by salmeterol results in the selective phosphorylation of ERK, a signaling pathway required for the translocation of the PHOX cytosolic subunit p47(phox) to the cell membrane.	salmeterol xinafoate	60-70	NSFL1 cofactor	Rattus norvegicus	201-204
19330844-5	2009	Mechanistic studies revealed the activation of microglia by salmeterol results in the selective phosphorylation of ERK, a signaling pathway required for the translocation of the PHOX cytosolic subunit p47(phox) to the cell membrane.	salmeterol xinafoate	60-70	cytochrome b-245 alpha chain	Rattus norvegicus	205-209
19330844-6	2009	Furthermore, we found ERK inhibition, but not protein kinase A (PKA) inhibition, significantly abolished salmeterol-induced superoxide production, p47(phox) translocation, and its ability to mediate neurotoxicity.	salmeterol xinafoate	105-115	Eph receptor B1	Rattus norvegicus	22-25
19330844-6	2009	Furthermore, we found ERK inhibition, but not protein kinase A (PKA) inhibition, significantly abolished salmeterol-induced superoxide production, p47(phox) translocation, and its ability to mediate neurotoxicity.	salmeterol xinafoate	105-115	NSFL1 cofactor	Rattus norvegicus	147-150
19330844-6	2009	Furthermore, we found ERK inhibition, but not protein kinase A (PKA) inhibition, significantly abolished salmeterol-induced superoxide production, p47(phox) translocation, and its ability to mediate neurotoxicity.	salmeterol xinafoate	105-115	cytochrome b-245 alpha chain	Rattus norvegicus	151-155
19666775-3	2009	Cultured human ASM cells and isolated rabbit ASM tissues exposed for 24 h to the long-acting beta2AR agonist salmeterol exhibited impaired acute beta2AR-mediated cAMP accumulation and relaxation, respectively, together with ASM constrictor hyperresponsiveness.	salmeterol xinafoate	109-119	adrenoceptor beta 2	Homo sapiens	145-152
19719779-1	2009	It has been demonstrated that the degree of agonist-induced desensitization of the beta(2)-adrenoceptor is related to agonist efficacy (strength of signalling), whereby high-efficacy agonists (e.g. formoterol) cause more phosphorylation and internalization of the receptor than low-efficacy agonists (e.g. salmeterol).	salmeterol xinafoate	306-316	adrenoceptor beta 2	Homo sapiens	83-103
19309351-0	2009	Opposite effect of fluticasone and salmeterol on fibronectin and tenascin-C expression in primary human lung fibroblasts.	salmeterol xinafoate	35-45	fibronectin 1	Homo sapiens	49-60
19594756-0	2009	Molecular mechanisms for the persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterol.	salmeterol xinafoate	98-108	adrenoceptor beta 2	Homo sapiens	70-89
19237390-5	2009	In a separate experiment, salmeterol effects on BDNF release by human peripheral blood mononuclear cells were assessed.	salmeterol xinafoate	26-36	brain derived neurotrophic factor	Homo sapiens	48-52
19237390-6	2009	RESULTS: Monotherapy with salmeterol significantly increased BDNF concentrations in serum and platelets.	salmeterol xinafoate	26-36	brain derived neurotrophic factor	Homo sapiens	61-65
19237390-8	2009	The findings were confirmed in vitro: salmeterol increased the release of BDNF by mononuclear cells, and this was inhibited by co-incubation with fluticasone.	salmeterol xinafoate	38-48	brain derived neurotrophic factor	Homo sapiens	74-78
19237390-9	2009	Increased BDNF concentrations in serum and platelets correlated with the deterioration of airway hyper-responsiveness following salmeterol monotherapy.	salmeterol xinafoate	128-138	brain derived neurotrophic factor	Homo sapiens	10-14
19237390-11	2009	CONCLUSION: Increased BDNF concentrations may underly the adverse effects of salmeterol monotherapy on airway responsiveness in asthma.	salmeterol xinafoate	77-87	brain derived neurotrophic factor	Homo sapiens	22-26
19309351-0	2009	Opposite effect of fluticasone and salmeterol on fibronectin and tenascin-C expression in primary human lung fibroblasts.	salmeterol xinafoate	35-45	tenascin C	Homo sapiens	65-75
19309351-5	2009	OBJECTIVE: In this study we investigated the effect of fluticasone and salmeterol, either alone or in combination, on fibronectin and tenascin-C protein, isoform, and mRNA levels in primary human lung fibroblasts.	salmeterol xinafoate	71-81	fibronectin 1	Homo sapiens	118-129
19309351-5	2009	OBJECTIVE: In this study we investigated the effect of fluticasone and salmeterol, either alone or in combination, on fibronectin and tenascin-C protein, isoform, and mRNA levels in primary human lung fibroblasts.	salmeterol xinafoate	71-81	tenascin C	Homo sapiens	134-144
19309351-7	2009	Using these two different conditions, the effects of fluticasone and salmeterol on fibronectin and tenascin-C protein and mRNA levels were analysed by immunoblotting and semi-quantitative RT-PCR.	salmeterol xinafoate	69-79	fibronectin 1	Homo sapiens	83-94
19309351-7	2009	Using these two different conditions, the effects of fluticasone and salmeterol on fibronectin and tenascin-C protein and mRNA levels were analysed by immunoblotting and semi-quantitative RT-PCR.	salmeterol xinafoate	69-79	tenascin C	Homo sapiens	99-109
19719334-1	2009	Salmeterol/fluticasone propionate (Seretide/Advair Diskus [dry powder inhaler] or Seretide/Advair inhalation aerosol [metered-dose inhaler]) is a fixed-dose combination inhalation agent containing a long-acting beta2-adrenoceptor agonist (LABA) plus a corticosteroid.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	211-229
18931328-2	2009	In this study, we explored the effect of a long-acting beta(2)-adrenergic agonist, salmeterol, on the CFTR-dependent secretory capacity of a human CF tracheal gland serous cell line (CF-KM4), homozygous for the delF508 mutation.	salmeterol xinafoate	83-93	CF transmembrane conductance regulator	Homo sapiens	102-106
18931328-3	2009	We showed that, compared with the untreated CF serous cells, a 24-hour pre-incubation period with 200 nM salmeterol induced an 83% increase in delF508-CFTR-mediated chloride efflux.	salmeterol xinafoate	105-115	CF transmembrane conductance regulator	Homo sapiens	151-155
18931328-9	2009	To demonstrate that the salmeterol effect was a CFTR-dependent mechanism, we showed that the incubation of salmeterol-treated CF serous cells with CFTR-inh172 suppressed the restoration of normal secretory functions.	salmeterol xinafoate	24-34	CF transmembrane conductance regulator	Homo sapiens	48-52
18931328-9	2009	To demonstrate that the salmeterol effect was a CFTR-dependent mechanism, we showed that the incubation of salmeterol-treated CF serous cells with CFTR-inh172 suppressed the restoration of normal secretory functions.	salmeterol xinafoate	24-34	CF transmembrane conductance regulator	Homo sapiens	147-151
18931328-9	2009	To demonstrate that the salmeterol effect was a CFTR-dependent mechanism, we showed that the incubation of salmeterol-treated CF serous cells with CFTR-inh172 suppressed the restoration of normal secretory functions.	salmeterol xinafoate	107-117	CF transmembrane conductance regulator	Homo sapiens	48-52
18931328-9	2009	To demonstrate that the salmeterol effect was a CFTR-dependent mechanism, we showed that the incubation of salmeterol-treated CF serous cells with CFTR-inh172 suppressed the restoration of normal secretory functions.	salmeterol xinafoate	107-117	CF transmembrane conductance regulator	Homo sapiens	147-151
19275519-0	2009	Acute and chronic lung function responses to salmeterol and salmeterol plus fluticasone propionate in relation to Arg16Gly beta(2)-adrenergic polymorphisms.	salmeterol xinafoate	60-70	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	123-129
19071226-4	2009	Bronchodilators are the foundation of treatment for COPD, and the long-acting beta2-agonists formoterol and salmeterol are both indicated for regular use by patients with stable COPD.	salmeterol xinafoate	108-118	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	78-83
19201814-7	2009	In contrast to the increased binding induced by the glucocorticoids, the beta(2)AR agonists isoproterenol, albuterol, and salmeterol all induced a decrease in EGFR binding.	salmeterol xinafoate	122-132	adrenoceptor beta 2	Homo sapiens	73-82
19201814-7	2009	In contrast to the increased binding induced by the glucocorticoids, the beta(2)AR agonists isoproterenol, albuterol, and salmeterol all induced a decrease in EGFR binding.	salmeterol xinafoate	122-132	epidermal growth factor receptor	Homo sapiens	159-163
19373630-12	2009	Salmeterol, fluticasone, and montelukast significantly suppressed IL-8 secretion from sodium sulfite-stimulated A549 cells (p < 0.01).	salmeterol xinafoate	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	66-70
19373630-15	2009	Salmeterol, fluticasone, and montelukast all have inhibitory effects on sodium sulfite-induced IL-8 production in A549 cells.	salmeterol xinafoate	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	95-99
19059194-4	2009	Noradrenaline and the selective beta2-adrenoceptor agonists isoprenaline and salmeterol stimulated osteoclast formation and bone resorption in BM osteoblast co-cultures and increased expression of RANK-L by osteoblasts.	salmeterol xinafoate	77-87	adrenoceptor beta 2	Homo sapiens	32-50
19059194-4	2009	Noradrenaline and the selective beta2-adrenoceptor agonists isoprenaline and salmeterol stimulated osteoclast formation and bone resorption in BM osteoblast co-cultures and increased expression of RANK-L by osteoblasts.	salmeterol xinafoate	77-87	TNF superfamily member 11	Homo sapiens	197-203
18829252-5	2008	Most of the drugs available for long-term management of COPD have significant effects on the frequency of exacerbations: tiotropium and salmeterol, each used alone, as well as fixed combinations of salmeterol/fluticasone or formoterol/budesonide.	salmeterol xinafoate	136-146	COPD	Homo sapiens	56-60
19059068-1	2008	beta2-Agonist medications, such as albuterol and salmeterol, are widely used to treat asthma.	salmeterol xinafoate	49-59	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	0-5
18586957-2	2008	In the present study, PGE(2), forskolin, and short-acting (salbutamol) and long-acting (salmeterol and formoterol) beta(2)-adrenoceptor agonists reduced the expression of ICAM-1 and the release of GM-CSF evoked by IL-1beta in ASM cells.	salmeterol xinafoate	88-98	adrenoceptor beta 2	Homo sapiens	115-135
19011503-0	2008	Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol.	salmeterol xinafoate	185-195	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	153-158
18586957-2	2008	In the present study, PGE(2), forskolin, and short-acting (salbutamol) and long-acting (salmeterol and formoterol) beta(2)-adrenoceptor agonists reduced the expression of ICAM-1 and the release of GM-CSF evoked by IL-1beta in ASM cells.	salmeterol xinafoate	88-98	intercellular adhesion molecule 1	Homo sapiens	171-177
18586957-2	2008	In the present study, PGE(2), forskolin, and short-acting (salbutamol) and long-acting (salmeterol and formoterol) beta(2)-adrenoceptor agonists reduced the expression of ICAM-1 and the release of GM-CSF evoked by IL-1beta in ASM cells.	salmeterol xinafoate	88-98	colony stimulating factor 2	Homo sapiens	197-203
18586957-2	2008	In the present study, PGE(2), forskolin, and short-acting (salbutamol) and long-acting (salmeterol and formoterol) beta(2)-adrenoceptor agonists reduced the expression of ICAM-1 and the release of GM-CSF evoked by IL-1beta in ASM cells.	salmeterol xinafoate	88-98	interleukin 1 beta	Homo sapiens	214-222
18310480-7	2008	There was, however, a significant reduction in SP-D levels with fluticasone and fluticasone/salmeterol compared with placebo (P = 0.002).	salmeterol xinafoate	92-102	surfactant protein D	Homo sapiens	47-51
18512086-0	2008	An insilico approach to high altitude pulmonary edema - Molecular modeling of human beta2 adrenergic receptor and its interaction with Salmeterol & Nifedipine.	salmeterol xinafoate	135-145	adrenoceptor beta 2	Homo sapiens	84-109
18512086-10	2008	From the present study, it can be concluded that the generated model of human beta(2) adrenergic receptor can be used for further studies related to this receptor and Salmeterol was found to have a high binding affinity with human beta(2) adrenergic receptor.	salmeterol xinafoate	167-177	adrenoceptor beta 2	Homo sapiens	78-105
18512086-10	2008	From the present study, it can be concluded that the generated model of human beta(2) adrenergic receptor can be used for further studies related to this receptor and Salmeterol was found to have a high binding affinity with human beta(2) adrenergic receptor.	salmeterol xinafoate	167-177	adrenoceptor beta 2	Homo sapiens	231-258
18600309-0	2008	Salmeterol with fluticasone enhances the suppression of IL-8 release and increases the translocation of glucocorticoid receptor by human neutrophils stimulated with cigarette smoke.	salmeterol xinafoate	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	56-60
18600309-0	2008	Salmeterol with fluticasone enhances the suppression of IL-8 release and increases the translocation of glucocorticoid receptor by human neutrophils stimulated with cigarette smoke.	salmeterol xinafoate	0-10	nuclear receptor subfamily 3 group C member 1	Homo sapiens	104-127
18600309-2	2008	Recently, we have demonstrated that combination of salmeterol and fluticasone propionate (FP) additionally suppress the production of IL-8 by human monocyte.	salmeterol xinafoate	51-61	C-X-C motif chemokine ligand 8	Homo sapiens	134-138
18565963-0	2008	Is salmeterol/fluticasone propionate equivalent to tiotropium bromide in the treatment of COPD?	salmeterol xinafoate	3-13	COPD	Homo sapiens	90-94
18256057-0	2008	Effects of formoterol and salmeterol on the production of Th1- and Th2-related chemokines by monocytes and bronchial epithelial cells.	salmeterol xinafoate	26-36	negative elongation factor complex member C/D	Homo sapiens	58-61
18256057-1	2008	It is unknown whether formoterol and salmeterol, two long-acting beta(2)-adrenoreceptor agonists, have regulatory functions in the production of T-helper cell (Th) type 2- and Th1-related chemokines by monocytes and bronchial epithelial cells.	salmeterol xinafoate	37-47	negative elongation factor complex member C/D	Homo sapiens	176-179
18256057-5	2008	Higher doses of salmeterol were required to enhance LPS-induced MDC expression in THP-1 cells.	salmeterol xinafoate	16-26	C-C motif chemokine ligand 22	Homo sapiens	64-67
18256057-2	2008	In the present study, the effects of formoterol and salmeterol on lipopolysaccharide (LPS)-induced expression of the Th2-related chemokine macrophage-derived chemokine (MDC; CCL22) and the Th1-related chemokine interferon-gamma-inducible protein (IP)-10 (CXCL10) were investigated in a monocytic cell line, THP-1, and in human primary monocytes.	salmeterol xinafoate	52-62	C-C motif chemokine ligand 22	Homo sapiens	139-167
18256057-6	2008	Formoterol and salmeterol could significantly suppress TARC expression in BEAS-2B cells.	salmeterol xinafoate	15-25	C-C motif chemokine ligand 17	Homo sapiens	55-59
18256057-2	2008	In the present study, the effects of formoterol and salmeterol on lipopolysaccharide (LPS)-induced expression of the Th2-related chemokine macrophage-derived chemokine (MDC; CCL22) and the Th1-related chemokine interferon-gamma-inducible protein (IP)-10 (CXCL10) were investigated in a monocytic cell line, THP-1, and in human primary monocytes.	salmeterol xinafoate	52-62	C-C motif chemokine ligand 22	Homo sapiens	169-172
18256057-2	2008	In the present study, the effects of formoterol and salmeterol on lipopolysaccharide (LPS)-induced expression of the Th2-related chemokine macrophage-derived chemokine (MDC; CCL22) and the Th1-related chemokine interferon-gamma-inducible protein (IP)-10 (CXCL10) were investigated in a monocytic cell line, THP-1, and in human primary monocytes.	salmeterol xinafoate	52-62	C-C motif chemokine ligand 22	Homo sapiens	174-179
18396264-6	2008	Bath application of the selective beta2-adrenoceptor agonist salmeterol (15 microM) facilitated the excitatory field synaptic potential evoked in the BLA by stimulation of the external capsule by 167.3+/-9.7 % of control amplitude.	salmeterol xinafoate	61-71	adrenoceptor beta 2	Rattus norvegicus	34-52
19124357-13	2008	CONCLUSION: In this trial, both arformoterol 50 microg QD and salmeterol 42 microg BID were well tolerated in patients with COPD.	salmeterol xinafoate	62-72	BH3 interacting domain death agonist	Homo sapiens	83-86
19014570-3	2008	The purpose of this study was to examine the duration of bronchodilation induced by the long-acting beta2-agonist salmeterol administered with an MDI and a spacer in a group of mechanically ventilated patients with exacerbation of chronic obstructive pulmonary disease (COPD).	salmeterol xinafoate	114-124	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	100-105
17993585-5	2008	The nonselective beta AR agonist isoproterenol and the beta 2AR-selective agonists albuterol and salmeterol inhibited EGF-stimulated proliferation by more than 50%, with half-maximal effects at 4.8 nM, 110 nM, and 6.7 nM, respectively.	salmeterol xinafoate	97-107	adrenoceptor beta 2	Homo sapiens	55-63
18259970-0	2008	Inhibition by salmeterol and cilomilast of fluticasone-enhanced IP-10 release in airway epithelial cells.	salmeterol xinafoate	14-24	C-X-C motif chemokine ligand 10	Homo sapiens	64-69
18259970-4	2008	This study examined the effects of fluticasone, salmeterol, and agents which raise intracellular cAMP (cilomilast and db-cAMP) on the expression of IP-10 and IL-8 protein and mRNA.	salmeterol xinafoate	48-58	C-X-C motif chemokine ligand 10	Homo sapiens	148-153
18259970-4	2008	This study examined the effects of fluticasone, salmeterol, and agents which raise intracellular cAMP (cilomilast and db-cAMP) on the expression of IP-10 and IL-8 protein and mRNA.	salmeterol xinafoate	48-58	C-X-C motif chemokine ligand 8	Homo sapiens	158-162
18259970-8	2008	The combination of salmeterol (1 micro M) and cilomilast (1-10 mu M) reduced IP-10 but had no effect on IL-8 protein.	salmeterol xinafoate	19-29	C-X-C motif chemokine ligand 10	Homo sapiens	77-82
18259970-9	2008	Salmeterol alone (1 micro M) and db-cAMP alone (1 mM) antagonised the effects of fluticasone on IP-10 but not IL-8 protein.	salmeterol xinafoate	0-10	C-X-C motif chemokine ligand 10	Homo sapiens	96-101
18259970-10	2008	In human airway epithelial cells, inhibition by salmeterol of fluticasone-enhanced IP-10 release may be an important therapeutic effect of the LABA/ICS combination not present when the two drugs are used separately.	salmeterol xinafoate	48-58	C-X-C motif chemokine ligand 10	Homo sapiens	83-88
17596271-3	2007	The present study investigates the effects of formoterol (FORM), salmeterol (SALM) and budesonide (BUD) on GR activation in bronchial epithelial cells via tumour necrosis factor-alpha-stimulated granulocyte-macrophage colony-stimulating factor (GM-CSF) release, GR nuclear translocation and GR-regulated reporter gene activity.	salmeterol xinafoate	65-75	nuclear receptor subfamily 3 group C member 1	Homo sapiens	107-109
18034897-0	2007	Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke.	salmeterol xinafoate	68-78	toll like receptor 4	Homo sapiens	25-29
18034897-9	2007	Stimulation with salmeterol (10-6 M) caused upregulation of TLR4 membrane protein presentation with no upregulation of mRNA, suggesting a post-translational effect.	salmeterol xinafoate	17-27	toll like receptor 4	Homo sapiens	60-64
18034897-10	2007	The effect of dexamethasone and salmeterol in combination was additive, with downregulation of TLR4 gene expression, and no change in membrane receptor expression.	salmeterol xinafoate	32-42	toll like receptor 4	Homo sapiens	95-99
17901197-4	2008	In contrast, simple glucocorticoid response element (GRE)-dependent transcription induced by dexamethasone, budesonide, and fluticasone was synergistically enhanced by beta(2)-adrenoceptor agonists, including salmeterol and formoterol, to a level that could not be achieved by glucocorticoid alone.	salmeterol xinafoate	209-219	adrenoceptor beta 2	Homo sapiens	168-188
17632023-5	2008	OBJECTIVES: The aim of the present study was to compare the bronchodilatory action of transdermal beta 2-agonist tulobuterol with that of inhaled long-acting beta 2-agonist salmeterol.	salmeterol xinafoate	173-183	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	158-164
17632023-14	2008	However, its bronchodilatory potency was about three times less than that of the inhaled beta 2-agonist salmeterol.	salmeterol xinafoate	104-114	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	89-95
17692547-3	2008	We have investigated the effect of fluticasone propionate, a corticosteroid, and salmeterol, a beta 2-adrenergic receptor agonist, on cigarette smoke extract-induced IL-8 production by human airway smooth muscle cells.	salmeterol xinafoate	81-91	C-X-C motif chemokine ligand 8	Homo sapiens	166-170
17596271-3	2007	The present study investigates the effects of formoterol (FORM), salmeterol (SALM) and budesonide (BUD) on GR activation in bronchial epithelial cells via tumour necrosis factor-alpha-stimulated granulocyte-macrophage colony-stimulating factor (GM-CSF) release, GR nuclear translocation and GR-regulated reporter gene activity.	salmeterol xinafoate	77-81	nuclear receptor subfamily 3 group C member 1	Homo sapiens	107-109
17596271-9	2007	It was concluded that in bronchial epithelial cells, inhibition of granulocyte-macrophage colony-stimulating factor synthesis by formoterol and salmeterol does not act via previously demonstrated glucocorticoid receptor-related mechanisms, suggesting an alternative pathway in these cells.	salmeterol xinafoate	144-154	colony stimulating factor 2	Homo sapiens	67-115
17689947-1	2007	OBJECTIVES: To identify the asthma patients, on short-acting beta2-agonists alone, who would benefit from initial maintenance therapy (IMT) with salmeterol/fluticasone (SFC) propionate 50/100 microg bd compared with fluticasone propionate (FP) 100 microg bd alone.	salmeterol xinafoate	145-155	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	61-66
17903241-8	2007	Similarly, TNFalpha, IFN gamma or salmeterol treatment augmented bradykinin induced IPx responses (127.4 +/- 8.3, 128.0 +/- 8.4 and 111.7 +/- 5.0%, P < 0.05).	salmeterol xinafoate	34-44	kininogen 1	Homo sapiens	65-75
17620004-2	2007	Forskolin (a potent activator of adenylyl cyclase), 8-bromo-cyclic AMP (a cyclic AMP analogue), salbutamol and salmeterol (two beta 2-adrenoceptor agonists), were used to increase cyclic AMP levels.	salmeterol xinafoate	111-121	beta-2 adrenergic receptor	Cavia porcellus	127-146
17932597-4	2007	METHODS: The effects of the LABAs salmeterol and formoterol on the synthesis of soluble interleukin-8 (IL-8), granulocyte-macrophage colony-stimulating factor (GM-CSF), and vascular endothelial growth factor (VEGF) in the human airway epithelial cell line A549 was investigated in vitro.	salmeterol xinafoate	34-44	C-X-C motif chemokine ligand 8	Homo sapiens	88-101
17932597-6	2007	RESULTS: Both salmeterol and formoterol significantly suppressed IL-8, GM-CSF, and VEGF secretion from tumor necrosis factor-alpha-stimulated A549 cells.	salmeterol xinafoate	14-24	C-X-C motif chemokine ligand 8	Homo sapiens	65-69
17932597-6	2007	RESULTS: Both salmeterol and formoterol significantly suppressed IL-8, GM-CSF, and VEGF secretion from tumor necrosis factor-alpha-stimulated A549 cells.	salmeterol xinafoate	14-24	colony stimulating factor 2	Homo sapiens	71-77
17932597-6	2007	RESULTS: Both salmeterol and formoterol significantly suppressed IL-8, GM-CSF, and VEGF secretion from tumor necrosis factor-alpha-stimulated A549 cells.	salmeterol xinafoate	14-24	vascular endothelial growth factor A	Homo sapiens	83-87
17932597-6	2007	RESULTS: Both salmeterol and formoterol significantly suppressed IL-8, GM-CSF, and VEGF secretion from tumor necrosis factor-alpha-stimulated A549 cells.	salmeterol xinafoate	14-24	tumor necrosis factor	Homo sapiens	103-130
17932597-7	2007	Results indicated that formoterol was more potent than salmeterol in suppressing IL-8 and VEGF production.	salmeterol xinafoate	55-65	C-X-C motif chemokine ligand 8	Homo sapiens	81-85
17932597-7	2007	Results indicated that formoterol was more potent than salmeterol in suppressing IL-8 and VEGF production.	salmeterol xinafoate	55-65	vascular endothelial growth factor A	Homo sapiens	90-94
17932597-8	2007	In contrast, salmeterol appeared to be more potent than formoterol in suppressing GM-CSF production.	salmeterol xinafoate	13-23	colony stimulating factor 2	Homo sapiens	82-88
17903241-11	2007	The HRH1 and BDKRB2 promoter regions were mapped in ASM and promoter-reporter analyses identified that salmeterol can induce HRH1 (>2 fold) and BDKRB2 (2-5 fold) transcription.	salmeterol xinafoate	103-113	histamine receptor H1	Homo sapiens	4-8
17903241-11	2007	The HRH1 and BDKRB2 promoter regions were mapped in ASM and promoter-reporter analyses identified that salmeterol can induce HRH1 (>2 fold) and BDKRB2 (2-5 fold) transcription.	salmeterol xinafoate	103-113	bradykinin receptor B2	Homo sapiens	13-19
17903241-11	2007	The HRH1 and BDKRB2 promoter regions were mapped in ASM and promoter-reporter analyses identified that salmeterol can induce HRH1 (>2 fold) and BDKRB2 (2-5 fold) transcription.	salmeterol xinafoate	103-113	histamine receptor H1	Homo sapiens	125-129
17903241-11	2007	The HRH1 and BDKRB2 promoter regions were mapped in ASM and promoter-reporter analyses identified that salmeterol can induce HRH1 (>2 fold) and BDKRB2 (2-5 fold) transcription.	salmeterol xinafoate	103-113	bradykinin receptor B2	Homo sapiens	147-153
17846318-6	2007	Human valve ICs treated with the selective beta2-AR agonist, salmeterol, in the presence of osteogenic medium showed a significant 5-fold decrease in the alkaline phosphatase (ALP) activity in comparison to cells treated with osteogenic medium only (P<0.05).	salmeterol xinafoate	61-71	adrenoceptor beta 2	Homo sapiens	43-51
17631879-0	2007	Combination of fluticasone propionate and salmeterol potentiates the suppression of cigarette smoke-induced IL-8 production by macrophages.	salmeterol xinafoate	42-52	C-X-C motif chemokine ligand 8	Homo sapiens	108-112
17631879-4	2007	The aim of this study was to determine whether combined fluticasone propionate, a corticosteroid, and salmeterol, a long-acting beta(2)-adrenoceptor agonist, can suppress IL-8 production by human macrophages.	salmeterol xinafoate	102-112	adrenoceptor beta 2	Homo sapiens	128-148
17631879-4	2007	The aim of this study was to determine whether combined fluticasone propionate, a corticosteroid, and salmeterol, a long-acting beta(2)-adrenoceptor agonist, can suppress IL-8 production by human macrophages.	salmeterol xinafoate	102-112	C-X-C motif chemokine ligand 8	Homo sapiens	171-175
17631879-7	2007	IL-8 release by cigarette smoke was significantly suppressed in a concentration-dependent manner by fluticasone and salmeterol.	salmeterol xinafoate	116-126	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
17631879-9	2007	Interestingly, preincubation of cells with suboptimal concentration of salmeterol for 4 h before fluticasone administration for 30 min potentiates the inhibitory effect of fluticasone on IL-8 release.	salmeterol xinafoate	71-81	C-X-C motif chemokine ligand 8	Homo sapiens	187-191
17846318-6	2007	Human valve ICs treated with the selective beta2-AR agonist, salmeterol, in the presence of osteogenic medium showed a significant 5-fold decrease in the alkaline phosphatase (ALP) activity in comparison to cells treated with osteogenic medium only (P<0.05).	salmeterol xinafoate	61-71	alkaline phosphatase, placental	Homo sapiens	154-174
17846318-6	2007	Human valve ICs treated with the selective beta2-AR agonist, salmeterol, in the presence of osteogenic medium showed a significant 5-fold decrease in the alkaline phosphatase (ALP) activity in comparison to cells treated with osteogenic medium only (P<0.05).	salmeterol xinafoate	61-71	alkaline phosphatase, placental	Homo sapiens	176-179
17636663-20	2007	AUTHORS" CONCLUSIONS: Long-acting beta-2 agonists, particularly salmeterol, are more effective than theophylline in improving morning and evening PEF, but are not significantly different in their effect on FEV1.	salmeterol xinafoate	64-74	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	34-40
20477262-2	2007	The long-acting beta2-agonist salmeterol and the corticosteroid fluticasone propionate can be administered in a combination inhaler.	salmeterol xinafoate	30-40	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	16-21
17636663-21	2007	There is evidence of decreased daytime and nighttime short-acting beta-2 agonist requirement with salmeterol.	salmeterol xinafoate	98-108	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	66-72
17636663-22	2007	Fewer adverse events occurred in participants using long-acting beta-2 agonists (salmeterol and formoterol) as compared to theophylline.	salmeterol xinafoate	81-91	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	64-70
17594245-1	2007	A 14-year-old female with perinatally acquired HIV on boosted protease inhibitor (PI) therapy with atazanavir and ritonavir rapidly developed cushingoid features with excessive weight gain and moon facies within 2 weeks of receiving inhaled fluticasone/salmeterol for asthma treatment.	salmeterol xinafoate	253-263	serpin family A member 13, pseudogene	Homo sapiens	62-80
17594727-7	2007	The 2 long-acting beta(2) adrenergic drugs are salmeterol and formoterol.	salmeterol xinafoate	47-57	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	18-24
17666315-2	2007	The study aimed at analyzing the efficacy of the fixed combination of the inhaled corticosteroid fluticasone propionate and the long-acting beta2-agonist salmeterol (FS) for maintenance treatment of moderate persistent asthma (GINA stage 3) within an observational design, mimicking "real-life" as closely as possible.	salmeterol xinafoate	154-164	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	140-145
17229563-0	2007	Effect of formoterol and salmeterol on IL-6 and IL-8 release in airway epithelial cells.	salmeterol xinafoate	25-35	interleukin-6	Sus scrofa	39-43
17229563-0	2007	Effect of formoterol and salmeterol on IL-6 and IL-8 release in airway epithelial cells.	salmeterol xinafoate	25-35	C-X-C motif chemokine ligand 8	Sus scrofa	48-52
17229563-6	2007	Formoterol and salmeterol both induced enhancement of IL-6 and IL-8 release and added to the effect of organic dust.	salmeterol xinafoate	15-25	interleukin-6	Sus scrofa	54-58
17229563-2	2007	The aim of this study was to find out whether the two long-acting beta(2)-agonists formoterol and salmeterol influence interleukin-6 (IL-6) and -8 (IL-8) release from airway epithelial cells in vitro.	salmeterol xinafoate	98-108	interleukin-6	Sus scrofa	119-132
17229563-6	2007	Formoterol and salmeterol both induced enhancement of IL-6 and IL-8 release and added to the effect of organic dust.	salmeterol xinafoate	15-25	C-X-C motif chemokine ligand 8	Sus scrofa	63-67
17395587-8	2007	Salmeterol caused an augmentation of rhinovirus-induced promoter activation via a mechanism dependent upon the c/EBP and/or CRE (cyclic AMP response element) cis-acting sites.	salmeterol xinafoate	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	111-116
17395587-3	2007	In this study we investigate the effects of common asthma treatments fluticasone propionate and beta(2) agonists salmeterol and salbutamol on IL-6 production in BEAS-2B and primary bronchial epithelial cells.	salmeterol xinafoate	113-123	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	96-103
17229563-2	2007	The aim of this study was to find out whether the two long-acting beta(2)-agonists formoterol and salmeterol influence interleukin-6 (IL-6) and -8 (IL-8) release from airway epithelial cells in vitro.	salmeterol xinafoate	98-108	interleukin 6	Sus scrofa	134-146
17229563-2	2007	The aim of this study was to find out whether the two long-acting beta(2)-agonists formoterol and salmeterol influence interleukin-6 (IL-6) and -8 (IL-8) release from airway epithelial cells in vitro.	salmeterol xinafoate	98-108	C-X-C motif chemokine ligand 8	Sus scrofa	148-152
16807266-7	2006	A comparable increase in intracellular cAMP concentration for PMNs activated with LTB(4) and TNF-alpha was caused by 1 muM cilomilast and 0.1 microM salmeterol.	salmeterol xinafoate	149-159	tumor necrosis factor	Homo sapiens	93-102
17395587-3	2007	In this study we investigate the effects of common asthma treatments fluticasone propionate and beta(2) agonists salmeterol and salbutamol on IL-6 production in BEAS-2B and primary bronchial epithelial cells.	salmeterol xinafoate	113-123	interleukin 6	Homo sapiens	142-146
17395587-4	2007	Salmeterol and salbutamol enhanced rhinovirus- and IL-1beta-induced IL-6 production; however, fluticasone treatment caused a reduction of IL-6 protein and mRNA.	salmeterol xinafoate	0-10	interleukin 1 beta	Homo sapiens	51-59
17395587-4	2007	Salmeterol and salbutamol enhanced rhinovirus- and IL-1beta-induced IL-6 production; however, fluticasone treatment caused a reduction of IL-6 protein and mRNA.	salmeterol xinafoate	0-10	interleukin 6	Homo sapiens	68-72
17395587-6	2007	The induction of IL-6 by salmeterol was dependent upon the beta(2) receptor and could also be induced by cAMP or cAMP-elevating agents forskolin and rolipram.	salmeterol xinafoate	25-35	interleukin 6	Homo sapiens	17-21
17395587-6	2007	The induction of IL-6 by salmeterol was dependent upon the beta(2) receptor and could also be induced by cAMP or cAMP-elevating agents forskolin and rolipram.	salmeterol xinafoate	25-35	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	59-66
16980556-0	2007	Salmeterol stimulation dissociates beta2-adrenergic receptor phosphorylation and internalization.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	35-60
16980556-1	2007	Salmeterol is a long-acting beta(2)-adrenergic receptor (beta(2)AR) agonist commonly used in the treatment of asthma and chronic obstructive pulmonary disease.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	28-55
16980556-1	2007	Salmeterol is a long-acting beta(2)-adrenergic receptor (beta(2)AR) agonist commonly used in the treatment of asthma and chronic obstructive pulmonary disease.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	57-66
16980556-6	2007	We determined the capacity of salmeterol to induce beta(2)AR endocytosis, G protein-coupled receptor kinase (GRK)-site phosphorylation, degradation, and beta-arrestin2 translocation in HEK293 cells as compared with other agonists of varying intrinsic efficacies.	salmeterol xinafoate	30-40	adrenoceptor beta 2	Homo sapiens	51-60
16980556-6	2007	We determined the capacity of salmeterol to induce beta(2)AR endocytosis, G protein-coupled receptor kinase (GRK)-site phosphorylation, degradation, and beta-arrestin2 translocation in HEK293 cells as compared with other agonists of varying intrinsic efficacies.	salmeterol xinafoate	30-40	arrestin beta 2	Homo sapiens	153-167
17196106-1	2006	BACKGROUND: Several studies have demonstrated that long-acting beta2-agonists such as salmeterol are beneficial in chronic obstructive pulmonary disease (COPD).	salmeterol xinafoate	86-96	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	63-68
17519082-1	2007	OBJECTIVE: To determine where in the treatment steps recommended by the British Thoracic Society and Scottish Intercollegiate Guidelines Network (BTS/SIGN) Asthma Guideline it is cost-effective to use salmeterol xinafoate/fluticasone propionate combination inhaler (SFC) (Seretide) compared with other inhaled corticosteroid (ICS) containing regimens (with and without a long acting beta-2 agonist (LABA)) for chronic asthma in adults and children.	salmeterol xinafoate	201-221	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	383-389
17446966-10	2007	CONCLUSIONS: Our data suggest that the serum eotaxin level, not peripheral blood EC or serum ECP level, declines during inhaled fluticasone plus salmeterol treatment and might serve as a surrogate marker of T helper 2 residual activity in pediatric asthma.	salmeterol xinafoate	145-155	C-C motif chemokine ligand 11	Homo sapiens	45-52
17458051-1	2007	(1) In France, two long-acting inhaled beta2 agonists (salmeterol and formoterol) are marketed for long term symptomatic treatment of asthma, in combination with antiinflammatory treatment with an inhaled steroid.	salmeterol xinafoate	55-65	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	39-44
16980556-8	2007	Salmeterol-induced receptor endocytosis was rescued, at least in part, by the overexpression of EGFP-beta-arrestin2.	salmeterol xinafoate	0-10	arrestin beta 2	Homo sapiens	101-115
17096182-10	2006	During the 4-week period of salmeterol administration, forced vital capacity, forced expiratory volume in 1 s, peak expiratory flow, MIP, and MEP improved significantly compared with placebo and baseline.	salmeterol xinafoate	28-38	cathepsin L	Homo sapiens	142-145
16772309-7	2006	CONCLUSIONS: The arginine-16 genotype of ADRB2 predisposes to exacerbations in asthmatic children and young adults, particularly in those exposed to regular salmeterol.	salmeterol xinafoate	157-167	adrenoceptor beta 2	Homo sapiens	41-46
17096182-12	2006	Increases in MIP and MEP during salmeterol administration suggest improvement in respiratory muscle strength.	salmeterol xinafoate	32-42	cathepsin L	Homo sapiens	21-24
17030231-3	2006	OBJECTIVE: We sought to evaluate the effects of variation in the beta2-adrenergic receptor gene (ADRB2) on clinical response to salmeterol administered with fluticasone propionate.	salmeterol xinafoate	128-138	adrenoceptor beta 2	Homo sapiens	65-90
16714334-9	2006	Pretreatment of airway epithelium or the E-cadherin-expressing L cells with the long-acting beta-agonist salmeterol prevented PAR2 activation from interrupting E-cadherin adhesion and compromising the airway epithelial barrier.	salmeterol xinafoate	105-115	cadherin 1	Homo sapiens	41-51
16714334-9	2006	Pretreatment of airway epithelium or the E-cadherin-expressing L cells with the long-acting beta-agonist salmeterol prevented PAR2 activation from interrupting E-cadherin adhesion and compromising the airway epithelial barrier.	salmeterol xinafoate	105-115	F2R like trypsin receptor 1	Homo sapiens	126-130
16714334-9	2006	Pretreatment of airway epithelium or the E-cadherin-expressing L cells with the long-acting beta-agonist salmeterol prevented PAR2 activation from interrupting E-cadherin adhesion and compromising the airway epithelial barrier.	salmeterol xinafoate	105-115	cadherin 1	Homo sapiens	160-170
17030231-3	2006	OBJECTIVE: We sought to evaluate the effects of variation in the beta2-adrenergic receptor gene (ADRB2) on clinical response to salmeterol administered with fluticasone propionate.	salmeterol xinafoate	128-138	adrenoceptor beta 2	Homo sapiens	97-102
17128593-10	2006	The present paper aims to characterize and compare the properties of long-term acting beta2-mimetics, with detailed focus on their two representatives, formoterol and salmeterol.	salmeterol xinafoate	167-177	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	86-91
16595015-7	2006	RESULTS: Both salmeterol and salbutamol inhibited NTHi induced tumor necrosis factor-alpha (TNFalpha) release by mouse alveolar macrophages in vitro by a beta receptor dependent mechanism.	salmeterol xinafoate	14-24	tumor necrosis factor	Mus musculus	63-90
17128593-4	2006	Inhalatory beta2-mimetics with long-term action (LABA), formoterol and salmeterol, possess a period of action longer than 12 hours.	salmeterol xinafoate	71-81	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	11-16
17128593-7	2006	Both formoterol and salmeterol are strong and effective beta2-agonists, but their different chemical structures produce different pharmacological properties.	salmeterol xinafoate	20-30	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	56-61
16863745-3	2006	We hypothesized that nebulization of a beta2-adrenoreceptor agonist, salmeterol xinafoate (SLM), during warm ischemia would increase lung tissue cyclic adenosine monophosphate (cAMP) levels, resulting in lung protection.	salmeterol xinafoate	69-89	adrenoceptor beta 2	Rattus norvegicus	39-59
16424444-2	2006	OBJECTIVES: We tested the hypothesis that inhaled combined long-acting beta2-agonist (salmeterol) and corticosteroid (fluticasone propionate) will reduce inflammation.	salmeterol xinafoate	86-96	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	71-76
16855959-10	2006	There was a significant change in forced expiratory volume in 1 second (FEV1) in favour of salmeterol 50 mcg twice daily (BID) of 51 mls (95% confidence intervals (CI) 32 to 70), end of study morning peak expiratory flow (PEF) 14.89 L/min (95% CI 10.86 to 18.91).	salmeterol xinafoate	91-101	BH3 interacting domain death agonist	Homo sapiens	122-125
16424382-5	2006	We investigated modulation of rhinovirus- and IL-1beta-induced bronchial epithelial cell chemokine production by salmeterol and fluticasone propionate, used at therapeutic concentrations, alone and in combination.	salmeterol xinafoate	113-123	interleukin 1 beta	Homo sapiens	46-54
16424382-10	2006	In primary cells, salmeterol alone reduced rhinovirus-induced CCL5 and CXCL10 and increased CXCL5 production in a dose-dependent manner but had no effect on CXCL8.	salmeterol xinafoate	18-28	C-C motif chemokine ligand 5	Homo sapiens	62-66
16424382-10	2006	In primary cells, salmeterol alone reduced rhinovirus-induced CCL5 and CXCL10 and increased CXCL5 production in a dose-dependent manner but had no effect on CXCL8.	salmeterol xinafoate	18-28	C-X-C motif chemokine ligand 10	Homo sapiens	71-77
16424382-10	2006	In primary cells, salmeterol alone reduced rhinovirus-induced CCL5 and CXCL10 and increased CXCL5 production in a dose-dependent manner but had no effect on CXCL8.	salmeterol xinafoate	18-28	C-X-C motif chemokine ligand 5	Homo sapiens	92-97
16595015-7	2006	RESULTS: Both salmeterol and salbutamol inhibited NTHi induced tumor necrosis factor-alpha (TNFalpha) release by mouse alveolar macrophages in vitro by a beta receptor dependent mechanism.	salmeterol xinafoate	14-24	tumor necrosis factor	Mus musculus	92-100
16595015-8	2006	In line, inhalation of either salmeterol or salbutamol was associated with a reduced early TNFalpha production in lungs of mice infected intranasally with NTHi, an effect that was reversed by concurrent treatment with the beta blocker propranolol.	salmeterol xinafoate	30-40	tumor necrosis factor	Mus musculus	91-99
16595015-9	2006	The clearance of NTHi from the lungs was impaired in mice treated with salmeterol or salbutamol, an adverse effect that was prevented by propranolol and independent of the reduction in TNFalpha.	salmeterol xinafoate	71-81	tumor necrosis factor	Mus musculus	185-193
16275368-0	2005	Adding salmeterol to an inhaled corticosteroid reduces allergen-induced serum IL-5 and peripheral blood eosinophils.	salmeterol xinafoate	7-17	interleukin 5	Homo sapiens	78-82
16449264-1	2006	BACKGROUND: Addition of the long acting beta2 agonist salmeterol to inhaled corticosteroids leads to better symptomatic asthma control than increasing the dose of inhaled corticosteroids.	salmeterol xinafoate	54-64	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	40-45
16449264-9	2006	However, adding salmeterol significantly reduced sputum ratios of alpha2-macroglobulin and albumin during the treatment period (p = 0.001).	salmeterol xinafoate	16-26	alpha-2-macroglobulin	Homo sapiens	66-86
16310375-7	2006	Moreover, salmeterol, a long-acting beta2-adrenoceptor agonist, inhibited the harmful effect of HHA at high frequencies (40-120 Hz), but without effect on MT and MST.	salmeterol xinafoate	10-20	adrenoceptor beta 2	Rattus norvegicus	36-54
16620353-3	2006	The aim of this study was to examine the development of tachyphylaxis to the long-acting beta2-agonist salmeterol using as a control therapeutic regimen the combination of ipratropium bromide and salbutamol sulphate.	salmeterol xinafoate	103-113	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	89-94
16432501-0	2006	Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.	salmeterol xinafoate	71-81	adrenoceptor beta 2	Rattus norvegicus	27-45
16432501-2	2006	Two beta(2)-agonists, formoterol and salmeterol, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater beta(2)-adrenoceptor selectivity.	salmeterol xinafoate	37-47	adrenoceptor beta 2	Rattus norvegicus	168-188
18046860-1	2006	Clinical trials of a combination therapy of an inhaled corticosteroid, fluticasone propionate (FP), with a long-acting beta2-agonist, salmeterol (Sal), have demonstrated a greater improvement in lung function and in quality of life measures after the combination compared with either component of alone.	salmeterol xinafoate	134-144	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	119-124
18046860-1	2006	Clinical trials of a combination therapy of an inhaled corticosteroid, fluticasone propionate (FP), with a long-acting beta2-agonist, salmeterol (Sal), have demonstrated a greater improvement in lung function and in quality of life measures after the combination compared with either component of alone.	salmeterol xinafoate	146-149	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	119-124
16275368-8	2005	By contrast, serum IL-5 was significantly reduced (geometric mean serum IL-5 [SEM]: 0.5 [0.3] vs 1.1 [0.3] pg/mL 1 hour and 0.6 [0.3] vs 1.1 [0.3] pg/mL 6 hours after challenge with fluticasone/salmeterol vs fluticasone alone pretreatment, respectively; P values < .05).	salmeterol xinafoate	194-204	interleukin 5	Homo sapiens	19-23
16304342-7	2005	Study 2: Salmeterol and albuterol reversed the HNE-induced depression in TMV to a similar degree over the 6-h time course.	salmeterol xinafoate	9-19	elastase, neutrophil expressed	Homo sapiens	47-50
16304342-9	2005	CONCLUSION: We conclude that salmeterol and albuterol can stimulate normal MCC and reverse HNE-induced mucociliary dysfunction and that salmeterol has a longer duration of action in these models of normal and abnormal MCC.	salmeterol xinafoate	29-39	elastase, neutrophil expressed	Homo sapiens	91-94
16210331-0	2005	Lung myofibroblasts as targets of salmeterol and fluticasone propionate: inhibition of alpha-SMA and NF-kappaB.	salmeterol xinafoate	34-44	nuclear factor kappa B subunit 1	Homo sapiens	101-110
16210331-4	2005	The beta2-agonist salmeterol (SMl) has on human lung myofibroblasts new direct anti-contractile/anti-inflammatory effects that are amplified by the combined use of low concentrations of the glucocorticoid fluticasone propionate (FP).	salmeterol xinafoate	18-28	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	4-9
16210331-4	2005	The beta2-agonist salmeterol (SMl) has on human lung myofibroblasts new direct anti-contractile/anti-inflammatory effects that are amplified by the combined use of low concentrations of the glucocorticoid fluticasone propionate (FP).	salmeterol xinafoate	30-33	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	4-9
16275368-10	2005	CONCLUSION: Adding salmeterol to fluticasone reduces allergen-induced serum IL-5 and peripheral blood eosinophils.	salmeterol xinafoate	19-29	interleukin 5	Homo sapiens	76-80
15994467-8	2005	Pretreatment with salmeterol inhibited LPS-induced neutrophil influx, neutrophil degranulation (myeloperoxidase), tumor necrosis factor alpha release, and HLA-DR expression (all p<0.05 vs. placebo/LPS), while not significantly influencing other responses.	salmeterol xinafoate	18-28	myeloperoxidase	Homo sapiens	96-111
16051698-0	2005	Characterization of isoprenaline- and salmeterol-stimulated interactions between beta2-adrenoceptors and beta-arrestin 2 using beta-galactosidase complementation in C2C12 cells.	salmeterol xinafoate	38-48	arrestin, beta 2	Mus musculus	105-120
16051698-0	2005	Characterization of isoprenaline- and salmeterol-stimulated interactions between beta2-adrenoceptors and beta-arrestin 2 using beta-galactosidase complementation in C2C12 cells.	salmeterol xinafoate	38-48	galactosidase, beta 1	Mus musculus	127-145
16051698-9	2005	Furthermore, the long-acting beta(2)-agonist salmeterol (-log K(D) for inhibition of [(3)H]CGP12177 binding = 8.7) behaved as an antagonist of isoprenaline-stimulated beta(2)-adrenoceptor-arrestin 2 interactions (-log K(D) = 8.0), whereas acting as a full agonist of cAMP accumulation in the same cells (-log EC(50) = 9.2).	salmeterol xinafoate	45-55	adrenergic receptor, beta 2	Mus musculus	167-187
16514718-0	2005	[Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial].	salmeterol xinafoate	52-62	COPD	Homo sapiens	102-106
15994467-8	2005	Pretreatment with salmeterol inhibited LPS-induced neutrophil influx, neutrophil degranulation (myeloperoxidase), tumor necrosis factor alpha release, and HLA-DR expression (all p<0.05 vs. placebo/LPS), while not significantly influencing other responses.	salmeterol xinafoate	18-28	tumor necrosis factor	Homo sapiens	114-141
15860753-9	2005	In addition, salmeterol in combination with FP enhanced glucocorticoid response element (GRE)-luciferase reporter gene activity and mitogen-activated protein kinase phosphatase 1 (MKP-1) and secretory leuko-proteinase inhibitor (SLPI) gene induction.	salmeterol xinafoate	13-23	dual specificity phosphatase 1	Homo sapiens	132-178
15860753-9	2005	In addition, salmeterol in combination with FP enhanced glucocorticoid response element (GRE)-luciferase reporter gene activity and mitogen-activated protein kinase phosphatase 1 (MKP-1) and secretory leuko-proteinase inhibitor (SLPI) gene induction.	salmeterol xinafoate	13-23	dual specificity phosphatase 1	Homo sapiens	180-185
16022567-1	2005	After the discovery of formoterol and salmeterol, new candidates for long-acting beta2-adrenoceptor agonists (LABAs) have emerged from various companies.	salmeterol xinafoate	38-48	adrenoceptor beta 2	Homo sapiens	81-99
15845862-4	2005	Salmeterol, but not salbutamol, inhibited IL-5 and IL-13 and enhanced IL-10 synthesis in these cultures.	salmeterol xinafoate	0-10	interleukin 5	Homo sapiens	42-46
15845862-4	2005	Salmeterol, but not salbutamol, inhibited IL-5 and IL-13 and enhanced IL-10 synthesis in these cultures.	salmeterol xinafoate	0-10	interleukin 13	Homo sapiens	51-56
15845862-4	2005	Salmeterol, but not salbutamol, inhibited IL-5 and IL-13 and enhanced IL-10 synthesis in these cultures.	salmeterol xinafoate	0-10	interleukin 10	Homo sapiens	70-75
15845862-6	2005	Allergen-specific T cell lines induced in the presence of salmeterol and fluticasone proprionate inhibited IL-5 and IL-13 production by allergen-specific Th2 cell lines in an IL-10-dependent manner.	salmeterol xinafoate	58-68	interleukin 5	Homo sapiens	107-111
15845862-6	2005	Allergen-specific T cell lines induced in the presence of salmeterol and fluticasone proprionate inhibited IL-5 and IL-13 production by allergen-specific Th2 cell lines in an IL-10-dependent manner.	salmeterol xinafoate	58-68	interleukin 13	Homo sapiens	116-121
15845862-6	2005	Allergen-specific T cell lines induced in the presence of salmeterol and fluticasone proprionate inhibited IL-5 and IL-13 production by allergen-specific Th2 cell lines in an IL-10-dependent manner.	salmeterol xinafoate	58-68	interleukin 10	Homo sapiens	175-180
15845862-7	2005	Thus fluticasone proprionate and salmeterol increased IL-10 and reduced Th2 cytokine synthesis additively in allergen stimulated human CD4+ T cells.	salmeterol xinafoate	33-43	interleukin 10	Homo sapiens	54-59
15655528-6	2005	Those beta2-adrenoceptor agonists used clinically for the treatment of asthma and COPD were beta2 selective: 29-, 61- and 2818-fold for salbutamol, terbutaline and salmeterol over beta1, respectively.	salmeterol xinafoate	164-174	adrenoceptor beta 2	Homo sapiens	6-24
15934804-15	2005	Long-acting bronchodilators, including beta- 2-adrenergic agonists such as salmeterol and formoterol, and the anticholinergic agent tiotropium, improve lung function and exercise tolerance, reduce symptoms, and modestly reduce exacerbation rates.	salmeterol xinafoate	75-85	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	39-46
15776342-9	2005	Therapeutic use exemptions in an abbreviated process are possible for the administration of glucocorticosteroids by non-systemic routes, as well as inhalative therapy with the beta-2-agonists formoterol, salbutamol, salmeterol, and termbutalin.	salmeterol xinafoate	216-226	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	176-182
15655528-6	2005	Those beta2-adrenoceptor agonists used clinically for the treatment of asthma and COPD were beta2 selective: 29-, 61- and 2818-fold for salbutamol, terbutaline and salmeterol over beta1, respectively.	salmeterol xinafoate	164-174	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	6-11
15715182-6	2005	beta2-agonists with longer durations of action, formoterol and salmeterol, were subsequently discovered or developed.	salmeterol xinafoate	63-73	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	0-5
15531761-5	2005	Eotaxin inhibition was transcriptional and additively enhanced by the glucocorticoid fluticasone and the beta(2)-agonist salmeterol, whereas MCP-1 inhibition was post-transcriptional and additively and synergistically enhanced by fluticasone and salmeterol, respectively.	salmeterol xinafoate	121-131	C-C motif chemokine ligand 11	Homo sapiens	0-7
15531761-5	2005	Eotaxin inhibition was transcriptional and additively enhanced by the glucocorticoid fluticasone and the beta(2)-agonist salmeterol, whereas MCP-1 inhibition was post-transcriptional and additively and synergistically enhanced by fluticasone and salmeterol, respectively.	salmeterol xinafoate	246-256	C-C motif chemokine ligand 11	Homo sapiens	0-7
15531761-6	2005	Coimmunoprecipitation revealed that 15d-PGJ(2) induced a protein-protein interaction between PPARgamma and the glucocorticoid receptor (GR) in TNFalpha-treated HASM cells, which was enhanced by fluticasone and salmeterol.	salmeterol xinafoate	210-220	peroxisome proliferator activated receptor gamma	Homo sapiens	93-102
15531761-6	2005	Coimmunoprecipitation revealed that 15d-PGJ(2) induced a protein-protein interaction between PPARgamma and the glucocorticoid receptor (GR) in TNFalpha-treated HASM cells, which was enhanced by fluticasone and salmeterol.	salmeterol xinafoate	210-220	nuclear receptor subfamily 3 group C member 1	Homo sapiens	111-134
15531761-6	2005	Coimmunoprecipitation revealed that 15d-PGJ(2) induced a protein-protein interaction between PPARgamma and the glucocorticoid receptor (GR) in TNFalpha-treated HASM cells, which was enhanced by fluticasone and salmeterol.	salmeterol xinafoate	210-220	nuclear receptor subfamily 3 group C member 1	Homo sapiens	136-138
15531761-6	2005	Coimmunoprecipitation revealed that 15d-PGJ(2) induced a protein-protein interaction between PPARgamma and the glucocorticoid receptor (GR) in TNFalpha-treated HASM cells, which was enhanced by fluticasone and salmeterol.	salmeterol xinafoate	210-220	tumor necrosis factor	Homo sapiens	143-151
15531761-7	2005	15d-PGJ(2), fluticasone, and salmeterol all inhibited TNFalpha-induced histone H4 acetylation at the eotaxin promoter and NF-kappaB p65 binding to the eotaxin promoter and induced PPARgamma and GR association with the eotaxin promoter, as analyzed by chromatin immunoprecipitation assay.	salmeterol xinafoate	29-39	tumor necrosis factor	Homo sapiens	54-62
15531761-7	2005	15d-PGJ(2), fluticasone, and salmeterol all inhibited TNFalpha-induced histone H4 acetylation at the eotaxin promoter and NF-kappaB p65 binding to the eotaxin promoter and induced PPARgamma and GR association with the eotaxin promoter, as analyzed by chromatin immunoprecipitation assay.	salmeterol xinafoate	29-39	C-C motif chemokine ligand 11	Homo sapiens	101-108
15531761-7	2005	15d-PGJ(2), fluticasone, and salmeterol all inhibited TNFalpha-induced histone H4 acetylation at the eotaxin promoter and NF-kappaB p65 binding to the eotaxin promoter and induced PPARgamma and GR association with the eotaxin promoter, as analyzed by chromatin immunoprecipitation assay.	salmeterol xinafoate	29-39	RELA proto-oncogene, NF-kB subunit	Homo sapiens	132-135
15531761-7	2005	15d-PGJ(2), fluticasone, and salmeterol all inhibited TNFalpha-induced histone H4 acetylation at the eotaxin promoter and NF-kappaB p65 binding to the eotaxin promoter and induced PPARgamma and GR association with the eotaxin promoter, as analyzed by chromatin immunoprecipitation assay.	salmeterol xinafoate	29-39	C-C motif chemokine ligand 11	Homo sapiens	151-158
15531761-7	2005	15d-PGJ(2), fluticasone, and salmeterol all inhibited TNFalpha-induced histone H4 acetylation at the eotaxin promoter and NF-kappaB p65 binding to the eotaxin promoter and induced PPARgamma and GR association with the eotaxin promoter, as analyzed by chromatin immunoprecipitation assay.	salmeterol xinafoate	29-39	peroxisome proliferator activated receptor gamma	Homo sapiens	180-189
15531761-7	2005	15d-PGJ(2), fluticasone, and salmeterol all inhibited TNFalpha-induced histone H4 acetylation at the eotaxin promoter and NF-kappaB p65 binding to the eotaxin promoter and induced PPARgamma and GR association with the eotaxin promoter, as analyzed by chromatin immunoprecipitation assay.	salmeterol xinafoate	29-39	nuclear receptor subfamily 3 group C member 1	Homo sapiens	194-196
15531761-7	2005	15d-PGJ(2), fluticasone, and salmeterol all inhibited TNFalpha-induced histone H4 acetylation at the eotaxin promoter and NF-kappaB p65 binding to the eotaxin promoter and induced PPARgamma and GR association with the eotaxin promoter, as analyzed by chromatin immunoprecipitation assay.	salmeterol xinafoate	29-39	C-C motif chemokine ligand 11	Homo sapiens	151-158
16060707-3	2005	In patients previously receiving as-required short-acting beta(2)-agonists (SABAs) or inhaled corticosteroids, salmeterol/fluticasone propionate was significantly more effective in providing asthma control than fluticasone propionate and in improving lung function and asthma symptoms than inhaled corticosteroids (at equivalent or higher dosages), salmeterol or montelukast (as monotherapy or in combination with fluticasone propionate).	salmeterol xinafoate	111-121	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	58-64
15536434-8	2004	FP plus salmeterol is also able to synergistically reduce the expression of phosphorylated IkappaBalpha, thus limiting nuclear factor kappaB activation.	salmeterol xinafoate	8-18	NFKB inhibitor alpha	Homo sapiens	91-103
15960557-12	2005	Initial evidence suggests that for patients with poorly reversible COPD and a documented history of frequent COPD exacerbations, the addition of salmeterol (a long-acting beta(2)-agonist) to fluticasone propionate (an inhaled corticosteroid) is potentially cost effective from the Canadian healthcare payer"s perspective.	salmeterol xinafoate	145-155	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	171-177
20704942-5	2004	Corticosteroids and long-acting beta2-agonists (salmeterol and formoterol) in fixed combination inhalers are currently the most effective therapy for asthma and are increasingly used in all patients with persistent symptoms.	salmeterol xinafoate	48-58	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	32-37
15083746-0	2004	Additive blockade of beta 2-integrin adhesion of eosinophils by salmeterol and fluticasone propionate.	salmeterol xinafoate	64-74	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	21-27
15309015-11	2004	The maximum response of fluticasone propionate against thrombin-induced proliferation is increased when it is combined with salmeterol.	salmeterol xinafoate	124-134	coagulation factor II	Rattus norvegicus	55-63
15241363-12	2004	CONCLUSION: These data suggest that beta2-agonists in combination with low doses of steroids can suppress T-cell proliferation and TH1 cytokine production from healthy individuals, but suppression of T cells with a combination of FP and salmeterol in asthmatic patients requires inhibition of phosphodiesterases.	salmeterol xinafoate	237-247	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	36-41
14729506-3	2004	Salmeterol dose- and time-dependently inhibited the lipopolysaccharide-induced influx of neutrophils into bronchoalveolar lavage fluid and lung tissue, and these pulmonary neutrophils displayed a reduced expression of CD11b at their surface.	salmeterol xinafoate	0-10	integrin alpha M	Mus musculus	218-223
14729506-4	2004	To determine the contribution of the salmeterol effect on neutrophil CD11b in the attenuated neutrophil recruitment, we treated mice intranasally exposed to lipopolysaccharide with salmeterol with or without a blocking anti-CD11b antibody.	salmeterol xinafoate	37-47	integrin alpha M	Mus musculus	69-74
14729506-5	2004	Anti-CD11b profoundly reduced lipopolysaccharide-induced neutrophil influx in bronchoalveolar lavage fluid, an effect that was modestly enhanced by concurrent salmeterol treatment.	salmeterol xinafoate	159-169	integrin alpha M	Mus musculus	5-10
14729506-6	2004	These data suggest that salmeterol inhibits lipopolysaccharide-induced neutrophil recruitment to the lungs by a mechanism that possibly in part is mediated by an effect on neutrophil CD11b.	salmeterol xinafoate	24-34	integrin alpha M	Mus musculus	183-188
14527924-5	2004	Western blot experiments showed that the 220-kD ZO-1 protein was decreased after PAO1 incubation but was still present in salmeterol-pretreated HAEC extracts.	salmeterol xinafoate	122-132	tight junction protein 1	Homo sapiens	48-52
15526805-1	2004	OBJECTIVES: To compare the effects of addition of montelukast or salmeterol to inhaled corticosteroids (ICS) on the response to rescue beta2-agonist use after exercise-induced bronchoconstriction.	salmeterol xinafoate	65-75	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	135-140
15339337-1	2004	BACKGROUND: The long acting beta2-agonists, salmeterol and formoterol, have been recommended, by some, as first line treatment of stable chronic obstructive pulmonary disease (COPD).	salmeterol xinafoate	44-54	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	28-33
15332410-0	2004	Additive blockade of beta2-integrin adhesion of eosinophils by salmeterol and fluticasone propionate.	salmeterol xinafoate	63-73	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	21-26
14527924-3	2004	We demonstrate in human airway epithelial cells (HAEC) that salmeterol induces a time-dependent increase in ZO-1 protein, although no significant change in ZO-1 transcripts was observed.	salmeterol xinafoate	60-70	tight junction protein 1	Homo sapiens	108-112
14527924-4	2004	When HAEC cultures were exposed to P. aeruginosa (PAO1) supernatants, apical expression of ZO-1 protein was maintained in salmeterol-pretreated HAEC cultures, whereas it disappeared after PAO1 exposure in cultures not pretreated with salmeterol.	salmeterol xinafoate	122-132	tight junction protein 1	Homo sapiens	91-95
14527924-4	2004	When HAEC cultures were exposed to P. aeruginosa (PAO1) supernatants, apical expression of ZO-1 protein was maintained in salmeterol-pretreated HAEC cultures, whereas it disappeared after PAO1 exposure in cultures not pretreated with salmeterol.	salmeterol xinafoate	234-244	tight junction protein 1	Homo sapiens	91-95
15083746-3	2004	The objective of this study was to determine the mechanisms of fluticasone propionate (FP) alone or in combination with salmeterol (SM) in blocking adhesion mediated by beta 2-integrin in human eosinophils.	salmeterol xinafoate	120-130	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	169-175
15083746-3	2004	The objective of this study was to determine the mechanisms of fluticasone propionate (FP) alone or in combination with salmeterol (SM) in blocking adhesion mediated by beta 2-integrin in human eosinophils.	salmeterol xinafoate	132-134	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	169-175
15083746-8	2004	SM alone modestly (approximately 30%) inhibited interleukin (IL)-5-induced eosinophil adhesion.	salmeterol xinafoate	0-2	interleukin 5	Homo sapiens	48-66
15083746-9	2004	Blockade of IL-5-induced eosinophil adhesion caused by 10(-7) M FP at 24 h was augmented by 10(-7) M SM from 41.5% to 72.5%.	salmeterol xinafoate	101-103	interleukin 5	Homo sapiens	12-16
15083746-12	2004	Blockade of beta 2-integrin-mediated eosinophil adhesion by fluticasone propionate is augmented by salmeterol.	salmeterol xinafoate	99-109	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	12-18
15083746-13	2004	Decreased adhesion results from augmented blockade of nuclear translocation of cytosolic phospholipase A2 caused by addition of salmeterol to fluticasone.	salmeterol xinafoate	128-138	phospholipase A2 group IVA	Homo sapiens	79-105
14662724-0	2004	Desensitisation of mast cell beta2-adrenoceptor-mediated responses by salmeterol and formoterol.	salmeterol xinafoate	70-80	adrenoceptor beta 2	Homo sapiens	29-47
14678342-0	2004	The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol.	salmeterol xinafoate	136-146	adrenoceptor beta 2	Homo sapiens	16-34
14662724-4	2004	By contrast, the long-acting beta(2)-adrenoceptor agonist salmeterol (10(-10)-10(-6) m) was about two-thirds less efficacious than either formoterol or isoprenaline as an inhibitor of histamine release.	salmeterol xinafoate	58-68	adrenoceptor beta 2	Homo sapiens	29-49
14662724-11	2004	The desensitisation induced by long-term treatments with salmeterol and formoterol was specific for beta(2)-adrenoceptor-mediated inhibition of histamine release as the inhibitory effects of alternative cAMP-elevating compounds, prostaglandin E(2), a receptor-mediated activator of adenylate cyclase, and forskolin, a direct activator of adenylate cyclase, were unaffected by desensitising treatments.	salmeterol xinafoate	57-67	adrenoceptor beta 2	Homo sapiens	100-120
14662724-14	2004	Isoprenaline, formoterol and salmeterol (all at 10(-6) m) reduced beta(2)-adrenoceptor density by 13+/-5 (P>0.05), 49+/-13 (P<0.05) and 35+/-17% (P>0.05), respectively.	salmeterol xinafoate	29-39	adrenoceptor beta 2	Homo sapiens	66-86
14662724-16	2004	These data indicate that long-term exposure of mast cells to both salmeterol and formoterol can cause substantial levels of desensitisation to beta(2)-adrenoceptor-mediated responses in mast cells.	salmeterol xinafoate	66-76	adrenoceptor beta 2	Homo sapiens	143-163
15182210-9	2004	Recently, long-acting beta2-adrenoceptor agonists (beta2-agonists) such as formoterol and salmeterol and anticholinergic medications including tiotropium bromide have been developed which may further improve symptom management in COPD patients.	salmeterol xinafoate	90-100	adrenoceptor beta 2	Homo sapiens	22-40
15350154-1	2004	The two inhaled long-acting beta2-adrenoceptor agonists, salmeterol and formoterol, have been studied extensively since their introduction in the early 1990s.	salmeterol xinafoate	57-67	adrenoceptor beta 2	Homo sapiens	28-46
15123228-6	2004	Salmeterol + rolipram synergistically enhanced the blockade of eotaxin-activated adhesion.	salmeterol xinafoate	0-10	C-C motif chemokine ligand 11	Homo sapiens	63-70
15123228-7	2004	Eotaxin also caused approximately 50% increase in surface CD11b expression, which was blocked additively by rolipram + salmeterol.	salmeterol xinafoate	119-129	C-C motif chemokine ligand 11	Homo sapiens	0-7
15123228-7	2004	Eotaxin also caused approximately 50% increase in surface CD11b expression, which was blocked additively by rolipram + salmeterol.	salmeterol xinafoate	119-129	integrin subunit alpha M	Homo sapiens	58-63
15219176-10	2004	CONCLUSIONS: Short-term treatment with the combined inhaled corticosteroid and long-acting beta(2)-adrenoceptor agonist fluticasone propionate/salmeterol resulted in greater control of lung function and symptoms than combined ipratropium bromide/albuterol bronchodilator therapy, in patients with COPD.	salmeterol xinafoate	143-153	adrenoceptor beta 2	Homo sapiens	91-111
15219176-10	2004	CONCLUSIONS: Short-term treatment with the combined inhaled corticosteroid and long-acting beta(2)-adrenoceptor agonist fluticasone propionate/salmeterol resulted in greater control of lung function and symptoms than combined ipratropium bromide/albuterol bronchodilator therapy, in patients with COPD.	salmeterol xinafoate	143-153	COPD	Homo sapiens	297-301
14681337-6	2004	Other classes of drugs that demonstrated inhibition of aldehyde oxidase included phenothiazines, tricyclic antidepressants, tricyclic atypical antipsychotic agents, and dihydropyridine calcium channel blockers, along with some other drugs, including loratadine, cyclobenzaprine, amodiaquine, maprotiline, ondansetron, propafenone, domperidone, quinacrine, ketoconazole, verapamil, tacrine, and salmeterol.	salmeterol xinafoate	394-404	aldehyde oxidase 1	Homo sapiens	55-71
15182210-9	2004	Recently, long-acting beta2-adrenoceptor agonists (beta2-agonists) such as formoterol and salmeterol and anticholinergic medications including tiotropium bromide have been developed which may further improve symptom management in COPD patients.	salmeterol xinafoate	90-100	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	22-27
14563743-7	2003	Salmeterol and fluticasone significantly increased FEV1 before a beta agonist was used and morning peak expiratory flow compared with montelukast and fluticasone (P < or = 0.001), whereas FEV1 after a beta agonist was used and improvements in asthma specific quality of life and nocturnal awakenings were similar between the groups.	salmeterol xinafoate	0-10	amyloid beta precursor protein	Homo sapiens	63-69
19807351-3	2003	Fluticasone propionate (Flixotide) and the long-acting beta2 agonist salmeterol (Serevent), are now available in the USA together in an easy to use dry powder inhaler Advair.	salmeterol xinafoate	69-79	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	55-60
19807351-3	2003	Fluticasone propionate (Flixotide) and the long-acting beta2 agonist salmeterol (Serevent), are now available in the USA together in an easy to use dry powder inhaler Advair.	salmeterol xinafoate	81-89	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	55-60
14699834-0	2003	[Salmeterol + fluticasone in COPD.	salmeterol xinafoate	1-11	COPD	Homo sapiens	29-33
14563743-7	2003	Salmeterol and fluticasone significantly increased FEV1 before a beta agonist was used and morning peak expiratory flow compared with montelukast and fluticasone (P < or = 0.001), whereas FEV1 after a beta agonist was used and improvements in asthma specific quality of life and nocturnal awakenings were similar between the groups.	salmeterol xinafoate	0-10	amyloid beta precursor protein	Homo sapiens	202-208
12897749-8	2003	RESULTS: Rolipram unmasked the inhibitory effect of beta(2)-adrenoceptor stimulation with salmeterol and significantly attenuated the stimulated release of AA and subsequent LTC(4).	salmeterol xinafoate	90-100	adrenoceptor beta 2	Homo sapiens	52-72
14627180-2	2003	After their introduction, beta2-agonists with a long duration of action--formoterol and salmeterol--became widely used as maintenance therapy with inhaled corticosteroids (ICS).	salmeterol xinafoate	88-98	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	26-31
12823118-6	2003	RESULTS: Compared to salmeterol alone (i.e. after the steroid washout), the use of fluticasone/salmeterol combination conferred significant improvements (P < 0.05) in all surrogate markers of inflammation apart from serum ECP.	salmeterol xinafoate	95-105	ribonuclease A family member 3	Homo sapiens	225-228
12796155-8	2003	RESULTS: Treatment with salmeterol, 50 micro g bid, showed no increased risk of cardiovascular adverse events (AEs) compared with placebo (relative risk, 1.03; 95% confidence interval, 0.8 to 1.3; p = 0.838).	salmeterol xinafoate	24-34	BH3 interacting domain death agonist	Homo sapiens	47-50
12796155-13	2003	CONCLUSIONS: Treatment with salmeterol, 50 micro g bid, does not increase the risk of cardiovascular AEs in this population of COPD patients compared with placebo.	salmeterol xinafoate	28-38	BH3 interacting domain death agonist	Homo sapiens	51-54
12747900-0	2003	Combined salmeterol and fluticasone for COPD.	salmeterol xinafoate	9-19	COPD	Homo sapiens	40-44
12810191-2	2003	There is increasing evidence that long-acting agents, such as the beta(2)-adrenoceptor agonists salmeterol and formeterol, and the new anticholinergic tiotropium bromide provide a better therapeutic option.	salmeterol xinafoate	96-106	adrenoceptor beta 2	Homo sapiens	66-86
12797494-0	2003	Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo.	salmeterol xinafoate	37-47	C-X-C motif chemokine ligand 8	Homo sapiens	56-69
12797494-3	2003	There is currently interest in the "neutrophil system" in asthma, and thus the aim of the present study was to investigate the effect of salmeterol on interleukin (IL)-8, neutrophils and myeloperoxidase (MPO) in persistent asthma.	salmeterol xinafoate	137-147	C-X-C motif chemokine ligand 8	Homo sapiens	151-169
12797494-4	2003	In the same 12-week double-blind parallel-group placebo-controlled study as described previously, the effects on bronchoalveolar lavage fluid (BALF) IL-8, neutrophils and MPO of introducing salmeterol (50 microg b.i.d.)	salmeterol xinafoate	190-200	myeloperoxidase	Homo sapiens	171-174
12797494-10	2003	In contrast, introducing salmeterol significantly reduced IL-8 and MPO levels, but did not affect BALF neutrophil numbers.	salmeterol xinafoate	25-35	C-X-C motif chemokine ligand 8	Homo sapiens	58-62
12797494-10	2003	In contrast, introducing salmeterol significantly reduced IL-8 and MPO levels, but did not affect BALF neutrophil numbers.	salmeterol xinafoate	25-35	myeloperoxidase	Homo sapiens	67-70
12797494-11	2003	Interestingly, salmeterol and fluticasone showed significantly contrasting effects on MPO and neutrophils, and there was a divergent effect on IL-8 levels that almost reached significance.	salmeterol xinafoate	15-25	myeloperoxidase	Homo sapiens	86-89
12747902-0	2003	Combined salmeterol and fluticasone for COPD.	salmeterol xinafoate	9-19	COPD	Homo sapiens	40-44
12747905-0	2003	Combined salmeterol and fluticasone for COPD.	salmeterol xinafoate	9-19	COPD	Homo sapiens	40-44
15025036-9	2003	Salmeterol together with BDP decreased sputum ECP from a pretreatment median value of 897.84 microg/l to 628.38 microg/l after 4 weeks, and ECP continued to decrease even after salmeterol withdrawal.	salmeterol xinafoate	0-10	ribonuclease A family member 3	Homo sapiens	46-49
12814152-2	2003	The long-acting beta2-agonist salmeterol has been shown in vitro to cause a significant increase in ciliary beat frequency.	salmeterol xinafoate	30-40	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	16-21
12728159-11	2003	Compared with placebo, TDI focal score improved in both the tiotropium group (1.1 (0.3) units, p<0.001) and the salmeterol group (0.7 (0.3) units, p<0.05).	salmeterol xinafoate	115-125	TLX1 neighbor	Homo sapiens	23-26
12578401-7	2003	Current evidence suggests that long-acting beta(2)-adrenoreceptor agonists such as salmeterol and the new long-acting anticholinergic agent tiotropium bromide are more efficacious than their shorter acting equivalents such as salbutamol and ipratropium bromide in terms of bronchodilation, improved well-being and a reduction in acute exacerbation rates.	salmeterol xinafoate	83-93	adrenoceptor beta 2	Homo sapiens	43-65
12621035-5	2003	To verify this, we evaluated the effects of a pharmacologically relevant concentration of salmeterol (2.10(-7) m), a long acting beta(2)AR agonist, on CFTR expression in primary human airway epithelial cells (HAEC).	salmeterol xinafoate	90-100	adrenoceptor beta 2	Homo sapiens	129-138
12621035-5	2003	To verify this, we evaluated the effects of a pharmacologically relevant concentration of salmeterol (2.10(-7) m), a long acting beta(2)AR agonist, on CFTR expression in primary human airway epithelial cells (HAEC).	salmeterol xinafoate	90-100	CF transmembrane conductance regulator	Homo sapiens	151-155
12621035-8	2003	Analyses of anti-EBP50 protein immunoprecipitate showed that salmeterol induced an increase in the amount of CFTR that binds to EBP50.	salmeterol xinafoate	61-71	SLC9A3 regulator 1	Homo sapiens	17-22
12621035-8	2003	Analyses of anti-EBP50 protein immunoprecipitate showed that salmeterol induced an increase in the amount of CFTR that binds to EBP50.	salmeterol xinafoate	61-71	CF transmembrane conductance regulator	Homo sapiens	109-113
12621035-8	2003	Analyses of anti-EBP50 protein immunoprecipitate showed that salmeterol induced an increase in the amount of CFTR that binds to EBP50.	salmeterol xinafoate	61-71	SLC9A3 regulator 1	Homo sapiens	128-133
12735660-1	2003	Several clinical trials have shown that the inhaled beta2-agonists with long-acting properties, formoterol and salmeterol, may be effective in acute exacerbations of chronic obstructive pulmonary disease (COPD).	salmeterol xinafoate	111-121	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	52-57
12594059-6	2003	In contrast, BK-induced IL-6 secretion was enhanced by exogenous prostaglandin E(2) and salmeterol.	salmeterol xinafoate	88-98	kininogen 1	Homo sapiens	13-15
12594059-6	2003	In contrast, BK-induced IL-6 secretion was enhanced by exogenous prostaglandin E(2) and salmeterol.	salmeterol xinafoate	88-98	interleukin 6	Homo sapiens	24-28
14719995-6	2003	However, in subsequent studies, the long-acting beta(2)-agonist salmeterol was not associated with increased asthma mortality.	salmeterol xinafoate	64-74	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	48-54
12917905-30	2003	Fewer adverse events occurred in subjects using long-acting beta-2 agonists(salmeterol and formoterol) as compared to theophylline.	salmeterol xinafoate	76-86	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	60-66
23300391-11	2003	Because the duration of bronchoprotection decreases with daily use (tachyphylaxis), long acting beta2-adrenergic agonists (e.g., formoterol, salmeterol) have a limited role in treating exercise-induced bronchospasm.	salmeterol xinafoate	141-151	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	96-101
12749831-0	2003	A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists.	salmeterol xinafoate	16-26	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	90-95
14510626-12	2003	The main pharmacological difference between the agents is that formoterol is a full beta2-adrenergic agonist, whereas salmeterol is a partial agonist at the beta2-adrenoceptor and has a unique pharmacological action.	salmeterol xinafoate	118-128	adrenoceptor beta 2	Homo sapiens	157-175
12850128-0	2003	Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline.	salmeterol xinafoate	0-10	BH3 interacting domain death agonist	Homo sapiens	50-53
12850128-3	2003	AIM: of the present small pilot study was to compare Salmeterol & Fluticasone (SM&FP) 50/250 microg bid via a single Diskus inhaler with SM 50 microg bid alone, and with placebo (P) in the treatment of moderate COPD.	salmeterol xinafoate	53-63	BH3 interacting domain death agonist	Homo sapiens	158-161
12166584-11	2002	With salmeterol, only serum EPX decreased, after 4 weeks.	salmeterol xinafoate	5-15	eosinophil peroxidase	Homo sapiens	28-31
12510953-1	2002	Long-acting beta2-agonists (formoterol and salmeterol) represent the latest advance in a series of improvements in beta-agonist asthma therapy since the introduction of isoprenaline.	salmeterol xinafoate	43-53	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	12-17
12503692-10	2002	In conclusion, a novel antineutrophilic effect of the inhaled long-acting beta2-adrenergic receptor agonist, salmeterol, in mild asthma is reported.	salmeterol xinafoate	109-119	adrenoceptor beta 2	Homo sapiens	74-99
12379559-7	2002	Combining salmeterol with fluticasone propionate counteracted goblet cell hyperplasia, but increased the amount of fibronectin and collagen in the airway wall.	salmeterol xinafoate	10-20	fibronectin 1	Rattus norvegicus	115-126
12236842-1	2002	The established place of regular long-acting beta2-adrenoceptor agonists at step 3 in asthma management guidelines has evolved as a consequence of evidence showing additive effects of salmeterol and formoterol on exacerbation rates, resulting in a putative inhaled corticosteroid sparing effect.	salmeterol xinafoate	184-194	adrenoceptor beta 2	Homo sapiens	45-63
14613397-1	2002	OBJECTIVE: To review the consistency of scientific, clinical, and economic evidence related to dual-controller therapy with inhaled corticosteroids (ICS) and the inhaled long-acting beta2-agonist (LABA) salmeterol in treating patients whose asthma is not controlled with ICS alone.	salmeterol xinafoate	203-213	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	182-187
14613398-6	2002	Overall cost per patient of dual-controller therapy consisting of fluticasone propionate and the inhaled long-acting beta2-agonist salmeterol was lower than a regimen consisting of either another inhaled corticosteroid with salmeterol or an inhaled corticosteroid with a leukotriene modifier.	salmeterol xinafoate	131-141	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	117-122
12205813-8	2002	Long-acting beta 2-agonists (formoterol, salmeterol) are not authorized in France in children under 4 to 5 years of age depending on the drug used.	salmeterol xinafoate	41-51	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	12-18
12072587-6	2002	Salmeterol increased mean rate-pressure product by 5% (salmeterol 8878 +/- 1560 vs. placebo 8414 +/- 1440 bpm x mm Hg, p = 0.04), although no increase in plasma norepinephrine, epinephrine, plasma renin activity or ventricular ectopy was detected.	salmeterol xinafoate	0-10	renin	Homo sapiens	197-202
12098582-4	2002	The beta(2)-adrenoceptor agonists clenbuterol (1-100 microM) and salmeterol (0.01-1 microM) induced profound morphological changes of cultured astrocytes which transformed into activated astroglia with pronounced dendrite-like processes.	salmeterol xinafoate	65-75	adrenergic receptor, beta 2	Mus musculus	4-24
12068339-0	2002	The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial.	salmeterol xinafoate	16-26	BH3 interacting domain death agonist	Homo sapiens	37-40
12068339-3	2002	OBJECTIVES: To compare the effect of adding salmeterol (50 microg bid) or placebo to concurrent anticholinergic therapy on symptom scores, quality of life, prebronchodilator lung function and exacerbations in patients with moderately severe COPD.	salmeterol xinafoate	44-54	BH3 interacting domain death agonist	Homo sapiens	66-69
14720033-1	2002	Beta2-adrenoceptor agonists (beta2-agonists) such as albuterol (salbutamol) and terbutaline and their long-acting analogs salmeterol and formoterol are widely used as bronchodilators in the treatment of asthma.	salmeterol xinafoate	122-132	adrenoceptor beta 2	Homo sapiens	0-18
14720047-1	2002	Salmeterol/fluticasone propionate is a fixed-dose combination of the long-acting beta2-adrenoceptor agonist salmeterol and the corticosteroid fluticasone propionate and is inhaled via the Diskus powder inhaler.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	81-99
14720033-1	2002	Beta2-adrenoceptor agonists (beta2-agonists) such as albuterol (salbutamol) and terbutaline and their long-acting analogs salmeterol and formoterol are widely used as bronchodilators in the treatment of asthma.	salmeterol xinafoate	122-132	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	29-34
11676144-4	2001	Combining an inhaled corticosteroid, fluticasone propionate with a long-acting beta 2-adrenergic bronchodilator, salmeterol in a single inhaler permits treatment of both the inflammatory and bronchoconstrictive components of asthma.	salmeterol xinafoate	113-123	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	79-85
14720076-1	2002	Salmeterol and formoterol are both long-acting beta(2)-adrenoceptor agonists (beta(2)-agonists).	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	47-67
14720076-1	2002	Salmeterol and formoterol are both long-acting beta(2)-adrenoceptor agonists (beta(2)-agonists).	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	47-53
11825095-1	2002	Salmeterol is an inhaled long-acting selective beta(2)-adrenoceptor agonist that is commercially available as the xinafoate (1-hydroxy-2-naphthoic acid) salt of the racemic mixture of the two optical isomers, (R)- and (S)-, of salmeterol.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	47-67
11770693-2	2001	Some patients, if previously instructed to double their inhaled corticosteroids, may double this product, inadvertently receiving higher doses of salmeterol, potentially causing systemic beta2-agonist-related effects.	salmeterol xinafoate	146-156	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	187-192
11770695-10	2001	Our results demonstrate that the use of an MDI and VHC provides a reasonable therapeutic approach for administration of salmeterol MDI to young children and other patients who have difficulties administering the MDI alone.	salmeterol xinafoate	120-130	MAFD2	Homo sapiens	43-46
11770695-10	2001	Our results demonstrate that the use of an MDI and VHC provides a reasonable therapeutic approach for administration of salmeterol MDI to young children and other patients who have difficulties administering the MDI alone.	salmeterol xinafoate	120-130	MAFD2	Homo sapiens	131-134
11770695-10	2001	Our results demonstrate that the use of an MDI and VHC provides a reasonable therapeutic approach for administration of salmeterol MDI to young children and other patients who have difficulties administering the MDI alone.	salmeterol xinafoate	120-130	MAFD2	Homo sapiens	131-134
11676144-5	2001	Combination treatment with fluticasone and salmeterol improves symptoms and lung function, reduces supplemental use of short-acting beta 2-adrenergic bronchodilator.	salmeterol xinafoate	43-53	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	132-138
11589265-2	2001	Formoterol and salmeterol are long-acting beta2-agonists.	salmeterol xinafoate	15-25	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	42-47
11589265-14	2001	Thus, although both formoterol and salmeterol are long-acting beta2-agonists, formoterol had a more rapid onset of action.	salmeterol xinafoate	35-45	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	62-67
11594259-1	2001	Salmeterol and formoterol are both beta 2-agonist bronchodilators with a long duration of action and are often classified together, yet they are distinctly different in their pharmacology.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	35-41
11435249-11	2001	The demonstrated fall in vessel number within the salmeterol-treated group may suggest an advantageous effect of long-acting beta2-agonists on this manifestation of airway remodeling over the 3-mo time scale of this study, which is complementary to the action of ICS on airway vascularity.	salmeterol xinafoate	50-60	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	125-130
11534892-4	2001	The development of beta2-agonists with long-acting properties, such as salmeterol and formoterol, has provided advantages over short-acting beta-agonists, such as prolonged bronchodilation, reduced day- and night-time symptoms and improved quality of sleep, and has reduced the requirement for short-acting beta2-agonists as relief medication.	salmeterol xinafoate	71-81	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	19-24
11534892-4	2001	The development of beta2-agonists with long-acting properties, such as salmeterol and formoterol, has provided advantages over short-acting beta-agonists, such as prolonged bronchodilation, reduced day- and night-time symptoms and improved quality of sleep, and has reduced the requirement for short-acting beta2-agonists as relief medication.	salmeterol xinafoate	71-81	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	307-312
11534896-6	2001	Thus, formoterol has higher intrinsic activity than salmeterol, which means that it is a full agonist, whereas salmeterol is a partial agonist on the beta2-receptor.	salmeterol xinafoate	111-121	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	150-155
11534896-9	2001	Salmeterol, on the other hand, may diffuse more slowly to the beta2-receptor because of its high lipophilicity explaining the slower onset of action.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	62-67
11534896-10	2001	Unlike salbutamol, which is hydrophilic and has a rapid onset and short duration of action, both formoterol and salmeterol possess adequate lipophilic properties to remain in the airway tissues as a depot in close vicinity to the beta2-receptor, explaining their long duration of effect.	salmeterol xinafoate	112-122	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	230-235
11534896-11	2001	The long duration of salmeterol has also been suggested to depend on an anchored binding within the beta2-receptor.	salmeterol xinafoate	21-31	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	100-105
11260155-1	2001	A previous study suggested that the long-acting beta2-adrenergic agonist salmeterol (SM) had inhibitory effects on bronchial mucosal inflammation 6 hours after allergen exposure.	salmeterol xinafoate	73-83	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	48-53
11510784-0	2001	Fluticasone and salmeterol downregulate in vitro, fibroblast proliferation and ICAM-1 or H-CAM expression.	salmeterol xinafoate	16-26	intercellular adhesion molecule 1	Homo sapiens	79-85
11413351-1	2001	BACKGROUND: In vitro the long acting beta2 agonist salmeterol can, in contrast to formoterol, behave as a partial agonist and become a partial antagonist to other beta2 agonists.	salmeterol xinafoate	51-61	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	37-42
11413351-1	2001	BACKGROUND: In vitro the long acting beta2 agonist salmeterol can, in contrast to formoterol, behave as a partial agonist and become a partial antagonist to other beta2 agonists.	salmeterol xinafoate	51-61	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	163-168
11316640-0	2001	Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.	salmeterol xinafoate	55-75	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	29-34
11250877-0	2001	Chronic systemic administration of salmeterol to rats promotes pulmonary beta(2)-adrenoceptor desensitization and down-regulation of G(s alpha).	salmeterol xinafoate	35-45	adrenoceptor beta 2	Rattus norvegicus	73-93
11250877-2	2001	The aim of the present study was to examine the effects of chronic infusion of the long-acting agonist salmeterol on pulmonary beta(2)-adrenoceptor function in Sprague-Dawley rats in vivo and to elucidate the molecular basis of any altered state.	salmeterol xinafoate	103-113	adrenoceptor beta 2	Rattus norvegicus	127-147
11250877-5	2001	3. beta(1)- and beta(2)-adrenoceptor density was significantly reduced in lung membranes harvested from salmeterol-treated animals, which was associated with impaired salmeterol- and PGE(2)-induced cyclic AMP accumulation ex vivo.	salmeterol xinafoate	104-114	adrenoceptor beta 2	Rattus norvegicus	16-36
11250877-5	2001	3. beta(1)- and beta(2)-adrenoceptor density was significantly reduced in lung membranes harvested from salmeterol-treated animals, which was associated with impaired salmeterol- and PGE(2)-induced cyclic AMP accumulation ex vivo.	salmeterol xinafoate	167-177	adrenoceptor beta 2	Rattus norvegicus	16-36
11282760-4	2001	We conducted a double-blind, placebo-controlled, crossover study of the effect of the long-acting beta(2)-agonist salmeterol on airway inflammation induced by segmental allergen challenge (SAC).	salmeterol xinafoate	114-124	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	98-104
11260155-1	2001	A previous study suggested that the long-acting beta2-adrenergic agonist salmeterol (SM) had inhibitory effects on bronchial mucosal inflammation 6 hours after allergen exposure.	salmeterol xinafoate	85-87	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	48-53
11293649-8	2001	Long-acting inhaled beta2 agonists (e.g. salmeterol, formoterol) are effective in managing nocturnal asthma that is inadequately controlled by anti-inflammatory agents.	salmeterol xinafoate	41-51	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	20-25
16263481-5	2001	Beta2-agonists have been characterised into those which directly activate the receptor (salbutamol/terbutaline), those which are taken up into a membrane depot (formoterol) and those which interact with a receptor-specific, auxiliary binding site (salmeterol).	salmeterol xinafoate	248-258	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	0-5
11368253-2	2001	This paper presents age- and gender-specific asthma death rates in patients prescribed the long-acting beta2-agonists salmeterol and bambuterol.	salmeterol xinafoate	118-128	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	103-108
11174215-9	2001	The superior control is likely a consequence of the complementary actions of the drugs when taken together, including the activation of the glucocorticoid receptor by salmeterol.	salmeterol xinafoate	167-177	nuclear receptor subfamily 3 group C member 1	Homo sapiens	140-163
11419918-1	2001	UNLABELLED: Inhaled salmeterol is a long-acting, selective beta2-adrenoceptor agonist bronchodilator.	salmeterol xinafoate	20-30	adrenoceptor beta 2	Homo sapiens	59-77
11149914-4	2001	We found that TNF-alpha stimulated eotaxin release (assayed by ELISA) from HASM cells and that the release was partially inhibited by salbutamol and salmeterol.	salmeterol xinafoate	149-159	tumor necrosis factor	Homo sapiens	14-23
11149914-4	2001	We found that TNF-alpha stimulated eotaxin release (assayed by ELISA) from HASM cells and that the release was partially inhibited by salbutamol and salmeterol.	salmeterol xinafoate	149-159	C-C motif chemokine ligand 11	Homo sapiens	35-42
11293649-12	2001	Studies comparing salmeterol to oral long-acting beta2 agonists reveal salmeterol to be superior to terbutaline and equivalent in efficacy to other oral agents.	salmeterol xinafoate	71-81	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	49-54
11115442-5	2000	Maximum significant increases in FEV(1) over baseline values that were observed after 3 months of treatment were as follows: salmeterol, 50 microg bid, 0.163 L (95% confidence interval [CI], 0.080 to 0.245 L); salmeterol, 50 microg, plus fluticasone propionate, 250 microg bid, 0.188 L (95% CI, 0.089 to 0.	salmeterol xinafoate	125-135	BH3 interacting domain death agonist	Homo sapiens	273-276
11129128-1	2000	UNLABELLED: The long-acting beta2-agonist salmeterol and the corticosteroid fluticasone propionate are available as a combination inhalation device for the treatment of persistent asthma.	salmeterol xinafoate	42-52	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	28-33
11213376-7	2000	Fixed combinations of the long-acting beta 2-agonist salmeterol and the inhaled corticosteroid fluticasone propionate were launched recently.	salmeterol xinafoate	53-63	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	38-44
11061043-5	2000	Current guidelines recommend adding a long-acting beta 2-agonist such as salmeterol to the inhaled corticosteroid.	salmeterol xinafoate	73-83	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	50-56
10950895-3	2000	METHODS: In a retrospective analysis of previously published data we have examined relationships between polymorphisms at codons 16 and 27 of the beta(2) adrenoceptor and clinical outcomes in a randomised, placebo controlled, crossover trial of regularly scheduled salbutamol and salmeterol in 115 patients with mild to moderate asthma.	salmeterol xinafoate	280-290	adrenoceptor beta 2	Homo sapiens	146-166
10983735-1	2000	Long-acting beta2 agonist bronchodilators (e.g. formoterol, salmeterol) are a new interesting therapeutic option for patients with chronic obstructive pulmonary disease (COPD).	salmeterol xinafoate	60-70	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	12-17
10936119-0	2000	Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism.	salmeterol xinafoate	42-52	adrenoceptor beta 2	Homo sapiens	112-132
10934892-1	2000	BACKGROUND: Salmeterol is a long-acting inhaled beta 2-agonist with a bronchodilating effect lasting over 10 to 12 hours.	salmeterol xinafoate	12-22	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	48-54
10873156-2	2000	Here, we tested the effects of the beta(2)-agonists salbutamol (Salbu) and salmeterol (Salme) on IL-8 release and tumor necrosis factor (TNF)-alpha-induced IL-8 release from ASM cells.	salmeterol xinafoate	75-85	C-X-C motif chemokine ligand 8	Homo sapiens	97-101
10873156-2	2000	Here, we tested the effects of the beta(2)-agonists salbutamol (Salbu) and salmeterol (Salme) on IL-8 release and tumor necrosis factor (TNF)-alpha-induced IL-8 release from ASM cells.	salmeterol xinafoate	87-92	C-X-C motif chemokine ligand 8	Homo sapiens	97-101
10873156-4	2000	TNF-alpha (10 ng/ml)-induced IL-8 release was markedly inhibited by the steroids dexamethasone (Dex) (0.1 to 10 microM) and fluticasone (Flut) (0.01 to 1 microM) but unaffected by Salbu, Salme, FSK, or 8-Br-cAMP.	salmeterol xinafoate	187-192	tumor necrosis factor	Homo sapiens	0-9
10873156-4	2000	TNF-alpha (10 ng/ml)-induced IL-8 release was markedly inhibited by the steroids dexamethasone (Dex) (0.1 to 10 microM) and fluticasone (Flut) (0.01 to 1 microM) but unaffected by Salbu, Salme, FSK, or 8-Br-cAMP.	salmeterol xinafoate	187-192	C-X-C motif chemokine ligand 8	Homo sapiens	29-33
10934892-2	2000	METHODS: A prospective, open, multi-centre study was performed to evaluate the efficacy and safety of inhaled salmeterol (50 micrograms BID) over a mean treatment period of 29 months (range: 4-1145 days) in 634 patients (54% male, age 45 +/- 15 years) with mild to moderate asthma or chronic obstructive pulmonary disease (COPD).	salmeterol xinafoate	110-120	BH3 interacting domain death agonist	Homo sapiens	136-139
10515401-0	1999	The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma.	salmeterol xinafoate	30-50	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	16-21
10516654-7	1999	However, all of the beta2 adrenoceptor agonists produced increases in CRE-driven luciferase activity, in cultured HASM transfected with the vector p6CRE/luc, which were equivalent or greater (salmeterol) than those seen with isoprenaline.	salmeterol xinafoate	192-202	adrenoceptor beta 2	Homo sapiens	20-38
10471277-0	1999	Probing the salmeterol binding site on the beta 2-adrenergic receptor using a novel photoaffinity ligand, [(125)I]iodoazidosalmeterol.	salmeterol xinafoate	12-22	adrenoceptor beta 2	Homo sapiens	43-69
10471277-1	1999	Salmeterol is a long-acting beta2-adrenergic receptor (beta 2AR) agonist used clinically to treat asthma.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	28-53
10471277-1	1999	Salmeterol is a long-acting beta2-adrenergic receptor (beta 2AR) agonist used clinically to treat asthma.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	55-63
10471277-3	1999	To determine the position of the phenyl ring of the aralkyloxyalkyl side chain of salmeterol in the beta 2AR binding site, we designed and synthesized the agonist photoaffinity label [(125)I]iodoazidosalmeterol ([125I]IAS).	salmeterol xinafoate	82-92	adrenoceptor beta 2	Homo sapiens	100-108
10653047-11	1999	Salmeterol caused a significantly greater reduction in daytime symptom score and use of as-needed beta2-agoinist therapy between sensitivity and treatment periods compared with placebo (P<0.05 for both).	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	98-103
10556111-0	1999	An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma.	salmeterol xinafoate	30-40	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	56-62
10573242-7	1999	Whereas baseline forced expiratory volume in one second (FEV1) improved in all treatment groups, only treatment with a combination of salmeterol and beclomethasone significantly inhibited the allergen-induced increase in serum ECP, and (primed/unprimed) PAF-release, suggesting inhibition of eosinophil priming after allergen challenge.	salmeterol xinafoate	134-144	ribonuclease A family member 3	Homo sapiens	227-230
10573242-10	1999	During monotherapy with salmeterol, an allergen-induced increase in serum ECP concentration and STZ (0.1 mg x mL(-1))-induced respiratory burst was observed, suggesting that treatment with salmeterol alone had no effect on priming-sensitive eosinophil cytotoxic mechanisms.	salmeterol xinafoate	24-34	ribonuclease A family member 3	Homo sapiens	74-77
10573242-10	1999	During monotherapy with salmeterol, an allergen-induced increase in serum ECP concentration and STZ (0.1 mg x mL(-1))-induced respiratory burst was observed, suggesting that treatment with salmeterol alone had no effect on priming-sensitive eosinophil cytotoxic mechanisms.	salmeterol xinafoate	189-199	ribonuclease A family member 3	Homo sapiens	74-77
10563469-1	1999	BACKGROUND: Salmeterol is a long-acting beta2-agonist which in animal studies has been shown to possess anti-inflammatory effects on early (EAR) and late (LPR) phase allergic responses.	salmeterol xinafoate	12-22	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	40-45
10515401-1	1999	Salmeterol xinafoate is an inhaled long-acting beta2-adrenoceptor agonist recently introduced for the treatment of asthma.	salmeterol xinafoate	0-20	adrenoceptor beta 2	Homo sapiens	47-65
10377209-1	1999	BACKGROUND: The long acting beta2 agonist salmeterol is very effective in preventing asthmatic responses to specific stimuli, and this effect could theoretically be due to some anti-inflammatory property in addition to bronchodilator property.	salmeterol xinafoate	42-52	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	28-33
10492055-1	1999	OBJECTIVES: The primary aim of the present study was to evaluate comparative trough effects of formoterol and salmeterol on beta2-adrenoceptor regulation and bronchodilator response after regular twice-daily treatment, with a secondary aim to evaluate any possible association with beta2-adrenoceptor polymorphism.	salmeterol xinafoate	110-120	adrenoceptor beta 2	Homo sapiens	124-142
10492055-0	1999	Comparative trough effects of formoterol and salmeterol on lymphocyte beta2-adrenoceptor--regulation and bronchodilatation.	salmeterol xinafoate	45-55	adrenoceptor beta 2	Homo sapiens	70-88
10084467-5	1999	sBPT was done in all subjects after a single dose (T1) and after 1 week of regular treatment with inhaled salmeterol (50 microg bid) (T2) in order to induce tolerance.	salmeterol xinafoate	106-116	BH3 interacting domain death agonist	Homo sapiens	128-131
10400406-1	1999	Current evidence suggests that addition of the long-acting beta2-agonist salmeterol to an inhaled corticosteroid in patients with persistent asthma symptoms provides greater clinical benefit than doubling the dosage of the inhaled corticosteroid.	salmeterol xinafoate	73-83	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	59-64
10359889-1	1999	BACKGROUND: Salmeterol, a long-acting beta2 -agonist, and zafirlukast, a leukotriene receptor antagonist, are both indicated for the treatment of asthma in adolescent and adult patients.	salmeterol xinafoate	12-22	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	38-43
10208192-0	1999	Efficacy of salmeterol xinafoate in the treatment of COPD.	salmeterol xinafoate	12-32	COPD	Homo sapiens	53-57
10208192-1	1999	STUDY OBJECTIVES: To examine and compare the efficacy and safety of salmeterol xinafoate, a long-acting inhaled beta2-adrenergic agonist, with inhaled ipratropium bromide and inhaled placebo in patients with COPD.	salmeterol xinafoate	68-88	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	112-117
10208192-8	1999	Analyses of time to first COPD exacerbation revealed salmeterol to be superior to placebo and ipratropium (p < 0.05).	salmeterol xinafoate	53-63	COPD	Homo sapiens	26-30
10208192-10	1999	CONCLUSIONS: These collective data support the use of salmeterol as first-line bronchodilator therapy for the long-term treatment of airflow obstruction in patients with COPD.	salmeterol xinafoate	54-64	COPD	Homo sapiens	170-174
10094216-7	1999	CONCLUSION: Initiation of maintenance therapy with salmeterol and fluticasone propionate in patients with asthma treated with short-acting beta2-agonists alone provides greater improvements in pulmonary function and symptom control than initiation of maintenance therapy with fluticasone propionate alone.	salmeterol xinafoate	51-61	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	139-144
10200132-0	1999	Cardiac side effects of long-acting beta-2 agonist salmeterol in asthmatic children.	salmeterol xinafoate	51-61	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	36-42
10070112-1	1999	The aim of the present study was to investigate the in vitro effects of the short-acting beta2-adrenoceptor agonist salbutamol and the long-acting beta2-adrenoceptor agonist salmeterol on hypoxia-induced rat diaphragm force reduction.	salmeterol xinafoate	174-184	adrenoceptor beta 2	Rattus norvegicus	147-165
10027845-1	1999	The long-acting beta2 sympathomimetics salmeterol and formoterol have been presumed to exert their prolonged action either by binding to an accessory binding site ("exo-site") near the beta2 adrenoceptor or by their high affinity for beta2 adrenoceptors and correspondingly slow dissociation.	salmeterol xinafoate	39-49	adrenoceptor beta 2	Rattus norvegicus	185-203
9873044-3	1999	Here, we describe the ligand-independent activation of GR by the beta2-adrenergic receptor (beta2-AR) agonists, salbutamol and salmeterol, in primary human lung fibroblasts and vascular smooth muscle cells.	salmeterol xinafoate	127-137	nuclear receptor subfamily 3 group C member 1	Homo sapiens	55-57
9873044-3	1999	Here, we describe the ligand-independent activation of GR by the beta2-adrenergic receptor (beta2-AR) agonists, salbutamol and salmeterol, in primary human lung fibroblasts and vascular smooth muscle cells.	salmeterol xinafoate	127-137	adrenoceptor beta 2	Homo sapiens	65-90
9873044-3	1999	Here, we describe the ligand-independent activation of GR by the beta2-adrenergic receptor (beta2-AR) agonists, salbutamol and salmeterol, in primary human lung fibroblasts and vascular smooth muscle cells.	salmeterol xinafoate	127-137	adrenoceptor beta 2	Homo sapiens	92-100
9873044-5	1999	Treatment of the cells with the beta2-AR agonists, salbutamol or salmeterol, resulted in translocation of GR into the nucleus beginning at 30 min, as shown by immunohistochemistry and Western blotting of cytosolic and nuclear cell extracts.	salmeterol xinafoate	65-75	adrenoceptor beta 2	Homo sapiens	32-40
9873044-5	1999	Treatment of the cells with the beta2-AR agonists, salbutamol or salmeterol, resulted in translocation of GR into the nucleus beginning at 30 min, as shown by immunohistochemistry and Western blotting of cytosolic and nuclear cell extracts.	salmeterol xinafoate	65-75	nuclear receptor subfamily 3 group C member 1	Homo sapiens	106-108
9873044-9	1999	The effects of the beta2-AR agonists, salbutamol and salmeterol, were dependent upon binding to the beta2-AR, because blocking of beta2-AR with propranolol abrogated GR activation.	salmeterol xinafoate	53-63	adrenoceptor beta 2	Homo sapiens	19-27
9873044-9	1999	The effects of the beta2-AR agonists, salbutamol and salmeterol, were dependent upon binding to the beta2-AR, because blocking of beta2-AR with propranolol abrogated GR activation.	salmeterol xinafoate	53-63	adrenoceptor beta 2	Homo sapiens	100-108
9873044-9	1999	The effects of the beta2-AR agonists, salbutamol and salmeterol, were dependent upon binding to the beta2-AR, because blocking of beta2-AR with propranolol abrogated GR activation.	salmeterol xinafoate	53-63	adrenoceptor beta 2	Homo sapiens	100-108
10027094-1	1999	The aim of this study was to investigate the effects of IL-10, a cell permeable analogue of cyclic AMP, dibutyryl-cAMP (db-cAMP), modulators of intracellular cyclic AMP such as phosphodiesterase (PDE) inhibitors and a beta 2-adrenoceptor agonist, salmeterol, on pulmonary inflammation following acute lung injury induced by endotoxin exposure in rats.	salmeterol xinafoate	247-257	interleukin 10	Rattus norvegicus	56-61
10027094-5	1999	Salmeterol (0.5 mg/mL) and IL-10 (0.1 microgram) only inhibit TNF-alpha increase in the BAL fluid and db-AMPc (2.5 micrograms/rat) was ineffective.	salmeterol xinafoate	0-10	tumor necrosis factor	Rattus norvegicus	62-71
10023791-2	1999	To determine whether this fall could be prevented by the long-acting beta-2 agonist salmeterol at both standard (2 puffs: 42 mcg BID) and high (4 puffs, 84 mcg BID) doses, we evaluated the effects of salmeterol vs. albuterol (2 puffs, 180 mcg QID, and 4 puffs, 360 mcg BID) in a placebo-controlled three-way random crossover, double-blind trial.	salmeterol xinafoate	84-94	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	69-75
10023791-10	1999	We recommend the use of high-dose salmeterol in hospitalized patients with FVC values of 40% of predicted or greater, starting with 2 and increasing to 4 puffs BID as tolerated.	salmeterol xinafoate	34-44	BH3 interacting domain death agonist	Homo sapiens	160-163
9817738-6	1998	beta2-Agonists have been characterized as those that directly activate the receptor (albuterol), those that are taken up into a membrane depot (formoterol), and those that interact with a receptor-specific auxiliary binding site (salmeterol).	salmeterol xinafoate	230-240	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	0-5
10546463-5	1999	The drug of first choice is ipratropium bromide, but useful are also beta2-agonists of short (albuterol) and long action (salmeterol) and theophylline.	salmeterol xinafoate	122-132	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	69-74
10091511-1	1999	Formoterol and salmeterol are two long acting beta 2 agonists available for the treatment of asthma which show differences in onset of action.	salmeterol xinafoate	15-25	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	46-52
9877002-1	1998	BACKGROUND: Salmeterol xinafoate is a highly selective beta2-adrenoceptor for the maintenance treatment of asthma in adults and children.	salmeterol xinafoate	12-32	adrenoceptor beta 2	Homo sapiens	55-73
9877002-5	1998	CONCLUSION: Salmeterol is a safe long-acting beta2-agonist very useful for maintenance treatment of asthma.	salmeterol xinafoate	12-22	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	45-50
9916607-4	1998	The primary objective of this open-label study was to compare the efficacy and tolerability of salmeterol 50 microg BID administered by metered-dose inhaler versus oral, titrated, sustained-release theophylline BID, both given for 3 months to patients with a clinical history of chronic bronchitis.	salmeterol xinafoate	95-105	BH3 interacting domain death agonist	Homo sapiens	116-119
9916607-14	1998	These data suggest that inhaled salmeterol 50 microg BID was more effective and better tolerated than oral, titrated theophylline and allowed better long-term control of airways obstruction and symptoms with improved lung function in patients with COPD.	salmeterol xinafoate	32-42	BH3 interacting domain death agonist	Homo sapiens	53-56
9789513-1	1998	BACKGROUND: Therapy with salmeterol, a long-acting, selective, inhaled beta 2-adrenergic agonist, is effective and safe for patients with persistent asthma; however, few long-term studies comparing salmeterol with current combination treatment regimens have been reported.	salmeterol xinafoate	25-35	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	71-77
10096840-1	1998	Salmeterol xinafoate is the first of a new class of long acting, selective beta2-adrenoceptor agonists introduced for the treatment of asthma.	salmeterol xinafoate	0-20	beta-2 adrenergic receptor	Canis lupus familiaris	75-93
9831907-0	1998	Influence of receptor number on the stimulation by salmeterol of gene transcription in CHO-K1 cells transfected with the human beta2-adrenoceptor.	salmeterol xinafoate	51-61	adrenoceptor beta 2	Homo sapiens	127-145
9769277-1	1998	We determined the effect of a long acting beta2-agonist, salmeterol, on aspirin-induced asthma (AIA) attacks and urinary release of eicosanoids in a double-blind, placebo-controlled, crossover study in 10 asthmatics sensitive to aspirin.	salmeterol xinafoate	57-67	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	42-47
10622090-1	1998	Salmeterol and formoterol belong to a new class of inhaled beta 2-agonists with a prolonged duration of action.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	59-65
9765503-0	1998	Identification of a key amino acid of the beta2-adrenergic receptor for high affinity binding of salmeterol.	salmeterol xinafoate	97-107	adrenoceptor beta 2	Homo sapiens	42-67
9765503-7	1998	These results indicate that Tyr308 in TMD VII is the major amino acid conferring the beta2-selective binding of salmeterol to the beta2AR and that the position of the ether oxygen in the side chain is also important for beta2-selective binding.	salmeterol xinafoate	112-122	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	85-90
9765503-2	1998	The beta2-selective binding of salmeterol was not affected by the exchange of TMD I between the beta1- and beta2ARs.	salmeterol xinafoate	31-41	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	4-9
9765503-7	1998	These results indicate that Tyr308 in TMD VII is the major amino acid conferring the beta2-selective binding of salmeterol to the beta2AR and that the position of the ether oxygen in the side chain is also important for beta2-selective binding.	salmeterol xinafoate	112-122	adrenoceptor beta 2	Homo sapiens	130-137
9765503-3	1998	The affinity of salmeterol was slightly decreased (32-fold) by replacement of TMD II of the beta2AR with the homologous region of the beta1AR; the affinity was strongly decreased (1870-fold) for the beta2AR with TMD VII of the beta1AR.	salmeterol xinafoate	16-26	adrenoceptor beta 2	Homo sapiens	92-99
9765503-7	1998	These results indicate that Tyr308 in TMD VII is the major amino acid conferring the beta2-selective binding of salmeterol to the beta2AR and that the position of the ether oxygen in the side chain is also important for beta2-selective binding.	salmeterol xinafoate	112-122	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	130-135
9765503-8	1998	A three-dimensional model of the salmeterol-beta2AR complex shows that the phenyl group of Tyr308 interacts with methylene groups near the protonated amine of salmeterol and the ether oxygen interacts with Tyr316.	salmeterol xinafoate	33-43	adrenoceptor beta 2	Homo sapiens	44-51
9765503-3	1998	The affinity of salmeterol was slightly decreased (32-fold) by replacement of TMD II of the beta2AR with the homologous region of the beta1AR; the affinity was strongly decreased (1870-fold) for the beta2AR with TMD VII of the beta1AR.	salmeterol xinafoate	16-26	adrenoceptor beta 1	Homo sapiens	134-141
9765503-3	1998	The affinity of salmeterol was slightly decreased (32-fold) by replacement of TMD II of the beta2AR with the homologous region of the beta1AR; the affinity was strongly decreased (1870-fold) for the beta2AR with TMD VII of the beta1AR.	salmeterol xinafoate	16-26	adrenoceptor beta 2	Homo sapiens	199-206
9765503-3	1998	The affinity of salmeterol was slightly decreased (32-fold) by replacement of TMD II of the beta2AR with the homologous region of the beta1AR; the affinity was strongly decreased (1870-fold) for the beta2AR with TMD VII of the beta1AR.	salmeterol xinafoate	16-26	adrenoceptor beta 1	Homo sapiens	227-234
9765503-4	1998	The affinity of salmeterol was partially restored by the introduction of TMD VII, but not TMD II, of the beta2AR into the beta1AR.	salmeterol xinafoate	16-26	adrenoceptor beta 2	Homo sapiens	105-112
9765503-4	1998	The affinity of salmeterol was partially restored by the introduction of TMD VII, but not TMD II, of the beta2AR into the beta1AR.	salmeterol xinafoate	16-26	adrenoceptor beta 1	Homo sapiens	122-129
9765503-6	1998	Two salmeterol derivatives with the ether oxygen at different positions in the side chain showed 33- and 64-fold decreased affinities for the wild-type beta2AR, and a derivative with no ether oxygen showed 147-fold decreased affinity for the wild-type beta2AR.	salmeterol xinafoate	4-14	adrenoceptor beta 2	Homo sapiens	152-159
9765503-6	1998	Two salmeterol derivatives with the ether oxygen at different positions in the side chain showed 33- and 64-fold decreased affinities for the wild-type beta2AR, and a derivative with no ether oxygen showed 147-fold decreased affinity for the wild-type beta2AR.	salmeterol xinafoate	4-14	adrenoceptor beta 2	Homo sapiens	252-259
9727872-2	1998	This VIP analog, cyclo-(Lys21-Asp25)Ac[Glu8 Lys12 Nle17 Ala19, Asp25 Leu26,Lys27,28,Gly29,30,Thr31]-VIP, which also has a lactam bridge, has been reported to have relaxant effects that are significantly more potent than other beta-agonists such as salbutamol and salmeterol.	salmeterol xinafoate	263-273	vasoactive intestinal peptide	Homo sapiens	5-8
9727872-2	1998	This VIP analog, cyclo-(Lys21-Asp25)Ac[Glu8 Lys12 Nle17 Ala19, Asp25 Leu26,Lys27,28,Gly29,30,Thr31]-VIP, which also has a lactam bridge, has been reported to have relaxant effects that are significantly more potent than other beta-agonists such as salbutamol and salmeterol.	salmeterol xinafoate	263-273	vasoactive intestinal peptide	Homo sapiens	100-103
9720821-1	1998	BACKGROUND: Salmeterol is a long-acting beta2-adrenergic agonist that is widely used in the treatment of asthma.	salmeterol xinafoate	12-22	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	40-45
9647268-1	1998	BACKGROUND: Salmeterol xinafoate is a long-acting, highly selective, beta2-adrenergic agonist that produces bronchodilation and clinically significant improvement in pulmonary function for up to 12 hours in patients with asthma.	salmeterol xinafoate	12-32	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	69-74
9596305-3	1998	The aim of this study was to evaluate the potential short-term, cardiovascular side effects of salmeterol, a long-acting and highly selective beta2-adrenoceptor agonist.	salmeterol xinafoate	95-105	adrenoceptor beta 2	Homo sapiens	142-160
9594486-0	1998	Salmeterol: a long-acting beta 2-agonist.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	26-32
9635933-1	1998	The aim of this study was to investigate whether regular treatment with inhaled salmeterol modifies the dose-response curve to the inhaled short-acting beta2-agonist terbutaline or affects the concentration of nitric oxide (NO) in exhaled air of children with asthma.	salmeterol xinafoate	80-90	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	152-157
9648959-2	1998	The aim of this study was to define whether beta2-receptor desensitization occurs after treatment with the long-acting beta2-agonist salmeterol, assessed by measuring the bronchodilator response to cumulative repeated doses of inhaled salbutamol before and after treatment.	salmeterol xinafoate	133-143	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	44-49
9648959-2	1998	The aim of this study was to define whether beta2-receptor desensitization occurs after treatment with the long-acting beta2-agonist salmeterol, assessed by measuring the bronchodilator response to cumulative repeated doses of inhaled salbutamol before and after treatment.	salmeterol xinafoate	133-143	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	119-124
9648961-1	1998	Long-acting beta2-adrenoceptor agonists such as salmeterol reduce airway responsiveness for at least 12 h, but this effect seems to decrease with regular use.	salmeterol xinafoate	48-58	adrenoceptor beta 2	Homo sapiens	12-30
9650812-5	1998	The beta-2 agonist salmeterol, the H1-receptor antagonist terfenadine and the phosphodiesterase inhibitor theophylline inhibited the release of IL-4 and IL-13 by more than 50% following 4 h of basophil stimulation with anti-IgE.	salmeterol xinafoate	19-29	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	4-10
9650812-5	1998	The beta-2 agonist salmeterol, the H1-receptor antagonist terfenadine and the phosphodiesterase inhibitor theophylline inhibited the release of IL-4 and IL-13 by more than 50% following 4 h of basophil stimulation with anti-IgE.	salmeterol xinafoate	19-29	interleukin 4	Homo sapiens	144-148
9650812-5	1998	The beta-2 agonist salmeterol, the H1-receptor antagonist terfenadine and the phosphodiesterase inhibitor theophylline inhibited the release of IL-4 and IL-13 by more than 50% following 4 h of basophil stimulation with anti-IgE.	salmeterol xinafoate	19-29	interleukin 13	Homo sapiens	153-158
9554653-4	1998	DATA SYNTHESIS: Salmeterol and formoterol are potent and selective beta2-adrenoceptor agonists with durations of action >12 h. Their major differences are that formoterol has a rapid onset of action and is a partial agonist of high intrinsic efficacy, whereas salmeterol has a delayed onset and is a partial agonist of low intrinsic efficacy.	salmeterol xinafoate	16-26	adrenoceptor beta 2	Homo sapiens	67-85
9594486-1	1998	Salmeterol xinafoate is a potent and highly selective beta 2-adrenoreceptor agonist with a duration of action greater than 12 hours.	salmeterol xinafoate	0-20	adrenoceptor beta 2	Homo sapiens	54-75
9594486-4	1998	Although there is some evidence that salmeterol induces some tolerance to the bronchoprotective effect of beta 2-agonist therapy, improvement in lung function and asthma symptoms scores, during both the daytime and nighttime, are sustained.	salmeterol xinafoate	37-47	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	106-112
9596106-1	1998	The aim of this study was to systematically compare the interaction of the long-acting beta2-adrenoceptor agonists formoterol and salmeterol with short-acting beta2-adrenoceptor agonists in contracted human bronchi.	salmeterol xinafoate	130-140	adrenoceptor beta 2	Homo sapiens	159-177
9535032-2	1998	The long-acting beta2-adrenoceptor agonist, salmeterol (10(-9)-10(-5) M), inhibited the IgE-mediated release of histamine from human lung mast cells (HLMC) in a dose-dependent fashion.	salmeterol xinafoate	44-54	adrenoceptor beta 2	Homo sapiens	16-34
9517390-0	1998	Salmeterol-induced desensitization, internalization and phosphorylation of the human beta2-adrenoceptor.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	85-103
9525449-1	1998	OBJECTIVE: We have previously found that beta2-adrenoceptor downregulation and bronchodilator desensitization to albuterol occurred at 36 hours after stopping regular treatment with twice daily salmeterol.	salmeterol xinafoate	194-204	adrenoceptor beta 2	Homo sapiens	41-59
9596106-8	1998	Salmeterol but not formoterol appears to antagonize the relaxation of human contracted bronchi induced by short-acting beta2-agonists.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	119-124
9517390-5	1998	We have compared the activation and desensitization of human beta2-adrenoceptor stimulation of adenylyl cyclase induced by salmeterol, adrenaline and salbutamol in a human lung epithelial line, BEAS-2B, expressing beta2-adrenoceptor levels of 40-70 fmol mg(-1), and in human embryonic kidney (HEK) 293 cell lines expressing 2-10 pmol mg(-1).	salmeterol xinafoate	123-133	adrenoceptor beta 2	Homo sapiens	61-79
9517390-7	1998	Salmeterol pretreatment of these cells induced a rapid and stable activation of adenylyl cyclase activity which resisted extensive washing and beta2-adrenoceptor antagonist blockade, consistent with binding to a receptor exosite and/or to partitioning into membrane lipid.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	143-161
9517390-12	1998	Our data suggest that the reduction in the rapid phase of desensitization of beta2-adrenoceptors after treatment with salmeterol or salbutamol is caused by a decrease in the rate of beta2-adrenoceptor kinase (betaARK) phosphorylation and internalization.	salmeterol xinafoate	118-128	adrenoceptor beta 2	Homo sapiens	77-95
9506248-4	1998	In single-dose studies comparing the two long-acting beta 2-agonists formoterol and salmeterol, significant bronchodilation is achieved more rapidly with formoterol than salmeterol.	salmeterol xinafoate	84-94	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	53-59
9506248-4	1998	In single-dose studies comparing the two long-acting beta 2-agonists formoterol and salmeterol, significant bronchodilation is achieved more rapidly with formoterol than salmeterol.	salmeterol xinafoate	170-180	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	53-59
9777883-3	1998	The influence of four beta2-agonists (salbutamol, terbutaline, formoterol, and salmeterol) and a corticosteroid (budesonide) on the release of interleukin-1beta (IL-1beta) and LTB4 was studied in a dose-response manner (10(-8)-10(-5) mol/L for beta2-agonists and 10(-10)-10(-6) mol/ L for budesonide).	salmeterol xinafoate	79-89	interleukin 1 beta	Homo sapiens	143-160
9482706-10	1998	Salbutamol and, to a lesser extent, salmeterol inhibited FMLP-, but not C5a-induced EPO release, while all the other drugs tested were inactive.	salmeterol xinafoate	36-46	formyl peptide receptor 1	Homo sapiens	57-61
9616529-7	1998	At the end of 12 months of treatment with salmeterol, the adjusted change from baseline for morning and evening peak expiratory flow rate (PEF) was 56 and 47 l min-1, respectively, and this was significantly greater than placebo (P < 0.01; P < 0.05).	salmeterol xinafoate	42-52	CD59 molecule (CD59 blood group)	Homo sapiens	160-165
9500298-1	1998	The objective of this study was to examine the bronchodilating effect of an inhaled long acting beta2-agonist (salmeterol) after a high dose of an inhaled short acting beta2-agonist (salbutamol) in asthma patients.	salmeterol xinafoate	111-121	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	96-101
9435156-3	1998	Salmeterol significantly inhibited IL-5-induced O2- release in a concentration-dependent manner with an IC50 of 2.2 X 10(-6) M (95% CI, 1.6-2.7 X 10(-6) M) and a maximal inhibition of about 70%.	salmeterol xinafoate	0-10	interleukin 5	Homo sapiens	35-39
9500298-1	1998	The objective of this study was to examine the bronchodilating effect of an inhaled long acting beta2-agonist (salmeterol) after a high dose of an inhaled short acting beta2-agonist (salbutamol) in asthma patients.	salmeterol xinafoate	111-121	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	168-173
9438493-4	1997	Treatment of mast cells with salmeterol or salbutamol (100 nmol/L) inhibited the IgE-dependent release of TNF-alpha (82% and 74%, respectively).	salmeterol xinafoate	29-39	tumor necrosis factor	Homo sapiens	106-115
9435156-5	1998	Salmeterol also significantly inhibited adherence induced by both IL-5 and PAF, whereas salbutamol had no significant effect on adherence induced by both agents.	salmeterol xinafoate	0-10	interleukin 5	Homo sapiens	66-70
9438493-5	1997	Moreover, 2-hour treatment with salmeterol, isoproterenol, or salbutamol inhibited mast cell cytotoxicity against a TNF-alpha-sensitive cell line, WEHI-164, with an IC50 of 71, 50, and 29 nmol/L, respectively.	salmeterol xinafoate	32-42	tumor necrosis factor	Homo sapiens	116-125
9438493-8	1997	In contrast, the inhibition of TNF-alpha release was increased 1 hour after removal of salmeterol and remained significant 24 hours later.	salmeterol xinafoate	87-97	tumor necrosis factor	Homo sapiens	31-40
19479397-1	1997	The introduction of long-acting beta(2)-adrenoceptor agonists such as salmeterol and formoterol has opened new perspectives for the treatment of asthma and, possibly, also COPD.	salmeterol xinafoate	70-80	adrenoceptor beta 2	Homo sapiens	32-52
9540365-10	1998	In conclusion, an inhaled corticosteroid (fluticasone) together with an inhaled long-acting beta 2 agonist (salmeterol) is an effective and well tolerated therapy in patients with obstructive airways disease.	salmeterol xinafoate	108-118	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	92-98
9461719-0	1997	[Salmeterol, a new long-acting beta 2-agonist in asthma treatment].	salmeterol xinafoate	1-11	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	31-37
9487346-1	1997	BACKGROUND: Salbutamol is the most widely prescribed short acting beta 2 agonist and salmeterol is the first long acting inhaled beta 2 agonist.	salmeterol xinafoate	85-95	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	129-135
9387945-1	1997	The long-acting beta2-agonist salmeterol inhibits in vitro the release of inflammatory mediators up to 20 h. These mediators are involved in ultrasonically nebulized distilled water (UNDW)-induced bronchoconstriction.	salmeterol xinafoate	30-40	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	16-21
9387958-3	1997	The aim of this study was to evaluate, prospectively, the effects of the long-acting beta2-agonist salmeterol in adult CF patients.	salmeterol xinafoate	99-109	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	85-90
9387958-7	1997	Salmeterol produced a significant increase in PEFR compared to the run-in period (morning 375+/-23 vs 332+/-23 L x min(-1), deltaPEFR +15.1+/-3.1%, p<0.003; evening 384+/-24 vs 349+/-24 L x min(-1), deltaPEFR +11.7+/-2.4%, p<0.04).	salmeterol xinafoate	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	115-121
9387958-7	1997	Salmeterol produced a significant increase in PEFR compared to the run-in period (morning 375+/-23 vs 332+/-23 L x min(-1), deltaPEFR +15.1+/-3.1%, p<0.003; evening 384+/-24 vs 349+/-24 L x min(-1), deltaPEFR +11.7+/-2.4%, p<0.04).	salmeterol xinafoate	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	193-199
9387958-9	1997	Thus, the long-acting beta2-agonist salmeterol provided clinical benefit to a majority of adult cystic fibrosis patients with airways obstruction.	salmeterol xinafoate	36-46	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	22-27
9426083-1	1997	Salmeterol and formoterol are two long-acting beta2-agonists for inhalation, currently being used in clinical practice.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	46-51
9426083-8	1997	We confirm that formoterol and salmeterol are both long-acting beta2-agonists, but with some differences in effect profile.	salmeterol xinafoate	31-41	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	63-68
9230234-7	1997	Secondly, the effect of 1 week of treatment with the long-acting beta2-agonist, salmeterol (50 microg b.i.d.	salmeterol xinafoate	80-90	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	65-70
9262535-1	1997	Salmeterol is a highly selective beta 2-adrenoreceptor agonist with a long duration of action--as long as 12 hours or more.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	33-54
9262535-4	1997	In patients who continue to have symptomatic asthma despite the regular use of an inhaled corticosteroid, salmeterol acts as a secondary controller of symptoms and reduces the need for inhaled short-acting beta 2-agonist "rescues".	salmeterol xinafoate	106-116	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	206-212
9257086-2	1997	Salmeterol xinafoate is a selective beta 2-adrenoceptor agonist indicated for the maintenance treatment of adults and children with asthma.	salmeterol xinafoate	0-20	adrenoceptor beta 2	Homo sapiens	36-55
9230722-1	1997	There is evidence that downregulation and desensitization of airway beta 2-adrenoceptors (beta 2-AR) develops after continuous exposure to long-acting beta 2-agonists such as formoterol and salmeterol.	salmeterol xinafoate	190-200	adrenoceptor beta 2	Homo sapiens	68-88
9230722-1	1997	There is evidence that downregulation and desensitization of airway beta 2-adrenoceptors (beta 2-AR) develops after continuous exposure to long-acting beta 2-agonists such as formoterol and salmeterol.	salmeterol xinafoate	190-200	adrenoceptor beta 2	Homo sapiens	90-99
9230722-1	1997	There is evidence that downregulation and desensitization of airway beta 2-adrenoceptors (beta 2-AR) develops after continuous exposure to long-acting beta 2-agonists such as formoterol and salmeterol.	salmeterol xinafoate	190-200	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	68-74
9310023-3	1997	Desensitization may be greater with the long-acting beta 2-agonist, salmeterol, given its greater duration of receptor occupancy.	salmeterol xinafoate	68-78	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	52-58
9316102-10	1997	Long-acting beta 2-agonists, such as salmeterol and formoterol, are now available as additional therapy to inhaled corticosteroids in patients who remain symptomatic despite at least a moderate dose of inhaled corticosteroid.	salmeterol xinafoate	37-47	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	12-18
9568547-1	1997	Salmeterol, a long-acting beta 2-adrenoceptor agonist, also possesses some anti-inflammatory properties, but whether eosinophils are the target of such action has been equivocal.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	26-45
9184473-0	1997	The interaction between salmeterol and the beta 2-adrenoceptor protein.	salmeterol xinafoate	24-34	adrenoceptor beta 2	Homo sapiens	43-62
9149578-10	1997	The percentage of 24-h days with supplemental inhaled beta 2-agonist use significantly decreased with salmeterol (85.9 +/- 9.4% vs 70.4 +/- 10.1% for placebo and salmeterol, respectively; p = 0.04).	salmeterol xinafoate	102-112	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	54-60
9113940-1	1997	OBJECTIVES: The long-acting beta2-adrenergic agonist salmeterol prevents exercise-induced asthma, but tolerance may develop to its bronchoprotective effect.	salmeterol xinafoate	53-63	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	28-33
9142928-6	1997	Preincubation of neutrophils with the long-acting beta2-adrenergic receptor agonist salmeterol (in the presence of IBMX) inhibited their fMLP-stimulated adhesion to epithelial cells, whereas pretreatment of epithelial cells did not influence the adhesion process.	salmeterol xinafoate	84-94	adrenoceptor beta 2	Homo sapiens	50-75
9142928-8	1997	Moreover, combinations of salmeterol or isoprenaline with IBMX inhibited fMLP-upregulated Mac-1 expression.	salmeterol xinafoate	26-36	integrin subunit beta 2	Homo sapiens	90-95
9105061-2	1997	Salmeterol xinafoate (SLM), a new long-acting beta2-agonist being used in the treatment of nocturnal airway obstruction, has proved to be very effective in this respect as well.	salmeterol xinafoate	0-20	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	46-51
9138705-0	1997	The duration of action of non-beta 2-adrenoceptor mediated responses to salmeterol.	salmeterol xinafoate	72-82	beta-2 adrenergic receptor	Cavia porcellus	30-49
9138705-2	1997	To investigate further the mechanism of the long duration of action of the selective beta 2-adrenoceptor agonist, salmeterol, we have determined the duration of action of some responses to salmeterol which are not mediated through beta 2-adrenoceptors.	salmeterol xinafoate	114-124	beta-2 adrenergic receptor	Cavia porcellus	85-104
9138705-2	1997	To investigate further the mechanism of the long duration of action of the selective beta 2-adrenoceptor agonist, salmeterol, we have determined the duration of action of some responses to salmeterol which are not mediated through beta 2-adrenoceptors.	salmeterol xinafoate	189-199	beta-2 adrenergic receptor	Cavia porcellus	85-104
9056046-8	1997	For predominantly beta 2-AR agonist such as salmeterol and salbutamol, potentiation of exercise hyperkalaemia occurs.	salmeterol xinafoate	44-54	adrenoceptor beta 2	Homo sapiens	18-27
9056046-10	1997	beta 2-AR partial agonist activity may also be expressed as antagonism in the presence of an exogenous full agonist, as for example attenuation of fenoterol induced responses by salmeterol.	salmeterol xinafoate	178-188	adrenoceptor beta 2	Homo sapiens	0-9
9012556-8	1997	The long-acting beta 2-agonist salmeterol, as a partial agonist, has the potential to attenuate the acute bronchodilator response to a higher activity beta 2-agonist such as salbutamol or fenoterol, although there is no evidence to date on whether this is relevant in the setting of acute asthma.	salmeterol xinafoate	31-41	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	16-22
9012556-8	1997	The long-acting beta 2-agonist salmeterol, as a partial agonist, has the potential to attenuate the acute bronchodilator response to a higher activity beta 2-agonist such as salbutamol or fenoterol, although there is no evidence to date on whether this is relevant in the setting of acute asthma.	salmeterol xinafoate	31-41	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	151-157
9200320-1	1997	The present randomized, double-blind placebo-controlled study aimed at investigating the possible improvement in endurance performance caused by inhaled salmeterol (long-acting beta 2-agonist) and salbutamol (short-acting) compared to placebo in 18 healthy well-trained athletes, aged 17-30 years old.	salmeterol xinafoate	153-163	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	177-183
9128847-5	1997	Pretreatment with salmeterol inhibited by 65% and 43% eosinophil aggregation induced by platelet-activating factor (PAF) and human recombinant C5a, respectively.	salmeterol xinafoate	18-28	PCNA clamp associated factor	Homo sapiens	88-114
9128847-5	1997	Pretreatment with salmeterol inhibited by 65% and 43% eosinophil aggregation induced by platelet-activating factor (PAF) and human recombinant C5a, respectively.	salmeterol xinafoate	18-28	PCNA clamp associated factor	Homo sapiens	116-119
9128847-5	1997	Pretreatment with salmeterol inhibited by 65% and 43% eosinophil aggregation induced by platelet-activating factor (PAF) and human recombinant C5a, respectively.	salmeterol xinafoate	18-28	complement C5a receptor 1	Homo sapiens	143-146
9138705-7	1997	In human neutrophils, salmeterol (1-100 microM) caused concentration-related inhibition of FMLP-induced O2- release.	salmeterol xinafoate	22-32	formyl peptide receptor 1	Homo sapiens	91-95
9093358-0	1997	Beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol.	salmeterol xinafoate	66-76	adrenoceptor beta 2	Homo sapiens	0-19
9007523-3	1996	We examined the effects of three selective beta 2-adrenoceptor agonists, salbutamol, salmeterol and formoterol on beta 2-adrenoceptor binding and mRNA levels in human lung in vitro.	salmeterol xinafoate	85-95	adrenoceptor beta 2	Homo sapiens	114-133
8942009-1	1996	The aim of the clinical study reported here was to investigate the efficacy of salmeterol, a new long-acting selective beta 2-agonist, in patients with bronchial asthma.	salmeterol xinafoate	79-89	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	119-125
9272575-7	1997	The beta 2AR agonist salmeterol blocked the proliferation of both S49 and carB beta 2Gs cells, while this treatment did not change the growth of wild-type cells.	salmeterol xinafoate	21-31	adrenergic receptor, beta 2	Mus musculus	4-12
9344832-2	1997	Since monocytes and lymphocytes play a major pathogenetic role in allergic asthma, this study was designed to evaluate the hypothesis that salmeterol, a beta 2-adrenoceptor agonist with a long duration of action, could inhibit in vitro the allergen-induced activation of blood mononuclear cells (BMCs).	salmeterol xinafoate	139-149	adrenoceptor beta 2	Homo sapiens	153-172
9007523-7	1996	Although treatment with salbutamol for 3 h did not change beta 2-adrenoceptor density, both salmeterol and formoterol reduced beta 2-adrenoceptor density, and exposure to each agonist for 24 h reduced beta 2-adrenoceptor density at all concentrations.	salmeterol xinafoate	92-102	adrenoceptor beta 2	Homo sapiens	126-145
9007523-7	1996	Although treatment with salbutamol for 3 h did not change beta 2-adrenoceptor density, both salmeterol and formoterol reduced beta 2-adrenoceptor density, and exposure to each agonist for 24 h reduced beta 2-adrenoceptor density at all concentrations.	salmeterol xinafoate	92-102	adrenoceptor beta 2	Homo sapiens	126-145
8870705-2	1996	The beta 2-agonist salmeterol inhibited the respiratory burst in a dose-dependent manner.	salmeterol xinafoate	19-29	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	4-10
8870705-8	1996	The results suggest that salmeterol is capable of down-regulating the neutrophil oxidative response to fMLP, also of co-operating with PGE2 and PDE-IV inhibitor RO 20-1724 in a manner not related to its beta 2-receptor binding activity.	salmeterol xinafoate	25-35	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	203-209
8723736-0	1996	The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A.	salmeterol xinafoate	27-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	107-112
8897082-0	1996	Diurnal change of bronchial caliber and airway responsiveness in asthmatics during long-term treatment with long-acting beta 2-agonist salmeterol.	salmeterol xinafoate	135-145	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	120-126
8899116-1	1996	The objective of the present study was to investigate the potential of the long-acting beta 2-agonist salmeterol as an inhibitor of various components of IgE-mediated inflammatory in man.	salmeterol xinafoate	102-112	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	87-93
8899116-9	1996	Both salmeterol and terbutaline very effectively inhibited the anti-IgE-induced extravasation of alpha 2-macroglobulin into skin chambers, with a significantly more sustained effect by salmeterol.	salmeterol xinafoate	5-15	alpha-2-macroglobulin	Homo sapiens	97-118
8885698-1	1996	The four beta 2-adrenoceptor agonists, clenbuterol, bambuterol, formoterol and salmeterol, are all long-acting bronchodilators, that have distinct mechanisms for their extended durations of action.	salmeterol xinafoate	79-89	adrenoceptor beta 2	Homo sapiens	9-28
8864548-10	1996	The beta 2-adrenoceptor agonists, salbutamol and salmeterol, concentration-dependently inhibited eosinophil aggregation induced by C5a and PAF and, again.	salmeterol xinafoate	49-59	beta-2 adrenergic receptor	Cavia porcellus	4-23
9064661-3	1996	The recent availability, in paediatrics, of long-acting beta 2 agonists, especially salmeterol, represents a big advantage with regard to compliance in therapies which last months, while the most recent corticosteroid, available in Italy as a spray, fluticasone, would have very few side effects.	salmeterol xinafoate	84-94	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	56-62
8853286-2	1996	Formoterol and salmeterol are the first members of a new generation of long-acting beta(2)-adrenoceptor agonists for inhalation.	salmeterol xinafoate	15-25	adrenoceptor beta 2	Homo sapiens	83-103
8853286-14	1996	Like all other beta(2)-adrenoceptor agonists in current clinical use, formoterol and salmeterol comprise racemic mixtures.	salmeterol xinafoate	85-95	adrenoceptor beta 2	Homo sapiens	15-35
8723736-1	1996	Salmeterol xinafoate (Serevent) is a long-acting beta2-adrenoceptor agonist, used in the treatment of asthma, that has bronchodilator and anti-inflammatory action.	salmeterol xinafoate	0-20	adrenoceptor beta 2	Homo sapiens	49-67
8723736-1	1996	Salmeterol xinafoate (Serevent) is a long-acting beta2-adrenoceptor agonist, used in the treatment of asthma, that has bronchodilator and anti-inflammatory action.	salmeterol xinafoate	22-30	adrenoceptor beta 2	Homo sapiens	49-67
8723736-5	1996	One microM ketoconazole, a selective inhibitor of CYP3A, substantially inhibited the metabolism of salmeterol to alpha-hydroxysalmeterol.	salmeterol xinafoate	99-109	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-55
8723736-10	1996	Insect cell microsomes that coexpressed human CYP3A and NADPH-P450 reductase were able to metabolize [14C]salmeterol to alpha-hydroxysalmeterol, thus confirming the role of CYP3A in catalyzing this reaction.	salmeterol xinafoate	106-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	46-51
8723736-10	1996	Insect cell microsomes that coexpressed human CYP3A and NADPH-P450 reductase were able to metabolize [14C]salmeterol to alpha-hydroxysalmeterol, thus confirming the role of CYP3A in catalyzing this reaction.	salmeterol xinafoate	106-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	173-178
8723736-11	1996	The therapeutic dose of salmeterol is very low, so it is unlikely that any clinically relevant interactions will be observed as a consequence of the coadministration of salmeterol and other pharmaceutical agents that are metabolized by CYP3A.	salmeterol xinafoate	24-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	236-241
8655889-1	1996	BACKGROUND: Inhalation of a single dose of the long-acting beta 2-adrenoceptor agonist salmeterol protects against methacholine-induced airway obstruction and other bronchoconstricting stimuli for at least 12 hours.	salmeterol xinafoate	87-97	adrenoceptor beta 2	Homo sapiens	59-78
8630590-4	1996	Both groups taking salmeterol showed an improvement of more than 45 L/min in their morning PEFR and 30 L/min in their evening PEFR, compared with respective improvements of 16 L/min and 6 L/min in the group taking BDP 1,000.	salmeterol xinafoate	19-29	B double prime 1, subunit of RNA polymerase III transcription initiation factor IIIB	Homo sapiens	214-219
8630591-7	1996	In [125I]iodocyanopindolol-labeled bronchial membranes, formoterol and salmeterol induced high-affinity states of the beta 2-receptor (pKh 9.6 +/- 0.4 and 10.4 +/- 0.7, respectively), the former inducing a higher percentage (57 +/- 6 versus 28 +/- 4, p < 0.05).	salmeterol xinafoate	71-81	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	118-124
8630591-10	1996	Formoterol and salmeterol were highly selective for the beta 2 versus beta 1-subtype (pKI values were 8.2 +/- 0.09 and 6.25 +/- 0.06 and 8.3 +/- 0.04 and 5.7 +/- 0.04, respectively).	salmeterol xinafoate	15-25	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	56-62
8630591-10	1996	Formoterol and salmeterol were highly selective for the beta 2 versus beta 1-subtype (pKI values were 8.2 +/- 0.09 and 6.25 +/- 0.06 and 8.3 +/- 0.04 and 5.7 +/- 0.04, respectively).	salmeterol xinafoate	15-25	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	70-76
8730730-4	1996	Oxidant production by FMLP- and calcium ionophore (A23187)-activated neutrophils was particularly sensitive to inhibition by low concentrations (0.3-3 microM) of salmeterol, while the responses of phorbol myristate acetate- and opsonised zymosan-stimulated cells were affected only by higher concentrations (3-50 microM) of the drug.	salmeterol xinafoate	162-172	formyl peptide receptor 1	Homo sapiens	22-26
8730730-7	1996	These anti-oxidative interactions of salmeterol with neutrophils were insensitive to propranolol but could be eliminated by washing the cells, or by pretreatment with low concentrations (1-2 microM) of the pro-oxidative, membrane-destabilizing phospholipids, lysophosphatidylcholine (LPC), platelet activating factor (PAF) and lysoPAF (LPAF).	salmeterol xinafoate	37-47	PCNA clamp associated factor	Homo sapiens	318-321
8730730-9	1996	At concentrations of 6.25-50 microM salmeterol interfered with several other activities of stimulated neutrophils, including intracellular calcium fluxes, phospholipase A2 activity and synthesis of PAF.	salmeterol xinafoate	36-46	phospholipase A2 group IB	Homo sapiens	155-171
8730730-9	1996	At concentrations of 6.25-50 microM salmeterol interfered with several other activities of stimulated neutrophils, including intracellular calcium fluxes, phospholipase A2 activity and synthesis of PAF.	salmeterol xinafoate	36-46	PCNA clamp associated factor	Homo sapiens	198-201
8730730-11	1996	In an assay of membrane-stabilizing activity, salmeterol (25 and 50 microM) neutralized the haemolytic action of LPC, PAF and LPAF.	salmeterol xinafoate	46-56	PCNA clamp associated factor	Homo sapiens	118-121
8730730-16	1996	We conclude that salmeterol antagonizes the pro-inflammatory, pro-oxidative activity of several bioactive lipids implicated in the pathogenesis of bronchial asthma, by a mechanism related to the membrane-stabilizing, rather than to the beta 2-agonist properties of this agent.	salmeterol xinafoate	17-27	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	236-242
8622643-0	1996	Comparison of duration of agonist action at beta 1- and beta 2- adrenoceptors in C6 glioma cells: evidence that the long duration of action of salmeterol is specific to the beta 2-adrenoceptor.	salmeterol xinafoate	143-153	adrenoceptor beta 2	Homo sapiens	173-192
8622643-3	1996	Salmeterol seemed to stimulate cAMP accumulation in C6 cells predominantly via activation of the subpopulation of beta 2-adrenoceptors.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	114-120
8622643-4	1996	However, at high (micromolar) agonist concentrations, salmeterol also activated beta 1-adrenoceptors, albeit with low potency and efficacy.	salmeterol xinafoate	54-64	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	80-86
8622643-5	1996	At high concentrations (30 microM), salmeterol attenuated cAMP responses mediated by activation of beta 1-adrenoceptors by isoprenaline (Kp = 1.6 microM), indicating that salmeterol exhibited a low affinity for beta 1-adrenoceptors in C6 cells.	salmeterol xinafoate	36-46	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	99-105
8622643-5	1996	At high concentrations (30 microM), salmeterol attenuated cAMP responses mediated by activation of beta 1-adrenoceptors by isoprenaline (Kp = 1.6 microM), indicating that salmeterol exhibited a low affinity for beta 1-adrenoceptors in C6 cells.	salmeterol xinafoate	36-46	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	211-217
8622643-5	1996	At high concentrations (30 microM), salmeterol attenuated cAMP responses mediated by activation of beta 1-adrenoceptors by isoprenaline (Kp = 1.6 microM), indicating that salmeterol exhibited a low affinity for beta 1-adrenoceptors in C6 cells.	salmeterol xinafoate	171-181	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	99-105
8622643-5	1996	At high concentrations (30 microM), salmeterol attenuated cAMP responses mediated by activation of beta 1-adrenoceptors by isoprenaline (Kp = 1.6 microM), indicating that salmeterol exhibited a low affinity for beta 1-adrenoceptors in C6 cells.	salmeterol xinafoate	171-181	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	211-217
8622643-8	1996	Salmeterol was found to persist at beta 2-adrenoceptors in C6 cells despite washing cell monolayers up to four times.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	35-41
8622643-9	1996	To determine the duration of action of salmeterol at beta 1-adrenoceptors expressed on the same cells, use was made of full/partial agonist interactions.	salmeterol xinafoate	39-49	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	53-59
8622643-11	1996	This observation provided convincing evidence to support the hypothesis that salmeterol exhibits sustained agonist activity at beta 2-adrenoceptors, but not beta 1-adrenoceptors, expressed on the same cells.	salmeterol xinafoate	77-87	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	127-133
8622643-12	1996	Therefore, the sustained activity of salmeterol at beta 2-adrenoceptors seems to be unique and does not result solely from its partitioning into bulk lipid of the plasma membrane.	salmeterol xinafoate	37-47	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	51-57
8730003-1	1996	Salmeterol is a selective long-acting beta 2-agonist bronchodilator considered to have added anti-inflammatory effects, but this is controversial.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	38-44
9388846-0	1996	[The effect of salmeterol on the activity of neutrophil chemotactic factor in patients with asthma].	salmeterol xinafoate	15-25	neutrophil cytosolic factor 4	Homo sapiens	45-74
9388846-4	1996	After treatment with salmeterol the decrease in NCF activity was 26 cell/10 HP (P < 0.01), while the decrease in another group treated with procaterol was 8 cell/10 HP (P > 0.05).	salmeterol xinafoate	21-31	neutrophil cytosolic factor 4	Homo sapiens	48-51
9388846-6	1996	In salmeterol treated group the decrease in NCF activity was more remarkable than the improvement in lung function.	salmeterol xinafoate	3-13	neutrophil cytosolic factor 4	Homo sapiens	44-47
8882590-2	1996	Salmeterol is a potent, selective and long acting beta 2-adrenoceptor agonist.	salmeterol xinafoate	0-10	beta-2 adrenergic receptor	Cavia porcellus	50-69
8882590-5	1996	The mechanism(s) underlying reassertion relaxation are unknown but may relate to high affinity binding of the long aliphatic side chain of salmeterol to an accessory site, distinct from the agonist recognition site, in or near the beta 2-adrenoceptor (exosite binding hypothesis).	salmeterol xinafoate	139-149	beta-2 adrenergic receptor	Cavia porcellus	231-250
8867181-6	1996	Salmeterol (long acting beta 2 agonist) and fluticasone (inhaled corticosteroid) are for use in the small proportion of asthmatics who have severe asthma.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	24-30
8658370-0	1996	Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol.	salmeterol xinafoate	84-94	adrenoceptor beta 2	Homo sapiens	18-37
8796447-0	1996	Salmeterol inhibits interferon-gamma and interleukin-4 production by human peripheral blood mononuclear cells.	salmeterol xinafoate	0-10	interferon gamma	Homo sapiens	20-36
8796447-0	1996	Salmeterol inhibits interferon-gamma and interleukin-4 production by human peripheral blood mononuclear cells.	salmeterol xinafoate	0-10	interleukin 4	Homo sapiens	41-54
8796447-9	1996	Similar to the results obtained after 24 h, IFN-gamma production after 96 h was biphasically inhibited by salmeterol, and this inhibition (60%) was significantly at 10(-5) M. Together, the present data provide clear evidence for concentration-dependent effects of beta-adrenoceptor agonists on the IL-4 and IFN-gamma production by human PBMC.	salmeterol xinafoate	106-116	interferon gamma	Homo sapiens	44-53
8796447-9	1996	Similar to the results obtained after 24 h, IFN-gamma production after 96 h was biphasically inhibited by salmeterol, and this inhibition (60%) was significantly at 10(-5) M. Together, the present data provide clear evidence for concentration-dependent effects of beta-adrenoceptor agonists on the IL-4 and IFN-gamma production by human PBMC.	salmeterol xinafoate	106-116	interleukin 4	Homo sapiens	298-302
8796447-9	1996	Similar to the results obtained after 24 h, IFN-gamma production after 96 h was biphasically inhibited by salmeterol, and this inhibition (60%) was significantly at 10(-5) M. Together, the present data provide clear evidence for concentration-dependent effects of beta-adrenoceptor agonists on the IL-4 and IFN-gamma production by human PBMC.	salmeterol xinafoate	106-116	interferon gamma	Homo sapiens	307-316
8606326-1	1996	OBJECTIVE: To examine the safety of the long-acting beta2-agonist, salmeterol, in general medical practice in the U.K. DESIGN: In Prescription-Event Monitoring (PEM) the exposure data are derived from prescriptions confidentially provided by the Prescription Pricing Authority.	salmeterol xinafoate	67-77	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	52-57
8564629-1	1996	BACKGROUND: The protective effect of a new long acting beta 2-agonist, salmeterol, against exercise-induced bronchoconstriction has been documented when given as inhaled aerosol.	salmeterol xinafoate	71-81	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	55-61
8746998-1	1996	The mechanisms behind the long duration of bronchodilating action of the beta 2-adrenoceptor agonists formoterol and salmeterol are only partially understood.	salmeterol xinafoate	117-127	adrenoceptor beta 2	Homo sapiens	73-92
8746998-4	1996	Both formoterol and salmeterol display a higher lipophilicity and have a higher affinity, selectivity, and potency than most short-acting agonists at the beta 2-adrenoceptor.	salmeterol xinafoate	20-30	adrenoceptor beta 2	Homo sapiens	154-173
8658370-1	1996	BACKGROUND: Salmeterol and formoterol have a lower intrinsic activity at beta 2 receptors than isoprenaline in human bronchus in vitro.	salmeterol xinafoate	12-22	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	73-79
8658370-2	1996	The aim of the present study was to evaluate in vivo the beta 2 agonist/antagonist activity of salmeterol and formoterol at rest with low endogenous adrenergic tone, on exercise with raised endogenous adrenergic tone, and in the presence of fenoterol, an exogenous full beta 2 receptor agonist.	salmeterol xinafoate	95-105	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	57-63
8658370-6	1996	Salmeterol and formoterol, like propranolol, potentiated the hyperkalaemic delta response to exercise compared with placebo, consistent with beta 2 antagonism: (mean difference and 95% confidence interval (CI) compared with placebo) salmeterol 0.20 (0.02 to 0.38) mmol/l, formoterol 0.17 (0.00 to 0.34) mmol/l, propranolol 0.45 (0.08 to 0.82) mmol/l.	salmeterol xinafoate	233-243	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	141-147
8658370-9	1996	CONCLUSIONS: At rest with low endogenous adrenergic tone salmeterol and formoterol showed equivalent beta 2 mediated agonist activity in terms of serum potassium and finger tremor responses.	salmeterol xinafoate	57-67	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	101-107
8658370-10	1996	In the presence of raised endogenous adrenergic tone at peak exercise and in the presence of fenoterol (an exogenous full beta 2 receptor agonist), salmeterol and formoterol, like propranolol, exhibited beta 2 receptor antagonism as evidenced by their attenuation of beta 2 receptor mediated responses.	salmeterol xinafoate	148-158	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	122-128
8658370-11	1996	The degree of beta 2 blockade with formoterol and salmeterol was comparable but less than with propranolol.	salmeterol xinafoate	50-60	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	14-20
7616798-6	1995	There was a significant reduction in lymphocyte beta-2 adrenoceptor density after salmeterol compared with placebo and run-in.	salmeterol xinafoate	82-92	adrenoceptor beta 2	Homo sapiens	48-67
7552926-1	1995	BACKGROUND: Salmeterol is the first long-acting inhaled beta 2-agonist available in the US for the maintenance treatment of asthma.	salmeterol xinafoate	12-22	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	56-62
8819183-1	1995	The long-acting beta 2-agonist salmeterol has been shown in several in vitro studies to produce non-beta-mediated relaxant effects.	salmeterol xinafoate	31-41	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	16-22
8556566-13	1995	After salmeterol treatment the mean ECP serum concentration had fallen significantly to 20.9 +/- 18.6 micrograms/L (P < 0.01), whereas after salbutamol treatment it was unchanged (42.0 +/- 25.1 micrograms/L).	salmeterol xinafoate	6-16	ribonuclease A family member 3	Homo sapiens	36-39
8556566-14	1995	Salmeterol treatment produced a decrease in ECP serum levels without any changes in blood eosinophil count.	salmeterol xinafoate	0-10	ribonuclease A family member 3	Homo sapiens	44-47
7648384-4	1995	This problem has been largely overcome with the development of a new generation of long-acting beta 2-agonists represented by salmeterol and formoterol (not currently available in the US).	salmeterol xinafoate	126-136	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	95-101
7648384-6	1995	SUMMARY: Preclinical studies have shown both salmeterol and formoterol to be potent and selective at beta 2-adrenoceptors but to have different mechanisms and durations of action.	salmeterol xinafoate	45-55	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	101-107
7648385-0	1995	Long-acting beta 2-agonist salmeterol compared with albuterol in maintenance asthma therapy.	salmeterol xinafoate	27-37	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	12-18
7541622-14	1995	It is concluded that rats treated chronically with the long-acting beta 2-adrenoceptor agonist salmeterol have an impaired secretion of salivary proteins and calcium and that the effect resembles that of salbutamol.	salmeterol xinafoate	95-105	adrenoceptor beta 2	Rattus norvegicus	67-86
7752089-1	1995	Salmeterol (SALM) is a long-acting beta 2 adrenoceptor agonist that causes prolonged relaxation of airway smooth muscle.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	35-54
7752089-7	1995	In cells obtained from four separate isolations, pretreatment with 10(-8)M SALM before addition of ALB blocked the inhibition of EPO release caused by 10(-8)M ALB alone (486 +/- 28 ng/10(6) cells for ALB alone vs. 902 +/- 32 ng/10(6) cells for SALM + ALB; P < .01; n = 4).	salmeterol xinafoate	75-79	eosinophil peroxidase	Homo sapiens	129-132
7713162-2	1995	In this study, we have investigated the acute anti-inflammatory effects of a short-acting (salbutamol) and a long-acting (salmeterol) beta 2-adrenoceptor agonist on 111In-accumulation and oedema formation in allergic and mediator-induced inflammation in guinea pig skin.	salmeterol xinafoate	122-132	beta-2 adrenergic receptor	Cavia porcellus	134-153
7882570-2	1995	Since salmeterol is a beta 2-agonist which activates adenylate cyclase, its ability to inhibit cytokine production was evaluated.	salmeterol xinafoate	6-16	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	22-28
7882570-6	1995	Salmeterol was able to inhibit the activation of both mouse and human T cells, as measured by proliferation and IL-2 secretion in response to anti-CD3 antibody, whereas albuterol was completely inactive in these assays.	salmeterol xinafoate	0-10	interleukin 2	Homo sapiens	112-116
7882570-8	1995	Paralleling the TNF-alpha inhibitory activity in vitro, oral dosing of salmeterol and albuterol inhibited LPS-induced increase in murine serum TNF level in vivo, with ED50s of approximately 0.1 mg/kg.	salmeterol xinafoate	71-81	tumor necrosis factor	Homo sapiens	16-25
7882570-11	1995	Salmeterol also had some protective effects in the galactosamine/LPS model of endotoxic shock, which is dependent upon TNF-alpha production.	salmeterol xinafoate	0-10	tumor necrosis factor	Homo sapiens	119-128
7882570-12	1995	Though salmeterol inhibited serum TNF-alpha levels by up to 94% in this assay, it protected less than 50% of the animals from the lethal effects of the LPS/galactosamine mixture.	salmeterol xinafoate	7-17	tumor necrosis factor	Homo sapiens	34-43
7552578-6	1995	These preparations have previously been shown to be equally sensitive to inhibition by the beta 2-adrenoceptor agonist salmeterol.	salmeterol xinafoate	119-129	beta-2 adrenergic receptor	Cavia porcellus	91-110
7768283-8	1995	Hence, the widely used beta 2-adrenoceptor agonists, salbutamol and salmeterol, are able to reduce endothelial permeability at nanomolar concentrations.	salmeterol xinafoate	68-78	adrenoceptor beta 2	Bos taurus	23-42
7780648-8	1995	However, when tissues were treated with beta 2-agonists and then washed for a period of 4 h, salmeterol was the only agonist which significantly inhibited the anti-IgE response.	salmeterol xinafoate	93-103	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	40-46
7858856-5	1994	We have therefore explored the ability of salmeterol to inhibit the relaxant response to beta 2-adrenoceptor agonists of different chemical structure and relatively higher efficacy in smooth muscle preparations from guinea-pig trachea and human bronchus.	salmeterol xinafoate	42-52	beta-2 adrenergic receptor	Cavia porcellus	89-108
7952550-1	1994	The long-acting beta 2-agonist salmeterol has been suggested to have other pharmacologic activities, that is, antiinflammatory capacities, in addition to its bronchodilator properties.	salmeterol xinafoate	31-41	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	16-22
7858856-14	1994	Salmeterol inhibits, competitively, relaxant responses to beta 2-adrenoceptor agonists with higher efficacy.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	58-77
7858856-16	1994	This contrasts with results obtained with sulfonterol and suggests that salmeterol interacts with the beta 2-adrenoceptor in a complex way.	salmeterol xinafoate	72-82	adrenoceptor beta 2	Homo sapiens	102-121
7939538-1	1994	The long-acting beta-2-agonist bronchodilators salmeterol and formoterol are relatively new drugs that may significantly improve the treatment of chronic bronchial asthma.	salmeterol xinafoate	47-57	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	16-22
7943228-0	1994	Anabolic effects of the beta 2-adrenoceptor agonist salmeterol are dependent on route of administration.	salmeterol xinafoate	52-62	adrenoceptor beta 2	Rattus norvegicus	24-43
7943228-8	1994	These results indicate that the potency of salmeterol in vivo is dependent on its route of administration and that slow-twitch muscles are less sensitive than mixed-fiber muscles to the anabolic effects of beta 2-adrenoceptor agonists.	salmeterol xinafoate	43-53	adrenoceptor beta 2	Rattus norvegicus	206-225
7955958-2	1994	A new long-acting beta 2-receptor agonist has recently become available: salmeterol.	salmeterol xinafoate	73-83	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	18-24
7914175-1	1994	New long-acting beta 2-adrenoceptor agonists, salmeterol and formoterol, have recently been marketed for treatment of asthma, but studies comparing the clinical efficacy of the two drugs have not been published.	salmeterol xinafoate	46-56	adrenoceptor beta 2	Homo sapiens	16-35
7936460-0	1994	Salmeterol: a long-acting beta 2-agonist for asthma.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	26-32
7909853-1	1994	OBJECTIVE: To compare the efficacy and safety of inhaled salmeterol xinafoate, a long-acting beta 2-adrenoceptor agonist, with that of albuterol, a short-acting inhaled beta 2-agonist, in the treatment of asthma.	salmeterol xinafoate	57-77	adrenoceptor beta 2	Homo sapiens	93-112
7915501-8	1994	Salmeterol was significantly more effective than SR-terbutaline in the following factors: number of patients without any awakening during the last week of treatment (50% vs 27%, P = 0.003), mean morning PEF (351 +/- 109 l/min-1 vs 332 +/- 105 l/min-1, P = 0.04), PEF diurnal variation 6 +/- 10% vs 11 +/- 12%, P = 0.01), overall assessment of efficacy by the patient and the investigator (P = 0.001 and 0.005, respectively), and daily rescue salbutamol intakes (P = 0.004).	salmeterol xinafoate	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	222-227
7915501-8	1994	Salmeterol was significantly more effective than SR-terbutaline in the following factors: number of patients without any awakening during the last week of treatment (50% vs 27%, P = 0.003), mean morning PEF (351 +/- 109 l/min-1 vs 332 +/- 105 l/min-1, P = 0.04), PEF diurnal variation 6 +/- 10% vs 11 +/- 12%, P = 0.01), overall assessment of efficacy by the patient and the investigator (P = 0.001 and 0.005, respectively), and daily rescue salbutamol intakes (P = 0.004).	salmeterol xinafoate	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	245-250
7915610-12	1994	Propranolol (10(-7) M) and the beta 2-specific antagonist, ICI 118551 (10(-6) M) blocked the protective effects of salmeterol completely, but atenolol (10(-6) M) was less effective.	salmeterol xinafoate	115-125	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	31-37
7915610-13	1994	These results suggested that the effects of salmeterol on pyocyanin-induced effects were mediated primarily via the stimulation of beta 2-adrenoceptors.	salmeterol xinafoate	44-54	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	131-137
7914175-3	1994	Although, both formoterol and salmeterol are highly selective for the beta 2-adrenoceptors (comparable to salbutamol and terbutaline), differences in their chemical structure suggest differences in their mechanisms of action or receptor specificity.	salmeterol xinafoate	30-40	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	70-76
7912202-3	1994	The comparative pharmacology, and molecular modelling of these drugs and of the beta 2-adrenoceptor and its ligand binding core have cast doubt on the exosite/exoceptor model previously proposed to explain the behaviour of salmeterol.	salmeterol xinafoate	223-233	adrenoceptor beta 2	Homo sapiens	80-99
7909285-1	1994	STUDY OBJECTIVE: A dose-ranging study was conducted to evaluate the efficacy and safety of a new long-acting, selective beta 2-adrenoceptor agonist, salmeterol.	salmeterol xinafoate	149-159	adrenoceptor beta 2	Homo sapiens	120-139
7912202-4	1994	We present evidence supporting a unifying hypothesis that the duration of action both of formoterol and salmeterol is determined principally by their physicochemical interactions with membrane lipid bilayers (plasmalemma diffusion microkinetic model), rather than putative distinct exosite/exoceptor binding sites in or near the beta 2-adrenoceptor.	salmeterol xinafoate	104-114	adrenoceptor beta 2	Homo sapiens	329-348
7925051-2	1994	Salmeterol (Hydroxynaphthoate) is a long acting selective beta-2-agonist.	salmeterol xinafoate	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	58-64
8149969-2	1994	In each case, these actions were mediated through beta 2-adrenoceptors, with formoterol being 50-120-fold more potent than salbutamol, and 2-27-fold more potent than salmeterol.	salmeterol xinafoate	166-176	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	50-56
7521712-0	1994	Influence of salmeterol, a long-acting beta 2-adrenoceptor agonist, on IgE-mediated histamine release from human basophils.	salmeterol xinafoate	13-23	adrenoceptor beta 2	Homo sapiens	39-58
7521712-0	1994	Influence of salmeterol, a long-acting beta 2-adrenoceptor agonist, on IgE-mediated histamine release from human basophils.	salmeterol xinafoate	13-23	immunoglobulin heavy constant epsilon	Homo sapiens	71-74
7521712-1	1994	Salmeterol, a long-acting beta 2-adrenoceptor agonist, prevents early and late asthmatic responses in atopic asthmatics and inhibits the release of inflammatory mediators from various cells and tissues.	salmeterol xinafoate	0-10	adrenoceptor beta 2	Homo sapiens	26-45
7521712-6	1994	At concentrations of between 1 and 100 microM salmeterol, concentration-dependent inhibition of release was found for Ag- and anti-IgE-mediated BHR.	salmeterol xinafoate	46-56	immunoglobulin heavy constant epsilon	Homo sapiens	131-134
7521712-7	1994	The Imax of anti-IgE-mediated BHR reached 46 +/- 16% at 30 microM salmeterol.	salmeterol xinafoate	66-76	immunoglobulin heavy constant epsilon	Homo sapiens	17-20
7521712-12	1994	We conclude that salmeterol significantly inhibits IgE-mediated histamine release from human leukocytes in the micromolar range.	salmeterol xinafoate	17-27	immunoglobulin heavy constant epsilon	Homo sapiens	51-54